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Cellular Mechanotransduction And Skeletal Muscle Regeneration In
Fibrodysplasia Ossificans Progressiva (fop)
Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease characterized by formation of extraskeletal bone, or heterotopic ossification (HO), in soft connective tissues like skeletal muscle. All cases with
classic clinical features of FOP carry a mutation in ACVR1 (R206H; c.617G>A), a cell surface receptor that
mediates bone morphogenetic protein (BMP) signaling, which is recognized for its chondro/osteogenicinduction potential. HO in FOP patients is qualitatively normal bone tissue; the ACVR1R206H mutation
induces misdirected cell fate decisions by tissue-resident mesenchymal stem cells to form this ectopic bone.
In addition to ligand-receptor signaling, mechanical cues from the physical environment direct cell fates.
While BMP ligands are established signaling molecules, less is known about signals from the surrounding
tissue physical properties or interactions with mechanical effectors by the BMP-pSmad1/5 pathway. Cells
perceive physical cues like substrate stiffness through surface mechanoreceptors; these mechanical inputs
modulate cell morphology and lineage through cytoskeletal and chromatin organization. Softer substrates
support adipo/myogenesis, while stiffer substrates promote chondro/osteogenesis. Primary mouse
embryonic fibroblasts (MEFs) isolated from our Acvr1R206H/+ mice that mimics the human disease are
used as an in vitro model system of mesenchymal stem cells (MSCs), including their ability to differentiate
into adipogenic, chondrogenic, and osteogenic lineages. We previously showed increased BMP signaling in
Acvr1R206H/+ MEFs as measured by phosphorylated Smad1/5/8 (pSmad1/5/8) protein levels in the
presence or absence of BMP ligand. We also found increased expression of direct downstream chondro/
osteogenic target genes of BMP such as Msx2, Id1, Sox9, and Runx2. Utilizing MEFs, we determined that
activation of the mechanotransductive effectors RHO/ROCK and YAP/TAZ were increased in
Acvr1R206H/+ MEFs. We found that Acvr1R206H/+ MEFs on softer substrates acquire a morphology, and
other responses to the physical environment, similar to control MEFs on stiffer substrates and that
Acvr1R206H/+ MEFs have a basal propensity for osteogenic differentiation. Our data support that the
combination of increased BMP pathway signaling, misinterpretation of soft substrates, and overall reduced
sensitivity to mechanical stimuli lower the threshold of Acvr1R206H/+ cells for commitment to chondro/
osteogenic lineages.
HO formation is often initiated by injury to skeletal muscle. In normal tissue, injury leads to recruitment of
fibroblasts to provide repair signals and stimulation of muscle progenitor cells (muscle stem cells, MuSCs) to
undergo myogenic differentiation to restore muscle tissue. Our lab previously demonstrated that in FOP,
repair initiates normally, however appears to diverge from the normal wound healing response at the
fibroproliferative stage. We have established that our Acvr1R206H/+ mouse model develops HO after
cardiotoxin (CTX) injury, and that injured skeletal muscle tissue from Acvr1R206H/+ is more fibrotic and
severely damaged compared to muscle of injured Acvr1+/+ animals, indicating that muscle repair is impeded
by the ACVR1R206H mutation. The regenerative potential of skeletal muscle is dependent on the function of
MuSCs. The regeneration process following CTX injury in Acvr1+/+ mouse skeletal muscle tissue results in
the formation of small, centri-nucleated myofibers 7-10-days post-injury. However, in Acvr1R206H/+ muscle
tissue, we find persistence of damaged myofibers at later time points and subsequent formation of HO.
Additionally, fibro/adipogenic progenitors (FAPs), another muscle-resident progenitor cell, are in close
association with regenerating muscle fibers and support myogenesis; these cells, considered mesenchymal
progenitors based on their ability to differentiate to adipocytes and osteoblasts, are a source of pro-myogenic
signals that support muscle regeneration. We demonstrated that Acvr1+/+ and Acvr1R206H/+ MuSCs and
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FAPs proliferate at similar levels after injury. While Acvr1+/+ MuSCs differentiate normally and form
branching myofibers, Acvr1R206H/+ MuSCs form underdeveloped fibers that fail to fuse in vitro. Acvr1+/+
FAPs cultured with Acvr1R206H/+ MuSCs leads to proper myofibers formation and fusion, while
Acvr1R206H/+ FAPs cultured with Acvr1+/+ MuSCs form undeveloped fibers. This suggests that the FAP
population under the influence of the ACVR1R206H mutation contributes largely to the poor muscle
regeneration seen in FOP lesions. The ACVR1R206H mutation also creates a hostile environment for repair,
hindering engraftment of transplanted Acvr1+/+ MuSCs. Taken together, our data exhibit the impact of the
ACVR1R206H FOP mutation on the differentiation capacity of myogenic progenitor cells to regenerate
skeletal muscle and the importance of environment during skeletal muscle regeneration.
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ABSTRACT
CELLULAR MECHANOTRANSDUCTION AND SKELETAL MUSCLE
REGENERATION IN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Alexandra K. Stanley
Eileen M. Shore, PhD; Foteini Mourkioti, PhD
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease
characterized by formation of extra-skeletal bone, or heterotopic ossification (HO), in soft
connective tissues like skeletal muscle. All cases with classic clinical features of FOP carry
a mutation in ACVR1 (R206H; c.617G>A), a cell surface receptor that mediates bone
morphogenetic protein (BMP) signaling, which is recognized for its chondro/osteogenicinduction potential. HO in FOP patients is qualitatively normal bone tissue; the ACVR1R206H
mutation induces misdirected cell fate decisions by tissue-resident mesenchymal stem
cells to form this ectopic bone.
In addition to ligand-receptor signaling, mechanical cues from the physical
environment direct cell fates. While BMP ligands are established signaling molecules, less
is known about signals from the surrounding tissue physical properties or interactions with
mechanical effectors by the BMP-pSmad1/5 pathway. Cells perceive physical cues like
substrate stiffness through surface mechanoreceptors; these mechanical inputs modulate
cell morphology and lineage through cytoskeletal and chromatin organization. Softer
substrates

support

adipo/myogenesis,

while

stiffer

substrates

promote

chondro/osteogenesis. Primary mouse embryonic fibroblasts (MEFs) isolated from our
Acvr1R206H/+ mice that mimics the human disease are used as an in vitro model system of
mesenchymal stem cells (MSCs), including their ability to differentiate into adipogenic,
chondrogenic, and osteogenic lineages. We previously showed increased BMP signaling
in Acvr1R206H/+ MEFs as measured by phosphorylated Smad1/5/8 (pSmad1/5/8) protein
vi

levels in the presence or absence of BMP ligand. We also found increased expression of
direct downstream chondro/osteogenic target genes of BMP such as Msx2, Id1, Sox9,
and Runx2. Utilizing MEFs, we determined that activation of the mechanotransductive
effectors RHO/ROCK and YAP/TAZ were increased in Acvr1R206H/+ MEFs. We found that
Acvr1R206H/+ MEFs on softer substrates acquire a morphology, and other responses to the
physical environment, similar to control MEFs on stiffer substrates and that Acvr1R206H/+
MEFs have a basal propensity for osteogenic differentiation. Our data support that the
combination of increased BMP pathway signaling, misinterpretation of soft substrates, and
overall reduced sensitivity to mechanical stimuli lower the threshold of Acvr1R206H/+ cells
for commitment to chondro/osteogenic lineages.
HO formation is often initiated by injury to skeletal muscle. In normal tissue, injury
leads to recruitment of fibroblasts to provide repair signals and stimulation of muscle
progenitor cells (muscle stem cells, MuSCs) to undergo myogenic differentiation to
restore muscle tissue. Our lab previously demonstrated that in FOP, repair initiates
normally, however appears to diverge from the normal wound healing response at the
fibroproliferative stage. We have established that our Acvr1R206H/+ mouse model develops
HO after cardiotoxin (CTX) injury, and that injured skeletal muscle tissue from
Acvr1R206H/+ is more fibrotic and severely damaged compared to muscle of injured
Acvr1+/+ animals, indicating that muscle repair is impeded by the ACVR1R206H mutation.
The regenerative potential of skeletal muscle is dependent on the function of MuSCs.
The regeneration process following CTX injury in Acvr1+/+ mouse skeletal muscle tissue
results in the formation of small, centri-nucleated myofibers 7-10-days post-injury.
However, in Acvr1R206H/+ muscle tissue, we find persistence of damaged myofibers at
later time points and subsequent formation of HO. Additionally, fibro/adipogenic
progenitors (FAPs), another muscle-resident progenitor cell, are in close association with
regenerating muscle fibers and support myogenesis; these cells, considered
vii

mesenchymal progenitors based on their ability to differentiate to adipocytes and
osteoblasts, are a source of pro-myogenic signals that support muscle regeneration. We
demonstrated that Acvr1+/+ and Acvr1R206H/+ MuSCs and FAPs proliferate at similar levels
after injury. While Acvr1+/+ MuSCs differentiate normally and form branching myofibers,
Acvr1R206H/+ MuSCs form underdeveloped fibers that fail to fuse in vitro. Acvr1+/+ FAPs
cultured with Acvr1R206H/+ MuSCs leads to proper myofibers formation and fusion, while
Acvr1R206H/+ FAPs cultured with Acvr1+/+ MuSCs form undeveloped fibers. This suggests
that the FAP population under the influence of the ACVR1R206H mutation contributes
largely to the poor muscle regeneration seen in FOP lesions. The ACVR1R206H mutation
also creates a hostile environment for repair, hindering engraftment of transplanted
Acvr1+/+ MuSCs. Taken together, our data exhibit the impact of the ACVR1R206H FOP
mutation on the differentiation capacity of myogenic progenitor cells to regenerate
skeletal muscle and the importance of environment during skeletal muscle regeneration.
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Chapter One:
Introduction

1

1.1 Bone morphogenetic protein (BMP) signaling
1.1.1 TGFβ superfamily ligands and receptors
The transforming growth factor (TGF)-β superfamily of receptors and ligands is
essential in establishing and patterning the body axis of developing vertebrates, and for
maintaining the homeostasis of numerous mature tissues (2-5). TGFβ family members
regulate cell processes such as migration, proliferation, differentiation, apoptosis, and
replenishment of stem cell pools (2, 6-10). The TGFβ family consists of 33 proteins
comprised of BMPS, TGFβs, activins, inhibins, nodal, myostatin, growth/differentiation
factors, and anti-Müllerian hormone (2, 9, 10). BMPs (bone morphogenetic proteins) are a
highly conserved sub-family of extracellular signaling proteins that regulate cell fate
decisions and have crucial roles in both embryonic developmental and post-natal life (2, 3,
5, 11)

. BMPs comprise the largest subgroup within the superfamily with more than twenty

ligands identified (12). BMPs function as morphogens during embryogenesis to pattern
the body axis and delineate the different germ layers (2, 4, 13, 14). In the adult, BMPs
function to stimulate endochondral bone formation, as well as regulate skeletal muscle
regeneration (6, 15-17).
BMP receptors complex into heterodimers during active signaling in response to
binding of BMP or growth-determining factor (GDF) ligands. These receptors are
serine/threonine transmembrane receptors categorized as type I or type II (Fig. 1.1) (9, 10,
18)

. The type I BMP receptors are Activin A receptors ACVRL1 (ALK1), ACVR1 (ALK2),

BMPR1A (ALK3), and BMPR1B (ALK6), and the type II receptors are ACTR2A,
ACTR2B and BMPR2. These receptors primarily respond to Activin A, GDF, and BMP
ligands (19); TGFβ receptors are similar in structure but have higher affinities for TGFβ
ligands. The TGFβ receptors include the type I receptors ACVR1B (ALK4), TGFBR1
(ALK5), and ACVR1C (ALK7), and the type II receptor TGFBR2 (9, 10). For both BMP and
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TGFβ receptors, type I receptors include an extracellular ligand binding domain, a
transmembrane domain, an intracellular glycine/serine (GS) domain, and protein kinase
domain. Type II receptors are highly similar to type I, but lack a GS domain

(19)

. In BMP

signal propagation, ligand binding to the receptor ligand binding domain (LBD) of type I
receptors stimulates the formation of heterotrimeric complex of two type I receptors and
two type II receptors (20, 21). The type II receptor then phosphorylates the GS-domain of
the type I receptor, thought to occur through a conformational change induced by ligand
binding. Phosphorylation of type I receptor GS domain initiates a downstream cascade
of phosphorylation of canonical and non-canonical effector proteins (Fig. 1.1) (19-21).
There are several endogenous inhibitors of BMP signaling, including, but not
limited to, Noggin, Chordin, and Gremlin; these proteins function to sequester BMP
ligands away from BMP and TGFβ receptors, thus preventing them from activating
downstream signaling (Fig. 1.1) (3, 22). Noggin and Chordin are especially active in
inhibiting BMP signaling during development; BMP, Noggin, and Chordin form
converging and competing morphogen gradients that heavily influence body patterning
in the embryo (22). The protein FKBP12 is an intracellular inhibitor of BMP signaling,
functioning to prevent receptor activity in the absence of ligand binding. FKBP12 binds to
type I receptors at a leucine/proline motif within the GS domain of the receptor; this
results in a conformation change that renders the receptor inactive. Upon formation of
complexes with receptors bound to ligand, FKBP12 dissociates from the receptor (Fig.
1.1) (23-25).
1.1.2 Signal propagation and pathways
BMPs signal both canonically and non-canonically. Canonical BMP signaling is
dependent on activity of the Smad family of proteins. Smad1/5/8/9 (and Smad2/3 in
TGFβ signaling) are known as regulatory Smads (R-Smads). Smad4 is referred to as a
3

Co-Smad, and facilitates translocation of R-Smads into the nucleus after
phosphorylation of the R-Smads. Smad6/7 are inhibitory Smads (I-Smads) and function
to suppress activity of the R-Smads (Fig. 1.1). R-Smads interact with the type I receptor
GS domain through a MH2 domain, with R-Smad phosphorylation occurring at the serine
SSXS motif in the last carboxy-terminal sequence of the MH2 domain (20, 21, 26). After
receptor phosphorylation, R-Smads subsequently bind to Smad4 in the cytoplasm and
this complex translocates into the nucleus via nuclear import factors Msk, Imp7, and
Imp8, and nucleoporins Sec13, Nup75, Nup 93, and Nup205 (27). The R-Smad-Smad4
complex recognizes a 5’-GTCT-3’ binding sequence (Smad-binding element) on the
promoters of Smad-responsive target genes (28). Smads have a low binding affinity for
DNA and also may also associate with specific DNA-binding cofactors to regulate
transcriptional activity (29). Smads activate many different genetic profiles, depending on
the identity of the expressing cells and tissue (26, 28). I-Smads are similarly structured as
R-Smads and Smad4, but lack the carboxy-terminal phosphorylation site (30). Smad6
functions to actively compete with Smad4 for binding with R-Smads, while Smad7
competes with R-Smads for binding of activated BMP and TGFβ receptors to prevent RSmad phosphorylation (Fig. 1.1) (26, 30).
Non-canonical BMP signaling begins similarly with heterotrimeric receptor
complexes as described for signaling through Smads, but targets and activates
extracellular signal-regulated kinases (ERK), protein kinase A (PKA), and transforming
growth factor beta-activated kinase 1 (TAK1) signaling pathways, which in turn mediates
map kinase p38 and C-jun N-terminal kinase (JNK) pathway signaling activity (Fig. 1.1).
These pathways play roles in immune cell function, cell viability, cell metabolism, and
other cellular processes (26, 31).

1.2 Endochondral ossification and the process of heterotopic ossification
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1.2.1 Forms of skeletogenesis
Bone formation during embryogenesis begins around E9.5 in mice (32) (third week
of gestation in humans) (33). The skeletal system is derived from the mesoderm layer of
the embryo, also known as the middle primary germ layer (33). There are two types of
bone that form. Intramembranous ossification arises from mesenchymal connective
(undifferentiated) tissue. Only a few bones form through intramembranous ossification,
including the flat bones of the face, most cranial bones, and the clavicles, and these
bones are more flexible prior to birth so allow easier passage of the shoulder and skull
through the birth canal (34). All the long bones, the rib cage, and the spinal column arise
from endochondral ossification. Endochondral ossification occurs through a cartilage
scaffold that is replaced by bone forming osteoblasts. The process takes much longer
than intramembranous ossification, and the resulting bones provide structural support
and shape to the body (34).
The framework for endochondral ossification to form long bones of the embryonic
skeleton, as well as to repair bone fracture in adult bones, begins with a cartilaginous
stage. Cartilage is formed by matrix produced by chondroblasts, precursors to
chondrocytes. Cartilage matrix is comprised of chondroitin sulfate, fibrous collagen,
hyaluronic acid, and water (35-37). Once matrix has enveloped the chondroblasts, they are
now chondrocytes, with their niche (aside from those in joint spaces) referred to as the
perichondrium (38). As chondrocytes become encased in more and more matrix, they
grow in size (hypertrophy) and then they begin to die because nutrients cannot penetrate
the mineralized matrix that is beginning to form. The cartilage also becomes
vascularized at this point, with blood vessels acting as the conduit by which osteogenic
precursor cells enter the perichondrium, transforming it to site of bone matrix production
(the periosteum) (37, 39). Osteoblasts secrete matrix that forms a collar of bone around the
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cartilage, creating a primary ossification center (36, 38). After birth, this sequence is
replicated within regions at the ends of the long bones (epiphyseal plates or growth
plates) and allows long bone lengthening and growth (36).
In both endochondral and intramembranous ossification, uncalcified matrix is
secreted by osteoblasts, and then becomes calcified within a few days of deposition.
Once encased in their own matrix niche (termed the periosteum), osteoblasts become
osteocytes and produce new matrix as needed throughout the lifespan of the organism
to maintain bone homeostasis (40). Bone remodeling is a balance between bone
formation by osteoblasts and resorption of mineralized bone matrix by osteoclasts.
Remodeling and bone quality are influenced by age, injury, diet, exercise, and genetics
(41)

. Bone is a complex multi-cellular system, with bone marrow making up the innermost

cavity of the bone, spongy trabecular bone at the ends of long bones, and a dense outer
layer of cortical bone to protect the bone. Trabecular bone (trabecula) is made of up
dense collagenous tissue, that forms a porous bone network, and is the site where blood
vessels condense into red marrow (42, 43). Cortical bone bears the weight of mechanical
loading by muscle tissue during stress and is highly resistant to bending and deformation
(42-44)

. Mature cartilage and bone arise during development from the multipotent

progenitor cell population mesenchymal stem cells (MSCs) (Fig. 1.2) (45).
1.2.2 Heterotopic endochondral ossification
Heterotopic ossification (HO) is a condition in which extra-skeletal bone forms
within soft connective tissues like tendon and skeletal muscle (46-48). The resulting bone is
normal bone; it is inappropriately located within the tissue due to misdirected cellular
signals (46-50). HO within the general population occurs more frequently as non-genetic or
acquired HO that is typically associated with sever tissue injury. Acquired HO in patients
with no known genetic predisposition can be the result of high energy war injuries
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(referred to as “blast injuries”) (51, 52), after extensive invasive orthopedic surgeries such
as hip replacements (53), burns, spinal cord injury, brain injury, and stroke (48, 54). In these
scenarios, HO can be surgically removed and generally does not reoccur

(51, 55)

.

HO can also be the result of specific genetic mutation, although this is much less
common than trauma-induced HO. Fibrodysplasia ossificans progressiva (FOP) is a rare
human genetic disease characterized by the formation of endochondral bone within
muscle and other soft connective tissues (47, 49, 56, 57). Although FOP is a genetic disease
and the gene mutation can be inherited from parents to children, most known cases of
FOP are due to de novo mutations. Analysis of FOP patients by our research group
(Shore, personal communication) has found that ~97% of patients with a classic clinical
presentation of FOP have the same autosomal dominant mutation (R206H; c.617G>A)
in the type l bone morphogenetic protein (BMP) receptor activin A receptor type 1
(ACVR1) (58-60). FOP patients clinically present with malformed great toes at birth, and
HO within skeletal muscle or connective tissue within the first five years of life (Fig. 1.3),
and FOP occurs in about 1 in 1.5 - 2 million people worldwide (46, 50). While HO can arise
spontaneously in FOP patients, it is also commonly induced by injury to skeletal muscle
(59, 61)

. In rare cases, HO has occurred in children with FOP after intramuscular vaccine

(62)

. Removal of HO is not a solution for FOP patients, as surgical trauma exacerbates

further ectopic bone growth (50, 51). Palliative treatments supply only limited relief from the
pain associated with HO, and there are currently no effective treatments to prevent
ectopic HO formation (50, 63, 64).
Another disease of genetic HO is Progressive Osseous Heteroplasia (POH).
POH is characterized by formation of HO that typically begins in the subcutaneous layer
of the skin then progressively extends into subcutaneous adipose tissues and skeletal
muscle tissue. POH is caused by mutations in the GNAS locus and can be inherited in
an autosomal dominant manner (65-67). The prognosis for treatment of POH is similar to
7

FOP; there are no curative therapies and removal of HO usually cannot be effectively
accomplished. Palliative treatments are able to relieve some of the pain associated with
HO in POH (68).
In the case of both FOP and POH, evidence suggests that the HO arises due to
aberrant cell fate decisions. For HO to occur, there must be a stimulating event
(mutation, injury, disease, surgery), a permissive environment, and resident cells with
chondro/osteogenic potential (49). Mesenchymal stem cells (MSCs) are multipotent
progenitor cells that reside in many tissues, including skeletal muscle and adipose tissue
(Fig. 1.2) (69-71). These cells have osteogenic (bone-forming) potential and altered
molecular signaling due to the genetic mutations in these diseases could be directing
these cells to an osteogenic lineage (72, 73). The bone that forms in either disease is
typically separate from the endogenous skeletal elements, although can later fuse to the
skeletal bone, indicating that HO is not simply an outgrowth from the periosteum due to
overactive osteoblasts or under-performing osteoclasts (59, 61, 72, 74, 75).

1.3 Fibrodysplasia ossificans progressiva
1.3.1 Clinical features
FOP is characterized by two prominent clinical features: malformation of the
great toe and progressive endochondral heterotopic ossification (HEO) (Fig. 1.3) (76).
Heterotopic ossification does not form during embryonic development so the only
indication at birth that a person has FOP is the great toe malformation. FOP can be
diagnosed on the basis of the toe malformation alone (47); however, more often the
patient is not diagnosed until other symptoms (i.e. HEO) begin to arise (49, 50).
Beginning in the first decade of life, children begin to suffer “flare ups”, or painful
episodes of inflammation in soft connective and skeletal muscle tissue. These “flare ups”
usually result in HEO formation in the area within weeks or months. HEO can arise
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spontaneously; however, it is often due to some kind of injury (i.e. falling down, bumping
into something, intramuscular trauma). Patients are unable to receive intramuscular
vaccinations and must been cared for by a dentist with experience in working with FOP,
so as to not cause trauma and subsequent fusion of the jaw (77). Attempts at surgical
removal of HEO only causes further trauma and stimulates new bone formation (49, 50, 76).
In the absence of injury, the sequence of body sites that are progressively
affected by HEO formation in a patient follows a similar pattern to embryonic skeletal
development, beginning in the dorsal, axial, proximal, and cranial regions, and then later
in the ventral, caudal, appendicular, and distal regions of the body. Most skeletal
muscles have the potential to be sites of HEO formation, with the exception of the
diaphragm, tongue, and extra-ocular muscles. There is no evidence of HEO in cardiac or
smooth muscles (46).
FOP is a very debilitating disease. Ectopic bone formation often forms in areas of
joints and can cause joint bridging and fusion, making the patient potentially unable to
walk, eat efficiently, and have difficulty breathing

(50)

. As HO progresses, the tissues in

which the bone is forming are reciprocally displaced or replaced. HEO arises
episodically, but accumulates over time. Patients often require lifelong help in the tasks
of daily life. The current average life expectancy for FOP patients is 40 years of age, with
cause of death commonly being thoracic insufficiency syndrome (50, 78).
1.3.2 Progression of FOP lesions
HO formation, both in FOP and in trauma-induced HO, occurs through a
progressive series of events that culminates in bone formation within skeletal muscle and
other soft connective tissues

(46, 48, 76, 79)

. While HO can arise spontaneously in FOP

patients, it is also commonly induced by injury to skeletal muscle. Injury stimulates an
inflammatory response, which facilitates wound healing by recruiting/activating fibroblasts
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and other cell types to the site of injury

(80)

. Although this repair process seems to initiate

normally in FOP, our data support divergence at the fibroproliferative stage, which persists
longer in Acvr1R206H/+ tissues

(46, 59, 61, 79)

. The fibroproliferative stage is followed by

(49, 81-84)

formation of cartilage and bone

(Fig. 1.4). The resulting bone appears

histologically normal and may even contain marrow elements (81, 83).
Normally, tissue damage and inflammation alter the tissue microenvironment,
activating previously quiescent cells that are mobilized to contribute to the repair of the
tissue and altering ECM production and physical/mechanical properties. The mechanical
signals received by fibroblasts transitions them to an activated myofibroblast state, with
increased mechanotransduction, de novo expression of alpha-smooth muscle actin
(αSMA), synthesis of ECM, and mobility and proliferation of myofibroblasts (85, 86). Chronic
activation of fibroblasts during repair results in fibrosis, causing permanent damage such
as scarring and organ malfunction (87). Under the influence of the ACVR1R206H mutation,
stiffening of the tissue in response to injury could promote chondro/osteogenic
differentiation of resident MSCs. Muscle stem cells (MuSCs) are the cell population
required for skeletal muscle regeneration
increased tissue stiffness

(90)

(88, 89)

, and MuSCs are negatively affected by

and chronic inflammation

(91)

. Another resident skeletal

muscle tissue progenitor population fibro/adipogenic progenitor cells (FAPs) are required
for activation of MuSCs during skeletal muscle regeneration (92). In disease settings, FAPs
have been shown to contribute to adipose deposits, fibrosis, and osteogenic differentiation
within skeletal muscle tissue

(93-95)

. Together, the negative impact of the state of FOP

muscle tissue after injury on MuSC function and the fibro/osteogenic potential of FAPs
may promote the progression of disease and formation of HO in FOP.
1.3.3 Mutations in ACVR1 cause FOP
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Although FOP is a genetic disease, given the severe and debilitating nature of
the condition, inheritance from one generation to the next is only occasionally seen. FOP
arise in most cases from a de novo mutation in the individual. 97% of patients with a
classic clinical presentation of FOP (HEO formation, great toe malformation (Fig. 1.3))
have the same autosomal dominant mutation (R206H; c.617G>A) in the type l bone
morphogenetic protein (BMP) receptor Activin A receptor type 1 (ACVR1) (59-61). ACVR1
was identified as the mutated gene in FOP in 2006. The R206H mutation is found within
the intracellular glycine/serine (GS) domain of the receptor (Fig. 1.1) (56). This missense
mutation increases both BMP ligand-dependent and ligand-independent signaling to
promote increased downstream chondro/osteogenic gene expression and HO formation
in FOP patients (49, 56, 57, 60). Other mutations have subsequently been identified in
ACVR1, causing classic FOP phenotypes, as well as additional complications (47, 96-100).
1.3.4 Knock-in mouse model of FOP
Obtaining samples of primary human tissues from FOP patients is incredibly
difficult as resection of bone or other tissue leads to further HO development. Genetically
engineered mouse models with the FOP mutation can provide alternate sources of cells,
as well as provide a system for detailed in vivo studies of the process through which
heterotopic bone forms. Acvr1R206H/+ knock-in mice were generated containing the
identical nucleotide substitution found in FOP patients (59, 61). The ACVR1 gene is highly
conserved between human and mouse such that Acvr1 was modified to replace the
identical codon 206 in exon 5 with the R206H mutation (CGC>CAC). A conditional-on
knock-in mouse Acvr1[R206H]FlEx was used to generate doxycycline-inducible global allele
expression. Acvr1[R206H]FlEx/+;Gt(ROSA)26Sortm1(rtTA*M2)Jae;Tg(tetO-Cre)1Jaw mice (which
we refer to as Acvr1R206H/+). To induce recombination and global expression of the
mutant allele, mice are fed a doxycycline diet chow for at least three consecutive days.
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Mice heterozygous for the ACVR1R206H allele are viable postnatally; mice homozygous
for the ACVR1R206H allele are non-viable. In order for the mice to survive with the
ACVR1R206H mutation, the mutation must be induced a few days prior to birth or
postnatally. These mice recapitulate the clinical manifestations of FOP, including
development of HEO and malformation of the great toes (59, 61, 101). These mice have
been utilized to demonstrate the histopathological progression of lesions after injury (61),
the increased immunological response (79), and the involvement of mechanical signaling
in FOP (73) (Fig. 1.4).

1.4 Regulation of Cell Fate by Mechanotransduction
1.4.1 Generalized role of ligands, receptors, and signaling proteins
The extra cellular matrix (ECM) collectively refers to the proteins and free-moving
endogenous ligands that surround cells within a tissue (102). The ECM functions to provide
structural integrity for cells

(103)

, form connections between tissues

(104, 105)

, and regulates

the flow of biochemical cues between cell/tissue types (106). Components of the ECM varies
among tissue types, with expression of different collagens, glycoproteins, and enzymes
that perform the distinctive functions each specific tissue requires (107). Matrix, also referred
to as substrate, can range from very soft to very stiff, depending on the composition and
the cells that reside there. Substrates are evaluated on their elasticity, or the ability of the
substrate to resist a distorting stress, or force, and return to its original shape once the
stress is removed

(108)

. The stiffness of a substrate is ability of the tissue to resist

deformation in response to applied force. This is quantified in SI units of kilopascals (kPa)
(109, 110)

. Neurons for example, reside in a very soft niche with a high elastic modulus/low

stiffness (<1kPa), while osteocytes reside in a much stiffer matrix with a low elastic
modulus/high stiffness (>50kPa)

(111, 112)

. Higher elasticity means more stress, or force, is

required to deform the tissue beyond the point where it cannot return to its original state
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(108, 109)

. A higher stiffness means the substrate is more resistant to deformation and is

therefore more rigid and able to bear higher forces (110). For example, a softer substrate is
more supportive of fat tissue, which stores nutrients for cellular energetics, while a stiffer
substrate is more supportive of tissues that perform a loadbearing role, like bone

(108, 110)

.

Cells secrete the various components of their ECM/substrate in order to set up a
suitable environment for their specific functions (113, 114), and also to interact with the ECM
through extracellular or transmembrane receptors (104, 115, 116). These interactions allow the
ECM to signal back to the cells and control cell fate decisions and other functions, a
process known as mechanotransduction

(109, 117)

. Mechanotransduction is the process by

which cells sense the physical state of their surrounding microenvironment and, via
intracellular signaling pathways, respond to these physical signals by subsequently
altering gene expression and protein production

(110, 117, 118)

. This process enables

substrate stiffness to modulate cell fate to give rise to a range of cell and tissue types with
diverse functions within a living organism

(111)

. Cell fates can be controlled by substrate

stiffness comparably to induction through exogenous ligands or growth factors: softer
substrates promote adipogenesis and myogenesis, while stiffer substrates support
chondrogenesis and osteogenesis

(111, 119, 120)

. In vivo, both substrate stiffness and

endogenous ligands influence cell fate decisions; in vitro, cell fate can be modulated solely
by mechanical manipulation of substrate stiffness

(111)

, however little is understood about

the influence of mechanical activity on cell fate as compared to biochemical signaling.
There are many transmembrane and intracellular signaling components that are
important for mechanotransduction

(104, 116, 121)

. Signaling begins with receptors that span

the cell membrane and bind to collagens, glycoproteins, proteoglycans, and endogenous
ligands

(116, 118, 122-124)

. These interactions stimulate downstream signaling cascades with

mechanotransductive effectors ultimately entering the nucleus and either modifying
genetic transcription directly or binding to other transcription factors to elicit expression of
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specialized genetic profiles to modify cellular motility, viability, shape, and identity

(109, 117,

124)

. Mechanotransduction is a key player in the homeostasis of diverse tissues; dynamic

changes allow a tissue to respond and adapt to growth, injury, and disease, in an attempt
to preserve proper functionality of the tissue. Improper mechanical signaling is often part
of the pathology of several disease states, fibrosis being a common consequence of
increased mechanotransductive signaling (125-127).
1.4.1.1 YAP/TAZ Signaling
The Hippo/Yes-associated protein (YAP) signaling pathway (128-131) is regulated by
ECM elasticity and cell geometry, and is a key regulator of downstream cell differentiation
(115, 132-136)

. YAP and its paralogue TAZ have been shown to be key factors in the regulation

of MSC lineage commitment, with YAP as the core component of the signaling pathway
(132)

. Under physiological conditions, YAP is phosphorylated by proteins upstream of the

Hippo/YAP signaling pathway via a series of kinase cascades

(137-139)

. Initially, MST1/2

binds to hSAV1, the human ortholog of the scaffold protein Salvador (SAV)

(140)

, which

forms a complex and phosphorylates LATS1/2. YAP is subsequently phosphorylated by
LATS1/2, which is regulated by MOB kinase activator 1A (MOB1)

(130, 131, 141)

.

Phosphorylation of YAP subsequently promotes cytoplasmic localization of YAP within the
YAP [serine (ser) 127]/14-3-3 protein complex. This prevents YAP-mediated
transcriptional activation in the nucleus and cytoplasmic YAP/TAZ eventually undergoes
proteasomal degradation (131, 137, 138, 141, 142) (Fig. 1.5).
Non-phosphorylated YAP/TAZ translocates into the nucleus and binds to its
transcriptional co-factor Transcriptional enhancer factor (TEF-1), also known as TEA
domain family member 1 (TEAD)

(86, 141)

. Binding of YAP/TAZ to TEAD is necessary for

transcriptional activation of YAP/TAZ target genes; both YAP and TAZ protein structures
contain a TEAD binding domain (TBD), although TEAD binding occurs slightly differently
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in YAP vs. TAZ (143). TEAD-YAP/TAZ transcriptional targets include genes involved in cell
growth and proliferation, most notably connective tissue growth factor (CTGF)

(144)

and

cysteine-rich angiogenic inducer 61 (CYR61) or CCN family member 1 (CCN1) (142, 145, 146)
(Fig. 1.5). CTGF is a matricellular protein that interacts with cytokines and growth factors
to modulate cell adhesion, migration, and remodeling of ECM. Increased CTGF has been
highly associated with the development of fibrosis in disease (144). Cyr61 is an extracellular
matrix (ECM)-associated signaling protein of the CCN family (CCN intercellular signaling
protein) and is a key regulator in cell adhesion, migration, proliferation, and osteogenic
differentiation through interaction with cell surface integrin receptors (142, 145, 146).
Activation of Hippo/YAP signaling is mainly mediated by substrate stiffness and
cell density

(115, 132-136, 147, 148)

. Cytoplasmic localization of YAP1 has been associated with

a soft extracellular environment, cellular apoptosis, and adipogenic differentiation

(103, 115,

132-136, 147)

. Nuclear localization of YAP1 is associated with a stiff extracellular environment,

cell motility, and chondro/osteogenic differentiation

(115, 132-136, 147-149)

. YAP/Hippo signaling

has been shown to strongly influence cell fate decisions in response to signals from the
extracellular environment, particularly in multipotent mesenchymal stem cells (MSCs) (150).
Of note, YAP/TAZ signaling is involved in endochondral bone development and
homeostasis

(149, 151, 152)

, as well as the maintenance of skeletal muscle tissue

(151, 153)

.

Within skeletal tissue, TAZ complexes with the pro-osteoblastic factor runt related
transcription factor 2 (RUNX2) to activate gene transcription that promotes osteogenesis
(152)

. TAZ also suppresses adipogenic factor peroxisome proliferator-activated receptor

gamma (Pparγ) to inhibit adipogenesis (154). YAP1 protein levels must be closely regulated
because YAP controls both chondrocyte hypertrophy and proliferation

(149, 155)

. In skeletal

muscle, YAP was identified to contribute to the regulation of muscle mass, with
overexpression of YAP being sufficient to induce skeletal muscle hypertrophy (151, 156).
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YAP/TAZ signaling has been highly implicated in disease, particularly in fibrosis of
various tissues
of organ size

(157)

. The Hippo pathway was first described in Drosophila as a regulator

(158)

, with this role subsequently confirmed in mammals

(159)

. Regulation of

organ/tissue size indicates a role for this pathway in maintenance of tissue homeostasis.
Nuclear localization of YAP/TAZ protein is associated with transcriptional activity of its
downstream target genes, leading to cellular proliferation and differentiation within many
tissue types

(157, 160)

. Mis-regulation of Hippo/YAP signaling has been demonstrated in

many tissue types as contributing to disease (161). In the liver, constitutively active nuclear
YAP expression aggravated the progression of hepatocellular carcinoma

(162)

. It was also

determined that development of fibrosis in the kidney is dependent on YAP-mediated
activation/proliferation of fibroblasts

(163)

. YAP nuclear expression has been implicated in

several other tissue types, including pancreas, intestine, and skin
localization is also dysregulated in multiple forms of cancer

(160, 164, 165)

. YAP/TAZ

(166-168)

. Forced expression of

nuclear YAP increased proliferation of post-mitotic adult cardiomyocytes to promote
regeneration following myocardial infarction (169). These data demonstrate the importance
of localization of YAP/TAZ in mechanotransduction and its implications for disease. Better
understanding of its regulation will provide potential insight into therapeutic approaches
involving Hippo-YAP/TAZ signaling.
1.4.1.2 Rho/ROCK Signaling
Rho GTPases are members of the Ras-related small GTPases, and act as
molecular switches, cycling between active GTP-bound states and inactive GDP-bound
states. Guanine nucleotide exchange factors (GEFs) control the exchange of GDP for
GTP to inactivate GTPases, while GTPase-activating proteins (GAPs) stimulate GTPase
activity

(170, 171)

. The Rho GTPases regulate downstream effectors such as Rho kinase

(ROCK), necessary for cell migration, adhesion, and differentiation
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(170, 172, 173)

. Rho

signaling through ROCK stimulates actin polymerization, a vital part of cell contractility
and cellular mechanotransduction

(173-175)

. One of the Rho GTPases, RhoA, regulates

ROCK to influence actin filament stability through myosin light chain (MLC) and cofilin
(Fig. 1.5) (176, 177). Actin polymerization/depolymerization controls cell contractility, motility,
and adhesion via major polymerization factors Arp2/3 and Formin (177, 178).
Activation of RhoA in mesenchymal cells is a major contributor to their
chondro/osteogenic cellular identity (172, 179). Osteogenic conditions increase cell
spreading, ECM production, BMP signaling, RhoA activation, and nuclear localization of
YAP (179, 180). Inhibition of Rho/ROCK signaling with Y272362 (Y27) suppressed BMP2induced osteogenic differentiation (179), demonstrating a requirement for cell spreading
and ROCK/myosin signaling in BMP-induced osteogenesis. YAP responds to cell-cell
contact and contractility signals mediated by Rho via serine/threonine kinase effector
Large Tumor Suppressor 1/2 (LATS1/2) (181, 182), with additional evidence supporting that
ROCK directly acts on YAP to increase YAP nuclear localization (139). BMP and YAP
signaling have also been shown to interact under osteogenic conditions through
Smad1/5; BMP induced nuclear localization of YAP and expression of YAP target genes
Cyr61 and CTGF pathway (183-185). Collectively these data suggest an intersection
between RhoA, YAP, and BMP signaling to simulated osteogenesis and cell contractility.
1.4.1.3 Intracellular signaling interactions with cytoskeletal proteins
Mechanical forces exerted by the ECM are transduced through transmembrane
receptors, such as integrins, which connect to actin cytoskeletal filaments through focal
adhesion complex proteins

(186)

. When cells adhere to the ECM, integrin receptors in the

cell membrane heterodimerize to bind ECM proteins while focal adhesion proteins
assemble intracellularly at the cell membrane to form focal adhesion complexes that
anchor actin filaments to the ECM

(122, 187, 188)

. Talin, vinculin, and paxillin are major
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components of focal adhesion complexes; talin directly connects integrins to actin with
support from vinculin

(116)

, while paxillin functions to join multiple actin filaments to create

actin stress fibers (Fig. 1.6)

(189, 190)

. Rho-GAPs respond to mechanical forces generated

by the extracellular matrix to activate Rho which in turn leads to stimulation of ROCK to
promote focal adhesion complex formation; continued activation promotes focal adhesion
complexes to become larger (more protein component deposition), and stress fiber
formation and increased cell contractility

(191-193)

. Actin filaments complex with the motor

protein myosin II to generate force to push the plasma membrane during cell migration
(Fig. 1.6) (194, 195).
Focal adhesions are also regulated by YAP signaling downstream from Rho (136,
181, 182, 187, 196)

. Inhibition of Rho resulted in cytoplasmic localization/inactivation of

YAP/TAZ and depolymerization of F-actin; however, interference with focal adhesion
components do not affect YAP/TAZ (181). Perturbation of F-actin stress fibers represses
nuclear YAP/TAZ (133), while F-actin capping or severing proteins, such as cofilin, confine
YAP/TAZ to the cytoplasm (181, 197).
Another downstream output of RhoA signaling is cellular contractility, mediated
by the actin and myosin cytoskeleton (198). Actin-myosin contractility modulates focal
adhesion assembly, stress fiber formation, and cell migration (199). Increased substrate
stiffness leads to the formation of more focal adhesions to better anchor the cell to its
substrate through increased contractility. Cell contractility is also a contributing factor to
osteogenic cell fate decisions (113, 200). Tension in contractile actomyosin fibers increases
activity of downstream effectors like YAP, resulting in osteogenic gene expression (Fig.
3.10) (147, 201).
In summary, extra- and intra- cellular mechanics majorly regulate cell survival,
migration, and identity. Rho/ROCK directly interprets signaling from the extracellular
matrix to influence cell contractility and YAP/Hippo signaling, while Hippo/YAP signaling
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responds to mechanical signaling by influencing cell fate. Only a few of the many pathways
involved in cellular mechanotransduction have been discussed in this brief summary.
Better understanding of the interactions of different mechanical pathways is necessary to
create therapeutic interventions that target mechanical signaling in disease states.

1.5 Muscle stem cells and fibro/adipogenic progenitor cells
Multiple stem/progenitor cell populations reside in skeletal muscle tissue. The
canonical muscle stem cell (MuSC; also known as a satellite cell) is essential for fiber
regeneration (88, 202, 203). MuSCs remain quiescent within the muscle tissue until activated
to begin proliferating (and self-renewing) to repair damaged muscle. When activated
after muscle injury, MuSCs proliferate, fuse, and ultimately repair damaged skeletal
muscle tissue (88, 204-206).
Another muscle-resident progenitor cell population, referred to as fibroadipogenic progenitors (FAPs), are necessary to stimulate MuSCs to begin muscle
regeneration. FAPs have been implicated as progenitors for ectopic fibrotic tissue, fat,
cartilage, and bone in muscle and other tissues (92, 93, 207). PDGFRα is generally
expressed by mesenchymal stem cells, pericytes, and other ‘stem’ cell types (208). To
date, PDGFRα is the most specific marker known of the FAP population (92, 209).
1.5.1 Embryonic Development of Muscle Progenitor Cells
Muscle stem cells are derived from the dermatomal germ layer of the developing
embryo. The primary myotome forms as a thin, single-cell layer beneath the epithelial
dermomyotome that spans the entire mediolateral axis of the somite (210, 211). At E5.0 in
the mouse, the primary myotome is fully formed and the secondary myotome begins to
form deeper into the other layers of the embryo, and primary and secondary myotome
fibers become incorporated into multinucleated myotubes at E11.5 in the mouse embryo
(212)

. The transcription factor Pax7 not required for the specification of MuSCs during
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development, but is a main and specific marker of MuSCs in adult skeletal muscle, with
Pax7 null mice drastically lacking MuSCs (88, 213-215). Another transcription factor of the
Pax family, Pax3, is expressed first in the presomitic mesoderm, then the
dermomyotome. Interestingly, ablation studies demonstrate that Pax3 expression is
necessary for the appearance of Pax7+ cells (216). Pax3 has also been shown to be
necessary for migration of MuSCs from the dermomyotome to the limb buds at E9-9.5
(216)

.
Pax7+/MyoD+/Myf5+/Mrf4+ stem cells begin to emerge during the perinatal stage

of skeletal muscle development (~E16.5) within the basal lamina of newly formed muscle
fibers. About 12 days after birth until about two weeks, Pax7+/Mfy5-low quiescent
MuSCs appear, suggesting that Myf5 is the earliest marker of terminal myogenic
differentiation (Fig. 1.11) (214, 217). Notch signaling is temporally regulated during
myogenic development; in early myogenic development, Notch is upregulated and
maintains Pax7+ expression in MuSCs (Pax7high). Once differentiation of these cells
begins, Notch and Pax7 (Pax7low) are downregulated by factors such as MyoD.
Prolonged Notch activation in Pax7+ cells maintains the stem cell pool by preventing
differentiation (218-220). BMP and WNT signaling have been implicated in affecting fetal
myogenic progenitor cell number. Overexpression of BMP4 resulted in increased MuSC
proliferation and decreased muscle differentiation. Inhibition of WNT or Notch signaling
decreases the amount of Pax7+ cells, and a drastic increase in muscle differentiation
that results in very small muscles (14). The number of adult MuSCs is established by
three weeks after birth, and after that, muscle growth occurs by hypertrophy of existing
myofibers (221).
Less is known about the developmental origin of FAPs, although there are data
based on platelet-derived growth factor receptor alpha (PDGFRα) expression that
suggests a neural crest origin. PDGFRα is the most specific marker for FAPs to date (92)
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and interestingly, PDGFRα may be critical for neural crest cell survival (222). PDGFRα
expression is first detected in the primitive endoderm and has been detected in the
developing limb buds at mouse E9.5, suggesting a role in embryonic limb development
. PDGFRα is also expressed in other organs such as kidney, adrenal glands, thymus,

(222)

diaphragm, and lungs (222). Expression in the heart and blood vessels is seen later in
development (~E10.5), and in the central nervous system by E14.5 (222). PDGFRα-/- mice
die in utero (209, 222). Regardless of their origin, FAPs reside in the interstitial space of
adult skeletal muscle and are more frequently observed in the perimysium and the
perivascular space (209). FAPs were initially described as fibro/adipogenic progenitor cells
that are necessary for muscle regeneration by Joe et al. 2010 (92). Multiple sources have
demonstrated the ability of FAPs to form intramuscular fat and fibrogenic cells

(209, 223)

.

PDGFRα is subject to intronic polyadenylation and this process influences FAP
activation, indicating that polyadenylation site choice can either cause a fibrotic response
of FAPs or normal support of myogenesis through modulation of TGFβ signaling

(224)

.

Little is known about epigenetic regulation of FAP-specific genes, in part due to the
necessity for a more specific marker for true myogenic-resident fibro/adipogenic
progenitors.
1.5.2 Quiescence in Skeletal Muscle Progenitor Cells
Many types of stem cells exist in a quiescent state within their native tissues
before they are activated by some kind of stimulus (i.e. injury, disease, senescence of
the tissue, replenishment of the stem cell pool, etc.) (225-227), and are defined by a state of
reversible mitotic arrest (219). Muscle stem cells lie quiescent within the basal lamina of
skeletal muscle tissue until activated by injury (88, 205). Pax7 is the most common marker
of quiescence MuSCs and labels all muscle stem cells in the adult muscle (88, 205). The
first cell division occurs about 12-24 hours after the cells have been activated, with faster
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divisions following the initial one (228). Myostatin, BMP2, and BMP4, all members of the
TGFβ family, have been shown to suppress muscle stem cell activation (4, 229, 230). Notch
signaling is also a key player in the maintenance of quiescence. Since Notch signaling is
important for the maintenance of mature skeletal muscle, it is important to note that
when Notch signaling is inhibited, muscle stem cells begin to spontaneously
differentiate, bypassing the normal S-phase in the cell cycle, leading to depletion of the
stem cell pool (228, 231). Notch is also able to prevent premature differentiation by inhibiting
MyoD expression until MuSCs are ready for differentiation, which cannot be rescued by
Pax3/Myf5 expression (232). Thus, Notch is required for muscle stem cell quiescence.
It was previously thought that muscle stem cells were either active or quiescent.
However, quiescence is not as simple as “on” or “off”. In response to muscle damage,
MuSCs become activated and re-enter the cell cycle. After one or more rounds of
proliferation, the vast majority of MuSC-derived muscle progenitors (called myoblasts)
exit the cell cycle and enter a terminal G0 phase that leads to differentiation, followed by
fusion to existing damaged muscle fibers to repair them or one-another to generate new
muscle fibers. During this process, a small portion of myoblasts do not differentiate and
instead enters a reversible G0 phase of the cell cycle, effectively replenishing the pool of
quiescent MuSCs (233). Recent studies have shown that the activity of muscle stem cells
is more complicated than simply active or quiescent. Rodgers et al. demonstrated that
MuSCs can exist in a “Galert” stage, in where the cells are not fully active but are on
“alert” to begin proliferation and subsequent differentiation in the event of a skeletal
muscle injury. These “primed” stem cells showed faster entry into the cell cycle
compared to true quiescent cells (“G0” cells) (234). These data provide evidence that
MuSCs can exist as “primed” to undergo differentiation when needed and implicates a
role for mTORC1 in MuSCs’ exit out of quiescence.
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The quiescent skeletal muscle niche is a hypoxic environment which decreases
mitochondrial numbers and elevates the level of reactive-oxygen species (ROS). ROS
damages cell membranes and can induce apoptosis (235). Quiescent MuSCs survive in this
hostile environment by adopting a condensed heterochromatic state to protect their DNA
from damage

(236)

and avoid apoptosis

(235, 237)

. MuSC quiescence is complex in its

regulation and further studies need to be conducted to fully understand this state.
Little is known about whether or not FAPs are a population capable of true
cellular quiescence. During skeletal muscle regeneration, the FAP population does
increase in number in order to stimulate the onset of repair, with the population
subsequently undergoing apoptosis once regeneration is underway (92). However, this
does not mean FAPs are truly quiescent. They might play other roles within skeletal
muscle tissue outside of regeneration (discussed further in upcoming sections).
1.5.3 The Skeletal Muscle Progenitor Cell Niche
MuSCs reside in a specialized anatomical niche located between the plasma
membrane of the muscle fiber and the surrounding basal lamina

(238, 239)

. The niche is

defined by the complex set of molecules surrounding the MuSC in its anatomical location
and the receptors that are expressed on the MuSC surface

(205)

. MuSCs are relatively

plastic and their ability to proliferate, self-renew, and differentiate is dependent on the
rigidity/stiffness of their niche environment and molecular signaling between MuSCs and
their environment. During quiescence, the basal lamina mainly consists of members of the
collagen and laminin family, in particular in laminin containing α2, β1, and γ1 subunits and
collagen IV

(205, 238)

. Quiescent, non-activated MuSCs are attached to the basal lamina

through the apically localized membrane receptors α7β1 integrin and dystroglycan

(240)

.

Other ECM components include vitronectin, laminins, perlecan, decorin, nidogen,
biglycan, and collagen VI. Quiescent MuSCs also express the transmembrane
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proteoglycans syndecan-3 and -4, which carry extracellular heparan sulfate and
chondroitin sulfate chains allowing for binding of several growth factors such as fibroblast
growth factors (FGFs), hepatocyte growth factor (HGF), vascular endothelial growth factor
(VEGF), and transforming growth factor beta 1 (TGFβ1). The sialomucin CD34 is an
important cell surface marker for identifying MuSCs (Fig. 1.7) (241-243), but it also may be a
marker of MuSCs with the most regenerative capacity. Jankowski et al. showed that
MuSCs positive for CD34 had higher fusion rates of mononuclear cells into myotubes and
also displayed higher expression of the mature muscle marker myosin heavy chain
(MyHC) (244, 245).
As discussed in the previous section, active Notch signaling in MuSCs is a key
regulator of MuSCs quiescence. In addition, syndecans can serve as co-receptors for
integrins to promote cell quiescence. Ablation of syndecan-3 causes spontaneous MuSC
activation in adult muscles, while loss of syndecan-4 has no effect on the stem cell pool
(246)

. Syndecan-3 was shown to promote Notch processing and activation, and loss of

syndecan-3 leads to reduced MuSC population expansion, delayed differentiation, and
increased cell death (247). Along with syndecan-3, MuSCs limit the impact of growth factor
signals in their niche by other mechanisms. These include the attenuation of FGFmediated ERK signaling by the receptor tyrosine kinase inhibitor Sprouty 1, as well as the
expression of the insulin-like growth factor-2 (IGF2) inhibitor insulin-like growth factorbinding protein 6

(236)

. During their initial proliferative phase, MuSCs secrete fibronectin,

which stimulates WNT7a to initiate expansion of the stem cell pool; fibronectin expression
is then downregulated during differentiation (Fig. 1.8) (248). Collectively, these data indicate
that MuSCs intrinsically modulate their niche in preparation for muscle regeneration.
While MuSCs reside in the basal lamina of muscle tissue, FAPs reside in the
muscular interstitial space (92). FAPs secrete collagens (I, II, III, VI) to form a dense
network that encapsulates muscle resident cells during the beginning stages of muscle
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regeneration (95, 249-251). This demonstrates FAP ability to remodel the MuSC niche to
facilitate muscle regeneration. However, too much collagen deposition can lead to
fibrosis of the muscle tissue and aberrant cell fate decisions (discussed in upcoming
sections). Collectively, these data indicate that MuSCs intrinsically modulate their niche
in preparation for muscle regeneration (Fig. 1.8).
1.5.4 Fibrosis within Skeletal Muscle
The efficiency of MuSCs and FAPs to orchestrate regeneration of damaged
muscle tissue is decreased by a stiffer tissue environment, as well as by advanced age
of the tissue. In cases of fibrosis, both MuSCs and FAPs upregulate their expression of
fibrotic collagens (I,II,III) and other fibrillar genes (Pdgfa, Tnc, Postn, Ctgf, Thbs2/4), and
the total number of FAPs increases (223, 251). Furthermore, FAPs also downregulate
expression of basal lamina ECM proteins (such as Col IV/V, lamina) and increases
expression of genes involved in fibrillar ECM formation (Aspn, Tgfβ1, WNT16, Mstn) and
remodeling (Prss12, Serpinb1a/b8, Loxl1) (80, 85, 126, 251, 252), indicating that FAPs are a
main cell source of fibrotic-ECM in skeletal muscle. Fibrotic skeletal muscle tissue is
indicatively stiffer than healthy muscle tissue (253). Trensz et al. showed cytoskeletal
disorganization and degeneration of myofibers concomitantly with increased tissue
stiffness (253). MuSCs in the presence of Col1 substrate in vitro downregulated their
expression of growth factors, pro-myogenic cytokines (IL-6, TNFα), and myogenic
regulatory factors (MRFs), indicating impaired myogenic differentiation in a fibrotic
environment. Cells cultured on laminin did much better in all categories (254).
Correspondingly, MuSCs cultured on 12-kPa substrates are able to engraft in vivo
significantly better than those cultured on 2-, 42-, and 100kPa. MuSC ability to selfrenew and maintain quiescence is also impaired on stiffer substrates, demonstrated by
decreased cell proliferation and downregulated expression of Pax7 (90). These data
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signify that pliant substrates are able to prevent premature differentiation and promote
stemness of MuSCs, and that both MuSCs and FAPs function to modulate the muscle
tissue environment to promote myogenesis (Fig. 1.10).
1.5.5 Differentiation and Regeneration of Muscle Progenitor Cells
Muscle stem cells are found within the basal lamina underneath the ECM of
skeletal muscle fibers (95, 238, 239). In the case of healthy, uninjured tissue, the MuSC
population is fairly sparse, comprising only 1-6% of total muscle nuclei (255). The
regenerative potential of skeletal muscle is dependent on the function of MuSCs

(205, 256)

.

Pax7 is necessary for muscle regeneration following acute injury (88, 256). Muscle
regeneration is characterized by a carefully regulated set of events. MuSCs that
maintain a high expression of Pax7 protein retain template DNA strands, exhibit lower
metabolic activity, and express stem cell markers, while MuSCs exhibiting low Pax7
expression (Fig. 1.11) undergo random DNA segregation and are myogenically
committed during the regeneration process (257). Normally quiescent MuSCs are
activated within 1-2 days after injury, quickly followed by proliferation peaking at 3-4
days, and then differentiation and maturation of cells until muscle architecture is restored
(14-21 days after injury) (205, 258, 259). During normal muscle response to injury,
inflammatory cells mediate turnover of damaged tissue (260, 261), and FAPs are activated
to stimulate ECM, with de novo expression of alpha-smooth muscle actin (αSMA) (126, 223,
251, 262)

, and increase proliferation of MuSCs which then undergo myogenesis, fuse, and

reconstitute the muscle (92) (Fig. 1.10 & 1.11). Muscle stem cells can be isolated and
cultured in vitro to study specific myogenic properties, as further described in

(263, 264)

.

Muscle stem cells are a small, but potent population. Sambasivan et al. utilized Pax7DTR/+
mice to demonstrate that eliminating 80-90% of muscle stem cells could still result in
muscle fiber repair 3-4 weeks after injury (265), and even a single muscle cell is able to
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repair muscle (266, 267). Both MyoD and Myf5 are part of the myogenic regulator factor
(MRF) family of transcription factors

(268)

and possess defined specific roles in MuSC

biology. MyoD is a regulator of myoblast differentiation potential, whereas Myf5 enables
transient myoblast amplification. Activated MuSCs first express either Myf5 alone or
MyoD alone, before co-expressing Myf5 and MyoD, and subsequently progressing
through the myogenic program (228). Taken together, these data implicate MyoD and
Myf5 as key regulators of muscle stem cell quiescence and proliferation.
Myogenin (Myog), a member of the MyoD/Myf5 MRF family, is another, if slightly
less important, regulator of myogenesis. Myogenin can be directly activated by Myf5,
while MyoD depends on Pax3/7 expression (269). Myog-/- MuSCs proliferate and
differentiate similar to wild-type in vitro but causes differential expression of genes
involved in cartilage homeostasis, cell metabolism, and inflammation

(270)

. Some studies

suggest that fast twitch muscle fibers express more MyoD and slow twitch fibers express
more Myogenin (271, 272), while others suggest fiber-type conversion is more complicated
. It is confirmed that Myog-/- mice show greater endurance during cardio exercise,

(273, 274)

and better efficiency in glycolytic metabolism during high-energy exercise and oxidative
metabolism during low-intensity exercise (275). This better performance comes at the
expense of impaired muscle growth and repair (276). Myogenin, along with IGF-1, also
regulate muscle hypertrophy and size (277, 278). Together these data indicate the
importance of Myogenin in maintaining the balance between muscle size and metabolic
function.
The final stage of muscle regeneration involves fusion of myoblasts to form
multinucleated myofibers (Fig. 1.9 & 1.11). Fusion is mediated by the muscle-specific
plasma membrane protein Myomaker, with its requirement at the step of membrane
fusion of individual myoblasts (279). An additional muscle-specific factor Myomerger is
also required for myoblast fusion, although its mechanism is not fully understood (280).
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Adhesion proteins like integrin-α3/β1, ADAM12, M-cadherin, and VCAM-1 (Fig. 1.7) are
also involved in fusion and are upregulated during the terminal stages of regeneration
(281)

.

1.5.5.1 Immune Cell Involvement in Muscle Repair
Within minutes of injury to skeletal muscle, innate immune cells are recruited to
the site of injury and begin the process of degrading the damaged tissue (Fig. 1.9).
Macrophages play the largest role in this process, but other innate immune cells are also
heavily involved

(260)

. Concomitant with neutrophils, M1 macrophages arrive first at the

injury site ~1 day after injury and secrete pro-inflammatory cytokines such as interferon-γ
(IFNγ) and TNFα and remove necrotic tissue

(260)

. Subsequent to phagocytosis of the

damaged tissue, M1 macrophages are replaced by a population of M2 macrophages, ~4
days after injury, that can attenuate the inflammatory response and promote tissue repair.
M2 macrophages are activated by anti-inflammatory Th2 cytokines interleukin-4 (IL-4), IL10, and IL-13

(260, 282)

. FAPs have been established as a possible source of STAT3-

inducing IL-6 during muscle repair

(92)

, implicating FAP necessity early in muscle

regeneration (Fig. 1.9). IL-4 is also required for activation of FAPs after muscle injury and
may act as a phagocytic cell type in the early stages of regeneration

(283)

. See following

section on FAPs in muscle regeneration for more information.
1.5.5.2 Asymmetric Division and Self-Renewal of Muscle Stem Cells
There are two schools of thought for how the stem cell pool is normally replenished
during MuSC division and differentiation: the “stochastic model” and asymmetric division.
The “stochastic model” says that when MuSCs divide, there is a short period of
proliferation and then some cells return to their quiescent state, while the others
differentiate (discussed in

(205)

). Asymmetric division is more widely supported and posits

that when MuSCs divide in response to injury, a small portion of MuSCs never lose
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expression of their stem cell marker Pax7 and become quiescent again within the niche
to replenish the stem cell pool, while most of the stem cells go on to express markers such
as MyoD/Myf5, differentiate, and fuse to form myofibers

(234)

. Inactive Notch is expressed

in quiescent MuSCs and then is cleaved and becomes active upon injury to the tissue.
The Notch antagonist Numb is expressed at one pole of a dividing MuSC so that only one
daughter cell will inherit Numb. Notch is then able to upregulate the expression of Pax7 in
the Numb-less cell to promote MuSC stemness

(284)

. These data support the asymmetric

division model as Notch will be activated in some cells and suppressed in others, allowing
some cells to remain quiescent and others to begin the process of muscle repair. Overall,
the majority of evidence in the literature supports the model of asymmetric division and its
importance for skeletal muscle repair and maintenance of the stem cell pool. MuSCs
represent a rare population and can be isolated from skeletal muscles using fluorescenceactivated sorting methods (FACS) based on cell surface markers (242). MuSCs isolated via
FACS have demonstrated that MuSCs are a heterogeneous population and only a small
proportion of isolated cells are true stem cells able to self-renew (205). Further identification
and characterization of the different MuSCs subpopulations will be important to evaluate
their exact behavior and design more accurate stem cell therapies during regeneration.
1.5.5.3 WNT Signaling in Muscle Regeneration
WNT (Wingless-type MMTV (mouse mammary tumor virus) integration site)
signaling is an important regulator of many adult stem cells

(285)

and has been proposed

to be critical for MuSCs and muscle regeneration (286). WNTs are secreted glycoproteins
that function as ligands, and β-catenin is the central mediator of canonical WNT
signaling. In the absence of WNTs, β-catenin is phosphorylated and targeted for
degradation. The binding of WNTs to their receptors leads to the formation of stabilized,
unphosphorylated β-catenin that translocates to the nucleus, where it binds to TCF/LEF
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proteins and activates transcription of WNT-responsive genes (285, 287). Non-canonical
WNT signaling is β-catenin-independent and involves several other signaling pathways
such as planar cell polarity (PCP), JNK, Akt/mTOR, and RhoA signaling

(288)

. Many

studies have identified WNT pathway components as being active during muscle
regeneration (289-292). Canonical WNT signaling is low during the initial stages of
myogenic differentiation, and then is most active, particularly WNT1 and WNT3 in
crosstalk with Notch, during the terminal stages to promote myogenic fusion. Inhibition of
WNT the proliferation phase has little effect on repair, but terminal differentiation is
stunted (289, 293). When β-catenin was deleted in MuSCs, regeneration still occurred, but
nascent fibers had larger cross-sectional areas and were shorter, indicating premature
myofibers differentiation (294). Constitutive activation of β-catenin does not largely affect
muscle stem cell differentiation but does appear to prolong the myoblast phase (292, 294).
β-catenin is also regulated partially by WNT ligands, Axin1 and Axin2. Axin1 is
ubiquitously expressed, while Axin2 is expressed only in specific tissues at specific
developmental stages and promotes β-catenin degradation. Axin1 is expressed during
proliferation of MuSCs, while Axin2 is activated during myogenic differentiation (295).
Taken together, these data suggest that canonical WNT/β-catenin signaling requires
temporal regulation in order for proper myogenic differentiation to proceed.
1.5.5.4 BMP Signaling in Muscle Regeneration
BMPs (bone morphogenetic proteins) are a highly conserved family of
extracellular signaling proteins that regulate cell fate decisions and have crucial roles in
both embryonic developmental and post-natal life (3-5). BMP signaling has been shown to
promote proliferation of MuSCs and repress their differentiation (15, 296-303). Injection of an
AAV-Nog (adeno-associated virus against the endogenous BMP antagonist Noggin)
caused a decrease in MuSC proliferation in vitro (230) by maintaining expression of Pax7
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, and a Noggin -/- mouse demonstrated a loss of Pax7+ cells (304). Similarly, delivery of

(15)

recombinant BMP4 to individual myofibers in vitro diminished the number of MuSCs with
the differentiating Pax7-MyoD+ genotype, and was rescued by the administration of
Noggin (300). Shi et al. also demonstrated that BMP signaling is downregulated during
terminal myogenesis, with a decrease of phosphorylation of Smad1/5/8 and subsequent
endogenous BMP4 expression, while showing that the BMP inhibitors Noggin and LDN
were able to induce myogenesis (299, 305). BMP2 has been shown to inhibit terminal
differentiation of myogenic cells by suppressing the transcriptional activity of MyoD and
Myogenin (303). It’s postulated that this feature of downregulation of BMP signaling
functions to prevent immature myogenic differentiation (300, 306), with the BMP ligands
being secreted from the MuSCs themselves or the macrophages involved in the injury
healing process (300). BMP pathway signaling assayed through pSmad1/5/8 levels was
shown to correspond with Myogenin levels, indicating a critical level of pSmad1/5/8 to
inhibit myogenic differentiation (8, 306). Inhibitor of differentiation 1 (Id1) is a BMP target
gene that is part of the Id family of proteins (1, 2, 3, and 4) that control the growth and
differentiation of different cell types (307-309). Expression of Id1 is increased upon muscle
injury (310) and Id1 expression has been detected in the nuclei of Pax7+ cells (311). Id1
mutant mice showed a reduced number of proliferating Pax7+ myoblasts after injury,
suggesting a role for Id1/BMP in positively regulating muscle stem cell proliferation. After
initial proliferation of muscle stem cells, once differentiation begins, Id1 expression is
downregulated, and MyoD and Myogenin are expressed (309, 311). Another BMP target
gene, Msx1 (from the muscle segment homeobox gene family), was shown to prevent
cellular differentiation of muscle stem cells by blocking cell cycle exit and inhibiting Pax3
expression in limb bud cultures (312). Thus, the temporal signaling of BMP is necessary
for proper myogenesis and muscle repair. See the Disease section for discussion on
when BMP and other signaling pathways go awry in skeletal muscle.
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1.5.5.5 FAPs in Muscle Regeneration
In normal healing, FAPs (marked by CD45-CD31-α7-integrin-Pdgfrα+Sca1+) are in
close association with regenerating muscle fibers and support myogenesis

(95, 207, 313-315)

.

These cells, considered mesenchymal progenitors based on their ability to differentiate
to adipocytes and osteoblasts, are a source of pro-myogenic signals that support muscle
regeneration (92, 262, 313, 316). FAPs are not inherently myogenic but are necessary in vivo
for muscle stem cell activation and proper skeletal muscle regeneration (92, 294, 314, 317).
Soon after the onset of skeletal muscle injury, the FAP population increases drastically
in number compared to muscle stem cells, with numbers peaking at 48-72 hours after
injury; their numbers return to pre-injury levels 96-120 hours after injury (92). Sometimes
referred to as myofibroblasts, FAPs also produce collagens, alpha-smooth muscle actin
(αSMA), and chondroitin sulfate proteoglycan (CSPG4, for stress fiber formation) to
prepare the niche for regeneration (80, 85, 126, 223, 251, 258, 262, 318). FAPs are found in the
interstitial space of muscle close to blood vessels and damaged and regenerating
myofibers (Fig. 1.8), supporting their role in modulating myogenesis, but FAPs do not
fuse with differentiating myofibers (92, 209). In co-cultures of FAPs and MuSCs, increasing
numbers of FAPs corresponded with higher MuSC expression of late muscle markers
Myogenin, Mrf4, and MyHC, and a reduction of Pax3/Pax7 expression, suggesting that
FAPs stimulate myogenic differentiation (92). While little is known about any pro-myogenic
signals that FAPs may secrete to facilitate stimulation of MuSCs during skeletal muscle
regeneration (Fig. 1.10), the anti-inflammatory myokines IL-6 and IL-10 (through
STAT3), TNF-α and TGFβ have be submitted as possible candidates (92, 313, 316, 319, 320).
Future work is aimed at identifying pro-myogenic signals secreted by FAPs to more
directly stimulate MuSCs in vivo.
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The early activation of FAPs after injury has been tied to the immune response.
Heredia et al. demonstrated that IL-4 is required for proper FAP activation and
stimulates FAP clearance of damaged muscle tissue shortly after injury. In the absence
of IL-4, FAPs failed to clear the muscular debris and instead formed adipogenic deposits
within injured muscle tissue (Fig. 1.10) (283). Reduction of IL-4, produced by eosinophils,
has also been shown to contribute to adipocyte fate decision in FAPs, demonstrating the
importance of IL-4 in FAP function (321). Furthermore, FAPs were shown to perform ~4
fold more efficiently at phagocytosing necrotic thymocytes and were found near necrotic
muscle fibers in vivo, indicating macrophage-like properties of FAPs that confer an
additional role in muscle regeneration (283), a unique function of FAPs that requires
further study. The recruitment of IgM and C3 complement necessary for clearance of
dead cells by phagocytosis also has been shown to be deficient in Sca1-/- mice, leading
to poor muscle repair in these mice and further implicating FAPs in the immune
response during muscle repair (322). Thus, FAP function in myogenic differentiation is
heavily tied to the immune system.
FAPs have been investigated as potential sources for fatty deposits within
muscle tissue occurs with fibrosis and muscular dystrophy (95, 209, 315, 323). Arrighi et al.
showed that FAPs can act similarly to white adipocytes, with expression of the
adipogenic genes PPARγ and C/EBPα and a lipid droplet phenotype; however, they do
not facilitate glucose uptake or express the beige/brown fat marker UCP1, indicating a
distinct role for their adipogenic ability within skeletal muscle tissue (209, 313). Evidence
suggests that muscle fibers are able to inhibit adipogenesis of FAPs by directly
interacting with them in vitro (315), although the mechanism behind this is unknown.
Uezumi et al. demonstrated that PDGFRα+ FAPs are able to differentiate into
extracellular matrix-producing cells, including several different collagen isoforms,
fibronectin, and α-smooth muscle actin (α-SMA) (95). α-SMA and increased ColI/II/III
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deposition is indicative of fibrosis (80, 85, 126, 223), supporting that FAPs can contribute to
fibrosis within skeletal muscle tissue in a disease setting (Fig. 1.10). Osteogenic
differentiation of FAPs has also been demonstrated in vitro (241) and in vivo (93). The
potential for adipogenic and osteogenic differentiation proposes FAPs as a skeletal
muscle resident mesenchymal stem cell population. See the Disease section for more
discussion on alternative cell fate ability of FAPs. Methods for isolating and culturing
FAPs can be found in Perdiguero and Cornelison 2017 (241).

1.5.6 Muscle Progenitor Cell Populations Implication in Disease

1.5.6.1 Ageing
MuSCs and FAPs are affected by tissue stiffness, disease states, and the
unavoidable condition of age. The total number of muscle stem cells declines with age,
along with functional capacity and strength of the tissue (324). The most important
difference between young and old MuSCs is their ability to engraft and repair muscle
tissue. Transplanting MuSCs from “old” mice (24 months) into injured muscles of “young”
(2months) mice showed that the “aged” MuSCs did not substantially contribute to the
muscle tissue during regeneration, with an estimated loss of two-thirds of the functional
capacity of MuSCs from aged mice compared to their young counterparts

(259)

. Aged

tissue sets up a negative feedback loop wherein the niche is depleted of extracellular
matrix (ECM) proteins, which causes MuSCs to become depleted, further reducing
secreted ECM proteins and altering the niche (325). Increased levels of FGF signaling
from the aged niche stimulate MuSCs to exit quiescence, eventually depleting MuSC
numbers (325). Quiescence is also affected by age. Aged MuSCs express higher levels of
MyoD and have an increased ability for myogenic differentiation both in vitro and in vivo
(237)

, suggesting that the maintenance of quiescence declines with age and leads to
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immature myogenic differentiation and poor regeneration with deficient myofibers. Age
has also been shown to have an effect on the function of FAPs. FAPs from aged mdx
mice inhibited muscle stem cell differentiation, while FAPs from young mdx mice could
support MuSC differentiation (326). Collectively, these data show that the functions of
MuSCs and FAPs are dramatically declined in muscular dystrophies, and this is
amplified by increased age of the muscle tissue.
1.5.6.2 Muscular Dystrophies
Muscular dystrophies are characterized by persistent fibrosis and replacement of
muscle tissue with scar tissue and fatty deposits. There are nine categories of muscular
dystrophies, with Duchenne Muscular Dystrophy (DMD) being the most pervasive. DMD
is an X-linked disorder that affects 1 in 5000 live male births and is caused by significant
deletion of the dystrophin gene. Dystrophin is a cytoplasmic protein that links the
cytoskeleton of muscle fibers to the extracellular matrix of the overall muscle tissue. The
complete or partial loss of dystrophin in muscular dystrophies impairs the ability of the
muscle to contract and causes the muscle to breakdown. This acts as a constant injury to
the muscle that depletes the MuSC pool
dysfunction of MuSCs

(327)

, presumably due to an autonomous

(240)

. Age further negatively affects MuSCs in the mdx mouse, with

muscle stem cell functionality diminished in old mdx mice and more severe disease
pathology (327).
Interestingly, it was shown that inflammatory cells directly regulate the survival of
FAPs through the expression of TNFα, thus controlling the generation of differentiated
fibrogenic cells. Pharmacological intervention with anti-fibrotic effects could be beneficial
to inhibit FAP-associated development of fibrosis in mdx mice by restoring FAP apoptosis
(328)

. Research focused on therapies for treating muscular dystrophies is an ever-

expanding pursuit within the skeletal muscle field.
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1.5.6.3 Other Diseases
Although muscular dystrophies are the most well-known diseases involving
MuSCs and FAPs, perturbation of these cells have been implicated in other genetic and
non-genetic diseases. Profound muscle wasting or cachexia, has been implicated in
certain cancers (329-331). Mice with pancreatic cancer demonstrate chronic Pax7
expression and MyoD inhibition due to activation of the transcription factor nuclear factor
kappa-light-chain-enhancer of activated B cell (NF-kB) signaling. Persistent Pax7
expression prevents muscle stem cell differentiation and prohibits muscle growth and
maximum force generated during muscle contraction (330, 332). Chronic NF-kB signaling
also allows cancer cells to evade macrophage phagocytic activity during the early
inflammation stages of muscle repair, thus contributing to the spread of cancer (333).
Amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder affecting upper and
lower extremity motoneurons, is caused by mutations in the superoxide dismutase 1
gene (SOD1) in some individuals (334). FAPs have been implicated in this disease as the
cells responsible for elevated fibrosis in skeletal muscle leading to degeneration of
motoneurons as seen in mice carrying a mutation in SOD1 (335). In the context of FOP,
Lees-Shepard et al. demonstrated FAPs as the main causative cell type for the
development of heterotopic endochondral bone within skeletal muscle (93).
In summary, MuSCs and FAPs are indispensable for muscle development and
regeneration after injury and are complexly regulated by many signaling pathways (Fig.
1.11). Age and disease negatively affect these populations and can be exacerbated by
dysfunction of these cells. Studies are needed to broaden our understanding of skeletal
muscle resident FAPs during muscle homeostasis and regeneration, especially their role
in activation of muscle stem cells. This knowledge will lead to understanding their role
during the development of disease and will be useful for designing further intervention.
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1.6 Project Summary
FOP is a rare genetic disease (OMIM: 135100), which often do not have an
identified genetic cause (336), so it is remarkable that the FOP causative mutation(s) are
known. We have previously shown that chondrogenesis is accelerated in
FOP/Acvr1R206H/+ cells (60), and that the inflammatory response is prolonged in FOP
tissues following injury (79). Our studies have driven drug discovery efforts, such that now
there is a clinical trial ongoing with the RARγ agonist Palovarotene (59). While there is a
fair amount known about FOP, there is still a lot we don’t understand. For example, why
there is one main casual mutation, yet patients demonstrate a wide range of symptom
severity (47). This is an ongoing line of inquiry in the lab.
A fundamental question is the mechanism by which cells within skeletal muscle
tissue are actually drawn down a chondro/osteogenic path. As described earlier
(Chapter 1.4), cellular sensing of environment (mechanotransduction) heavily influences
cellular identity (111, 119). We determined that HO progression driven by the FOP
ACVR1R206H mutation is influenced by disrupted mechanotransduction (73). However, the
molecular signaling involved in mis-regulation of mechanotransduction in FOP was
undetermined. In Chapter Three, we demonstrate that increased mechanical signaling
through YAP/TAZ and RhoA/ROCK combine with increased BMP pathway signaling
through ACVR1 to increase cellular contractility and push cells down a
chondro/osteogenic lineage pathway, contributing to the progression of disease in FOP.
Another unexplored question in FOP is what is the impact of the ACVR1R206H
mutation on skeletal muscle regeneration. The direct impact on the ability of progenitor
cells to functionally repair muscle has never before been investigated. The regeneration
process following cardiotoxin (CTX) injury in Acvr1+/+ mouse skeletal muscle tissue
results in the formation of small, centri-nucleated myofibers 7-10-days post-injury.
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However, in Acvr1R206H/+ muscle tissue we find persistence of damaged myofibers at
later time points and subsequent formation of HO (Fig. 1.4). The mechanism behind this
persistent damage of tissue was not well understood. We established that differentiation
of the myogenic progenitor muscle stem cells (MuSCs) is hindered under the influence
of the FOP mutation, and that arbiters of myogenesis, fibro/adipogenic progenitor cells
(FAPs), can also hinder the maturity of muscle regeneration in Acvr1R206H/+ tissue. FAPs
also have osteogenic potential and may contribute directly to the development of HO
(Chapter Four).
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Figure 1.1 BMP and TGFβ signaling pathways.
BMP and TGFβ receptor activation of canonical (Smad-dependent) and non-canonical (Smadindependent) signaling cascades. Modulation of signaling by intracellular antagonists is included.
Inset depicts model of important regions in the type 1 BMP receptor structure. Abbreviation: ECD,
extracellular domain; TMD, transmembrane domain; LBD, ligand binding domain. Asterix denotes
location of FOP ACVR1R206H mutation.
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Figure 1.2 Multipotent lineages of mesenchymal stem (progenitor) cells (MSCs).
Schematic of the multiple lineages that can be taken by MSCs, depending on tissue
microenvironment, extracellular matrix (ECM), endogenous ligands, etc. Intermediate progenitors
are denoted in the commitment stage, with the fully mature cell types below in the maturation
stage. The individual steps from MSC to mature cell type vary in number/complexity depending
on cell type.
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Figure 1.3 Clinical diagnostic features of FOP.
A) Three-dimensional reconstructed CT scan demonstrating the extensive progressive HEO
observed in FOP. B) Radiograph showing the typical hallux valgus. Figure panels taken from
Shore EM and Kaplan FS. Nat Rev Rheumatol. 2010 (49).
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Figure 1.4 Schematic of improper muscle regeneration in FOP.
Wound healing begins with inflammation and invasion of immune cells to injury site, followed by
degradation of the muscle and a fibroproliferative intermediate. In Acvr1R206H/+, wound healing
diverges from the normal progression at this stage and ectopic cartilage and bone are eventually
formed within the injury site. Schematic based on Stanley AK, Shore EM, and Mourkioti F.
Encyclopedia of Tissue Engineering and Regenerative Medicine. 2019 (337). Bottom images
adapted from Chakkalakal SA et al. J Bone Miner Res. 2016 (59).
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Figure 1.5 YAP/TAZ and Rho/ROCK signaling.
Activation of Rho and YAP/TAZ signaling through mechano-receptors and GPCRs. Genetic and
mechanical outputs of YAP/TAZ protein localization indicated.

43

Figure 1.6 Rho/ROCK signaling regulates cell contractility.
Mechanism of stress fiber and focal adhesion formation. Mechanical effector Rho is activated by
ECM forces, which stimulate the formation of focal adhesion complexes and polymerization of
actin to form stress fibers. Transmembrane integrin receptors heterodimerize, while various focal
adhesion proteins (simplified in this schematic) complex to form focal adhesion complexes.
Paxillin, a member of the focal adhesion protein family, functions to connect actin filaments to
form actin stress fibers and increase cellular contractility.
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Figure 1.7 Cell surface markers and muscle transcriptional regulators in MuSCs.
Numerous proteins are expressed on MuSCs and are used as markers to distinguish between
surrounding cell types within skeletal muscle. Due to heterogeneity in the MuSC population, it’s
unlikely that all of these markers are expressed on a single MuSC at the same time. However,
this schematic summarizes the cellular location of markers used to identify MuSCs. From Stanley
AK, Shore EM, and Mourkioti F. Encyclopedia of Tissue Engineering and Regenerative Medicine.
2019 (337).
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Figure 1.8 Characteristics of the MuSC and FAP niche.
Schematic of the MuSC and FAP niche. MuSCs reside between the basal lamina and the muscle
fiber sarcolemma where they interact with components of the extracellular matrix of the niche.
MuSCs bind to collagen IV and laminin. They in turn bind to collagen VI and several
proteoglycans including perlecan and decorin. Collagen type VI integrates the basal lamina with
the interstitial extracellular matrix composed primarily of collagen types I and III and fibronectin,
which is secreted by FAPs and myofibroblasts.
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Figure 1.9 Progression of skeletal muscle regeneration after injury.
A) Before injury, MuSCs lie quiescent within basal lamina of muscle fibers, while FAPs inhabit the
interstitial space. B) Upon injury, macrophages are recruited to the site of injury and produce
inflammatory cytokines and damaged tissue is removed. C) FAPs and myofibroblasts secrete
collagen. D) FAPs stimulate MuSCs to proliferate. E) Committed MuSCs form myoblasts and
FAPs undergo apoptosis. F) Myocytes fuse and form multinucleated myofibers. Thus, mature
skeletal muscle regeneration is complete. From Stanley AK, Shore EM, and Mourkioti F.
Encyclopedia of Tissue Engineering and Regenerative Medicine. 2019 (337).

47

Figure 1.10 Relationship between MuSCs and FAPs.
FAPs may stimulate myogenic differentiation in MuSCs by secreting IL-6, IL-10, TNFα, or TGFβ.
In the presence of anti-inflammatory cytokines, both cell types are able to proliferate and MuSCs
eventually undergo myogenic differentiation. In the presence of prolonged inflammatory cytokines
and/or other disease settings, increased matrix deposition by MuSCs/FAPs leads to fibrosis and
FAPs undergo adipogenic differentiation to form intra-muscular fatty deposits, further weakening
muscular structural integrity.
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Figure 1.11 Summary of stages of myogenic differentiation and the signaling pathways
involved.
During quiescence, Pax3/7 are the primary markers of muscle stem cells. After activation due to
injury or growth, MuSCs cells still initially express these markers but at lower levels and begin to
express Myf5. Asymmetric division causes some cells to become committed to the myogenic
lineage and others to self-renew beck into a quiescent state. Quiescent MuSCs decrease with
age. During the proliferative stage, committed myoblasts lose expression of Pax3/7 and begin to
express MyoD, thus designating them as myoblasts. During this stage, BMP, Notch, and growth
factor signaling is prominently active, and WNT signaling is suppressed. In early myogenic
development, Notch is upregulated and maintains Pax7+ expression in MuSCs (Pax7high). Once
differentiation of these cells begins, Notch and Pax7 (Pax7low) are downregulated by factors such
as MyoD. M1 macrophages work to phagocytose damaged tissue and release pro-inflammatory
cytokines. Proliferation is also lessened with age. After a period of proliferation and migration out
of the niche, myoblasts, now called myocytes, express Myogenin, and WNT signaling is activated
to promote fusion. Myonuclei fuse to form myotubes and finalize repair/growth of the muscle. M2
macrophages secrete anti-inflammatory cytokines and inhibit myoblast migration to promote the
beginnings of fusion. The differentiation is severely impaired in many disease settings, as well as
age. Up arrows indicate signaling pathways/cell types that stimulate the phase of muscle
regeneration indicated, and down arrows indicate signaling pathways/cell types/diseases that
antagonize the indicated of muscle regeneration. Modified from Stanley AK, Shore EM, and
Mourkioti F. Encyclopedia of Tissue Engineering and Regenerative Medicine. 2019 (337).
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Chapter Two:
Materials and Methods
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2.1 Study Animals
We the conditional-on knock-in mouse Acvr1[R206H]FlEx was used to generate doxycyclineinducible global allele expression Acvr1[R206H]FlEx/+;Gt(ROSA)26Sortm1(rtTA*M2)Jae;Tg(tetOCre)1Jaw mice (which we refer to as Acvr1R206H/+), as described (59, 101). Acvr1+/+ controls
were littermates that did not contain an Acvr1R206H allele. To induce recombination and
global expression of the mutant allele, 4-week-old mice were provided a doxycycline diet
chow (625mg/kg, Envigo RMS Inc., TD 01306) for at least three consecutive days. Crerecombination was verified by PCR. Littermate Acvr1+/+ controls were also treated with
doxycycline chow.
For ubiquitous GFP animals, the C57BL/6-Tg(CAG-EGFP)131Osb/LeySopJ
mouse (which we refer to as Ubiquitous GFP) was obtained from Jackson
labs and bred with Acvr1[R206H]FlEx/+;Gt(ROSA)26Sortm1(rtTA*M2)Jae;Tg(tetOCre)1Jaw mice. Ubiquitous GFP mice were also bred together to maintain the
line. All procedures were reviewed and approved by the Institutional Animal Care and
Use Committee at University of Pennsylvania.

2.2 PCR Genotyping of embryos and mice
2.2.1 Genomic DNA extraction
A portion of individual embryo heads or tail snips from 3-week-old weaned mice was
digested at 95°C in lysis buffer with the KAPA Express Extraction kit (KAPA Bioscience).
The concentration of collected DNA was determined using the absorbance ratio
(260/280) quantified by a NanoDrop spectrophotometer (Thermo Fisher Scientific).
2.2.2 Preparation of PCR reaction
PCR amplification was performed in a reaction containing 50ng genomic DNA template,
20μM each forward and reverse primer [Sigma], 1x buffer, and 0.5x KAPA Extraction kit
polymerase in a total volume of 20μl (brought to volume with water) as directed by KAPA
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Express Extraction kit (KAPA Bioscience). Primer sequences and reaction protocols are
listed in Tables 2.1-2.5.

2.3 Isolation and cultures of MEFs
2.3.1 Isolation
Mouse embryos (E13.5) with head and viscera removed were minced with scissors in
50ml conical tube and digested with 2.5ml 0.25% Trypsin-EDTA (Gibco) for 30 minutes,
mixing every 10 minutes. Cell suspension was diluted with 8.5ml growth media (high
glucose DMEM (Gibco); 10% FBS (Gibco); 1% antibiotic-antimycotic (Gibco)) and total
diluted cell suspension from one embryo was seeded per 10cm plate after thorough
mixing by pipet. Plates were incubated at 37°C with 5% CO2. Non-adherent cells were
discarded after 24 hours. Genotypes of MEFs and presence of the ACVR1R206H mutation
were confirmed by PCR (primers in Table 2.1). Acvr1+/+ controls were littermates that did
not contain an Acvr1R206H allele.
2.3.2 Cell Culture
MEFs were always passaged at 1:5 ratio upon 100% confluence and expanded in
growth media (DMEM supplemented with 10% FBS and 1% antibiotic-antimyotic).
Frozen stocks were generated by freezing one 28 confluent 10cm plate of cells per vial
in 1.0ml freezing media (95% FBS; 5% DMSO (Sigma)) and stored in liquid nitrogen.
MEFs were frozen after the first passage such that 5 vials per original embryo were
obtained. Thawed vials of MEFs were expanded 1:5 in growth media and not used
beyond passage 6 for experiments.

2.4 Biomechanical Methods
2.4.1 Preparation of polyacrylamide (PA)-hydrogels
Stiffness of native tissues were mimicked using an adjustable polyacrylamide (PA)
hydrogel system. PA hydrogels were prepared as described (73, 338). Elastic moduli of the
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gels were verified through AFM force spectroscopy (339). Fibronectin (20 mg/mL, Sigma
Aldrich, catalog F1141) coating of gel surfaces was accomplished after treatment with 2
mg/mL sulfo-SANPAH (No. 22589; Pierce Protein Biology/Life Technologies, Rockford,
IL) as previously described in (338).
2.4.2 Cell Culture on PA Hydrogels
Subconfluent MEFs were seeded onto freshly prepared PA-hydrogels (described above)
at 5x103 cells/cm2. Cells were cultured in Dulbecco’s modified Eagle’s medium, high
glucose (DMEM, Gibco, catalog 11885-084) containing 10% fetal calf serum (FCS,
Gibco, catalog 10438034) before being placed on PA gels and then in DMEM/1%FCS in
basal media experiments on PA gels. After 18 hours, cells on hydrogels were fixed in 4%
paraformaldehyde/PBS (Thermo Fisher Scientific, catalog J19943-K2). Bipotential
adipogenic/osteogenic media was generated by mixing (1:1) adipogenic and osteogenic
media (see sections 2.8.6.1 and 2.8.6.2; without addition of BMP ligand), based on the
method described previously (340) for 72 hours on PA gels and harvested for qRT-PCR
analysis.
2.4.3 Rho activity assay
Cells were cultured to confluence in 15-cm plates to obtain sufficient protein amounts for
active Rho pull down. Cell lysis and pull down of active Rho used 550 µg of total protein
following manufacturer’s instructions (Active Rho Pull-Down and Detection Kit; Thermo
Scientific; catalogue 16116). Proteins were electrophoresed through 10% Tris–glycine
gels (Invitrogen), transferred onto nitrocellulose membranes (Invitrogen) and detected
with anti-Rho antibody. Additional blots for total Rho and β-actin were run for all samples
as loading controls. For validation by ELISA, the G-LISA kit from Cytoskeleton Inc was
used (RhoA activation assay biochemistry kit, catalog BK124; Total RhoA ELISA
biochemistry kit, catalog BK150). The absorbance values (600nm for activated RhoA,
490nm for total Rho) as quantified by a Synergy microplate reader (BioTek).
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2.4.4 Analysis of tissue and cellular stiffness using atomic force microscopy
Mouse quadriceps muscles were injected with 100 µl CTX solution (10 µM in phosphatebuffered saline (PBS); Calbiochem). Muscle injury by CTX injection is a standard
experimental approach in muscle regeneration studies (341-344). PBS injection in
Acvr1R206H/+ and Acvr1+/+ littermates served as controls. This approach for injury induction
of HO has been well characterized (59, 79), with heterotopic bone forming at 10–14 days
and robust fibroproliferation at 4–5 days. Animals were killed at the fibroproliferative
stage to isolate lesion tissue and surrounding skeletal muscle. Tissues were embedded
in optimal cutting temperature media (OCT; CryoPrep; American MasterTech Scientific)
and serially sectioned at 20-µm thickness for AFM analysis or 10 µm for histology and
immunohistochemistry. Tissue and nuclear stiffness were measured via
nanoindentation using an atomic force microscope equipped for simultaneous optical
imaging (Agilent ILM 6000 mounted on a Nikon inverted microscope)

(345-347)

. For tissue

analysis, unfixed 20-µm cryosections were hydrated and probed using cantilevers with 1µm spherical tips and a nominal spring constant of a 0.6 N/m (Novascan). For each
location measured, four force curves were collected over a 15 µm × 15 µm region that
was visually identified as healthy muscle, degrading muscle, or fibroproliferative lesion
tissue. For all measurements, actual cantilever spring constants were determined via the
thermal fluctuation method. For both tissue and cell measurements, the first 300nm of
indentation was fitted using a Hertzian contact model to estimate stiffness (elastic
modulus). After applying the Grubbs’ test for outliers, estimated moduli were averaged
over each tissue location or cell and considered as one data point.
2.4.5 Traction Force Microscopy (TFM)
Traction force microscopy was performed as described previously (135, 345). Briefly, prior to
polymerization, polyacrylamide (PA) hydrogels were UV-cured to a modulus of 10kPa
(as verified by AFM). Hydrogels were subsequently washed three times with PBS and
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incubated with fibronectin solution (20 µg/ml, F1141, Sigma Aldrich) for 1 hour. MEFs
were seeded on PA hydrogels at 1000 cells/cm2 and cultured for 18 hours in DMEM/10%
FCS before carrying out traction force microscopy (TFM). Cells (phase) and embedded
beads (0.2-µ-diameter fluorescent microspheres, F8810, Invitrogen, Carlsbad, CA) were
imaged using ZEISS Axio AXIO Observer fluorescence microscope at 40X
magnification. Image sequences for each cell were taken before and after cell lysis with
lysis buffer (10% Sodium dodecyl sulfate and Triton X-100 at 1:100). TFM data analysis
was performed using a Fourier transform traction cytometry plugin in Image J and a
custom MATLAB (The MathWorks) as in (135, 345) . In some studies, cells were treated
with 10μM Fasudil (Sigma Aldrich, catalog CDS021620), a potent RhoA inhibitor (348), for
30 min before measurement of traction forces.

2.5 Treatment with growth factors and small molecules
2.5.1 Chemical inhibitors/agonists
In some experiments, cells were treated with 50nM LDN-193189 (Sigma, catalog
SML0559) for 2 hours, 10uM Y272362 (Tocris, catalog 1254) for 1 hour, or 2µg/ml CNO3
(Cytoskeleton Inc, Denver CO, catalog CNO3-A) for 3 hours (all in DMEM/1%FCS).
2.5.2 siRNA knockdown
MEFs (5x103 cells/cm2) were cultured in DMEM/10%FCS for 24 hours then were
transfected in DMEM/1%FCS for 24 hours with 2 mg/mL of siRNAs targeting YAP1
mRNA (siYAP1:5’-GGCCAGAGAUAUUUCCUUATT-3’and 5’UAAGGAAAUAUCUCUGGCCTT-3’) (synthesized by Dharmacon, Inc) using
Lipofectamine RNAimax (Invitrogen, catalog 1875238) following the manufacturers'
instructions. Knock-down efficiency was validated by RT-PCR for YAP1 mRNA and by
Western Blot for YAP1 protein (Fig. 3.11).

2.6 Gene Expression Analysis
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2.6.1 RNA extraction and RT-PCR analysis
RNA was isolated from MEF monolayers on PA gels using Accumax (Sigma, catalog
A7089) for 10 min at room temperature, followed by TRIzol extraction (Thermo Fisher,
catalog 15596026). Genomic DNA was removed from RNA samples by digestion with
RNase-free DNase (Promega, catalog M6101). RNA concentration was determined by
spectrophotometer (NanoDrop) and equivalent amounts for each sample were used for
cDNA synthesis using High Capacity RNA-to-cDNA reagents (Applied Biosystems,
catalog 4385612). Quantitative RT-PCR analysis was performed to detect mRNA
expression of PPARγ, LP1, CEBPβ, Sox9, Runx2, Osx, YAP, TAZ, and Gapdh. Realtime quantitative PCR reactions contained forward/reverse primers (0.37mM), cDNA (1:5
dilution), and Fast SYBR Green PCR Master Mix (Applied Biosystems; 4385612); each
sample was analyzed in triplicate. Target gene mRNAs were quantified from standard
curves and normalized to Gapdh followed by normalization to respective gene
expression by Acvr1+/+controls. Forward and reverse primer sequences are in Table 2.6.

2.7 Immunochemical Methods
2.7.1 Immunofluorescent Experiments (Mechanotransduction)
After 18 hours, cells on hydrogels were fixed in 4% paraformaldehyde/PBS (Thermo
Fisher Scientific, catalog J19943-K2), followed by Alexa Fluor 488 Phalloidin (Invitrogen,
catalog A12379, 1:1000) to visualize the actin cytoskeleton and DAPI Fluoromount-G
(SouthernBiotech, catalog 0100-20) for nucleus staining as previously described in (73).
RUNX2 protein localization was visualized with primary RUNX2 antibody (Cell Signaling;
catalogue 12556; 1:800), followed by detection with Alexa Fluor 488 anti-rabbit antibody
(Invitrogen; catalog A12379; 1:1000); Alexa Fluor 546 phallodin (Invitrogen;
catalog A22283; 1:1000) was used to label F-actin simultaneously. YAP1 (Abcam,
catalog 52771, 1:200) protein was detected with Alexa Fluor 546 (Invitrogen, catalog
A11035, 1:1000). Cell contractility was evaluated with primary paxillin antibody (Cell
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Signaling Technologies, catalog 3674, 1:500) followed by detection with Alexa Fluor 594
anti-rabbit antibody (Invitrogen, catalog A22107MP). Imaging used an Eclipse 90i
microscope (Nikon) at consistent exposure times. Cell morphology parameters, YAP1
localization, and focal adhesion number were analyzed in ImageJ. Graphs of cell
morphology measurements and YAP1 localization measurements represent the average
of 3-4 individual experimental means, with each mean of a single experiment
representing the mean of individual cell measurements. For YAP1 localization, nuclear
images were utilized to delineate the nuclear area from the cytoplasmic region, and the
average fluorescent intensity over each region was calculated using Image J.
2.7.2 Western Blotting
MEFs were recovered from PA gels using Accumax (Sigma, catalog A7089) for 10
minutes at room temperature. Cells were lysed in buffer (RIPA, Sigma-Aldrich, catalog
R0278) supplemented with Halt Protease and Halt Phosphatase Inhibitor Cocktails
(Thermo Fisher Scientific, catalog 87785), cleared by centrifugation and quantified using
BCA Protein Kit (Thermo Fisher Scientific, catalog 23227). Proteins were
electrophoresed through 4-12% Bis-Tris protein gels (Thermo Fisher Scientific, catalog
12313623) and transferred to polyvinylidene difluoride (PVDF) membranes (Thermo
Fisher Scientific, catalog 88585). Membranes were blocked in Odyssey Blocking Buffer
(LI-COR, catalog 927-40100) and incubated overnight at 4ºC with primary antibody for
YAP1 or p-YAP1 or RhoA or pSmad2/3 or pSmad1/5, and Gapdh (Abcam, catalog
56701, 1:1000; Cell Signaling Technologies, 4911S, 1:1000; Novus Biologicals, 1:500,
NB100-91273; Cell Signaling Technologies, 8828S, 1:500; Cell Signaling Technologies,
13820S, 1:500; Cell Signaling Technologies, 5174S, 1:2000, respectively) then with IR
Dye 800CW goat anti-rabbit IgG (LI-COR Biosciences, catalog 926-32211, 1:10,000) in
Odyssey blocking buffer for 1 hour at room temperature. Following washing with trisbuffered saline with Tween20 (TBS-T) 2 X 5minutes, membranes were imaged with
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Odyssey Infrared Imaging System (LI-COR Biosciences, model 9120) and protein levels
quantified with Image Studio Lite 5.2 (LI-COR Biosciences). Phospho-YAP and total
YAP values were normalized to Gapdh to correct for variation in protein loading.

2.8 Proliferation and In vitro experiments with MuSCs and FAPs
2.8.1 Skeletal Muscle Injury
Acvr1R206H/+ mice were fed a doxycycline chow diet (625 mg/kg doxycycline chow; Envigo
Laboratories, Madison, WI, USA; TD.01306) for 5 days prior to cardiotoxin injection to
induce mutant gene expression. Tibialis anterior and gastrocnemius muscles of mice (at
2 months of age) were injured by injecting 20 µL of 25µM cardiotoxin from Naja
mossambica mossambica (Sigma‐Aldrich, St. Louis, MO, USA; C9759). Mice were
euthanized by CO2 asphyxiation and muscle tissue was collected at different days postinjury.
2.8.2 BrdU injection
2.5mg BrdU (Roche) was injected intraperitoneally (100mg/kg) in PBS with a 29-gauge
insulin syringe 24 hours before cell isolation. BrdU is stored at -80°C prior to injection.
2.8.3 FACS
2-month old mice were sacrificed, and the tibialis anterior, quadriceps and
gastrocnemius muscles were dissected from both hind legs. Muscle was finely minced
and placed in a gentleMACS C tube (Miltenyi Biotec) containing 0.15% collagenase in
10 mL DMEM. Tubes were loaded into a MACS Dissociator (Miltenyi Biotec) and the
manufacturer’s spleen-02 program was run twice. Tubes were incubated in a humidified
37ºC/5% CO2 incubator for 30 min, subjected to the spleen-02 program again, and
incubated at 37ºC for 1 hr. 50 microliters of 2% collagenase (Sigma-Aldrich) and 50 µL
of 4.8 U/mL dispase (Roche) was added, and tubes were vortexed at maximum speed
prior to a 30-min incubation at 37ºC. Cells were passed through a 21-gauge needle until
all muscle was broken apart. The remaining cell slurry was filtered through a 40 µM cell
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strainer that was prewet with 10 mL of cold myoblast media (DMEM:F12; 15% FBS, 1X
anti/anti (Amphotericin B, Penicillin, Streptomycin); all from Gibco; the strainer was
rinsed with an additional 10 mL of cold myoblast media, and cells were pelleted at
300xg/4ºC. Cells were incubated with 1mL 1X red cell lysis buffer (eBioscience) for 5
min at room temperature and 9 mL cold FACS buffer (2.5% GS (goat serum; 16210072,
Gibco), 2 mM EDTA (Invitrogen), pH 8.0 in 1X PBS) was added. Cells were spun and
resuspended in 1mL of FACS buffer containing antibodies raised against antigens
CD45, CD31, CD11b, and Sca1 (see Table 2.7) prior to an incubation on ice for 45 min.
Cells were centrifuged and resuspended in 100 µL of FACS buffer containing antibodies
CD34, and α7- integrin, as well as streptavidin-PE-Cy7 (Table 2.7). Cells were incubated
in the dark for 90 min on ice, with agitation occurring every 30 min. FACS buffer was
added up to 1 mL final volume, and cells pelleted and resuspended in FACS buffer, and
the viability dye 7-aminoactinomycin D (7-AAD; Sigma-Aldrich) was added (final
concentration 4 µg/mL). Cells were placed in flow cytometry tubes with cell strainers (BD
Biosciences) before collection by FACS. MuSCs were sorted using a BD Aria II.
Information about lasers and filter sets can be found in Table 2.8. MuSCs were sorted
into 1.5 mL microcentrifuge tubes containing 500 µL of cold myoblast media
(DMEM/Ham’s F12; 15% FBS; 1% NEAA (Gibco), 1% GlutaMAX (Gibco), 1% anti-anti
(Fisher Scientific)). FAPs were sorted into 1.5 mL microcentrifuge tubes containing 500
µL of cold FAP media (DMEM; 20% FBS; 1X anti-anti). The collection tubes were
maintained at 4ºC during the sort process using a circulating water system. Data was
collected from 20,000 total events, and analyzed using FlowJo 10.1 software.
2.8.4 Cell Culture
Both MuSCs and FAPs were grown on collagen-coated (C8919, Sigma) 6-well chamber
slides (company) and maintained in growth media composed of Ham’s F-10 (Gibco) or
DMEM (Gibco) and 15% and 20% FBS respectively (Omega Scientific) with 10mg/ml
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hFGF (G5071, Promega). Both were expanded and passaged by dissociation with
Accumax (Millipore). Once cells were confluent, they were cultured with myogenic
differentiation media composed of DMEM with 5% HS (horse serum; 16050-122, Gibco).
Cells stained for Hoechst and MyHC (mixed FAPs and MuSCs/condition media
experiments) were cultured for 14 days before staining and analysis. For mixed cell
experiments, MuSCs and FAPs were seeded 1:1 (2,000 cells/well each cell type) and
cultured in myogenic differentiation media for a week, with the media replenished every
other day. For condition media experiments, FAPs were cultured in FAP media for a
week, which was then collected, and MuSCs were then cultured in conditioned media for
a week.
2.8.5 Differentiation of Cells
2.8.5.1 Adipogenesis
FAPs were cultured to confluence in FAP growth media prior to the addition of
adipogenic media (10% FBS, 1μM dexamethasone, 10mg/ml insulin, 0.5mM 3-isobutyl1-methylxanthine (IBMX) (Sigma), and 10μm rosiglitazone (Cayman Chemical) in high
glucose DMEM) which was replenished every 3 days during assay. After 7 days, wells
were fixed with 4% paraformaldehyde (Electron Microscopy Sciences). Fixed wells were
stained with 0.2% Oil Red O (Sigma) in 60% Isopropanol for 10 minutes and imaged
while covered in water. Isopropanol was used to extract Oil Red O content of dried wells
and the solution from each well was divided to triplicates into a 96-well plate. The
absorbance values (550nm) as quantified by a Synergy microplate reader (BioTek) were
normalized to total protein content of replicate wells using the Pierce BCA Protein Assay
Kit (Thermo Fisher Scientific).
2.8.5.2 Osteogenesis
FAPs were cultured to confluence in FAP growth media prior to addition of osteogenic
media (10% FBS, 50μg/ml ascorbic acid, 10mM β-glycerophosphate (Sigma) (with or
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without the addition of BMP4 ligand as indicated), in high glucose DMEM) which was
replenished every 3 days during assay. After 14 days, weeks, wells were fixed with 4%
paraformaldehyde. Fixed wells were stained with Alizarin Red S (Ricca Chemical) for 5
minutes or BCIP/NBT Alkaline Phosphatase stain (Ross Inc.) for 15 minutes. A solution
of 0.5N HCl, 5% SDS was used to extract deposited Alizarin Red stain and the solution
from each well was divided into triplicate well of a 96-well plate and absorbance was
read at 405nm by a Synergy microplate reader.
2.8.6 Staining (BrdU, Hoechst, MyHC)
For detection of BrdU, MuSCs/FAPs were plated on collagen-coated 6-well chamber
slides after FACS isolation at 37°C overnight. Cells were briefly washed with PBS and a
warm fixative (70mL EtOH, 30mL 50mM glycine (pH 2, Santa Cruz) was added for 20
min at room temperature (RT). Cells were then washed for 10 min with PBS at RT and
blocked with blocking buffer (20% GS/0.3% Triton-X in PBS) for 1 hour at RT. Cells were
then stained with anti-BrdU antibody (anti-mouse, Roche) in Incubation buffer (1:10;
Roche) for 30 min at 37°C. After washing in PBS for 10 minutes twice, secondary Alexa
Fluor 488-conjugated goat anti-mouse IgG (1:1000 in blocking buffer) and incubated in
the dark for 1 hour at RT. Cells were washed, chambers removed, and coverslips were
mounted with fluoromount G plus DAPI (SouthernBiotech). For Hoechst staining, cells
were washed with PBS and Hoechst H3570 solution was added for 30 min at 37°C in the
dark. Cells were then fixed in 4% paraformaldehyde for 15 min.
For MyHC staining, cells were fixed with 4% paraformaldehyde/PBS for 20 min and
washed once with PBS. Cells were permeabilized with 0.5% triton X-100/PBS for 30
min, washed twice with PBS, and blocked for 1 hr at room temperature in 3% BSA/PBS.
Cells were stained for MyHC (Developmental Studies Hybridoma Bank, clone BF-G6;
1/10 in 3% BSA/PBS) overnight at 4ºC, washed with PBS, and stained with Alexa Fluor
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488-conjugated goat anti-mouse IgG (Life Technologies; 1/500 in 3% BSA/PBS) at room
temperature for 1 hr. Cells were washed, chambers removed, and coverslips were
mounted with fluoromount G plus DAPI (SouthernBiotech).
2.8.7 Imaging and analysis
Cells stained for BrdU and Hoechst were imaged using an Eclipse TE2000-U inverted
fluorescent microscope (Nikon) and BrdU/Hoechst-positive cells were quantified in
Image J. For MyHC staining, cells were imaged an Axio observer microscope (Zeiss). In
cases of Hoechst and MyHC stained cells, the fusion index was calculated as the
number of nuclei in multinucleated myotubes divided by the total number of nuclei (as in
(349)

).

2.9 In vivo MuSC transplant
2.9.1 Injury, irradiation, and transplant
Tibialis anterior muscles of mice (at 2 months of age) were injured by injecting 20 µL of
25µM cardiotoxin from Naja mossambica mossambica (Sigma‐Aldrich, St. Louis, MO,
USA; C9759). Before transplantation, Acvr1+/+ and Acvr1R206H/+ mice were anesthetized
with ketamine (2.4 mg per mouse) and xylazine (240 µg per mouse) by intraperitoneal
injection. We then irradiated hindlimbs by a single 21 Gy dose in a Gammacell 40
Exactor (MDS Nordion), with the rest of the body was shielded in a lead jig. We
performed transplantations the day after irradiation. After isolation of MuSCs by FACS
from age matched ubiquitous-GFP mice, 30,000 MuSCs were suspended in 20 µL PBS
and injected into injured and irradiated TAs using a 29-gauge insulin syringe. At 21 days
post-transplantation, mice were euthanized by CO2 asphyxiation and muscle tissue was
collected.
2.9.2 Micro-computed topography analysis
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After transplantation, mice were euthanized and both tibias collected and fixed for 2
hours in 4% paraformaldehyde at 4°C. HO was detected and quantified in high‐
resolution, cross‐sectional reconstructed images of paraformaldehyde (PFA)‐fixed hind
limbs using a micro–computed tomography (μCT) VivaCT40 imager (Scanco Medical
AG, Brüttisellen, Switzerland) at a source voltage of 55 kV, a source current of 145 µA,
and an isotropic voxel size of 19.0 µm. Three‐dimensional renderings to quantify HO
were reconstructed using Scanco μCT V6.1 software from regions of interest that were
free‐hand drawn around HO every 5 to 10 reconstructed slices and then interpolated for
total volume. Users ensured that the HO region of interest did not include skeletal bone.
Thresholding values for HO detection ranged from 240 to 1000 Hounsfield units.
2.9.3 Muscle cryosection
After µCT or after injury, TAs were extracted from the tibias and decalcified in 10%
EDTA (pH 7) for 72 hours. TAs were then suspended in 30% sucrose overnight and
embedded in Optimal Cutting Temperature (O.C.T.) Compound (Sakura) the next
morning. Cryosections (10 µm slices) from Acvr1+/+ and Acvr1R206H/+ mice were cut onto
Superfrost Plus microscope slides (Fisher Scientific). Slides were stained with
hematoxylin and eosin (H&E).

2.10 Histological Methods
Cryosections (10 µm slices) from Acvr1+/+ and Acvr1R206H/+ mice were stained with
hematoxylin and eosin (H&E) to visualize gross tissue morphology (as in (350)). Alcian
blue hematoxylin/orange G stain to visualize HO within skeletal muscle was done
according to the protocol from the University of Rochester Medical Center, Center for
Musculoskeletal Research Histology Core. For GFP detection, cells were permeabilized
in 0.2% TritonX-100/PBS for 10 min. After blocking in blocking buffer (2% bovine serum
albumin (BSA)/PBS), antibody against wheat germ agglutin (WGA, Sigma; 1/1000) were
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diluted in blocking buffer and incubated in a dark, humidified chamber for 1 hour. Slides
were washed with PBS and incubated with DAPI (20ug/ml in PBS, Sigma) for 5 mins in
the dark and then mounted with Prolong Diamond (Thermo Fisher Scientific).

2.11 Imaging and analysis
Muscle tissue sections from injured and transplanted mice were imaged using an Eclipse
90i microscope (Nikon). Centri-nucleated myofibers and GFP-positive cells were
quantified in Image J.

2.12 Statistical analysis
Data were analyzed statistically using GraphPad (La Jolla, CA, USA) Prism 7 software.
Results are presented as the mean ± SD or SEM. Paired or unpaired data sets were
analyzed using two-tailed, unpaired, equal variance Student’s t test or one-way ANOVA
(Tukey’s multiple comparison post-hoc test) to determine significance. Differences were
considered statistically significant at p<0.05. Significance and sample size are indicated
for each data set in the figure legends.
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Heterozygous Knock-In R206H mice
Forward Primer
Reverse Primer

3'-TGTATTGCAGGACGCTGGAAG-5' (ES2935)
3'-CCCCTGAAGTGGAATAACCA-5' (ES2936)

Denature
Anneal
Extension
Cycles

94°C, 0:30 minute
55°C, 0:30 minute
72°C, 0:30 minute
35

Agarose
Amplification

4.00%
WT allele- 300bp; FOP allele- 350bp

Table 2.1 PCR reaction conditions to detect Acvr1R206H/+ MEFs.
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Ubiquitous GFP mice
oIMR0872

5'-AAGTTCATCTGCACCACCG-3' (ES4191)

oIMR1416
oIMR7338
oIMR7339

5'-TCCTTGAAGAAGATGGTGCG-3' (ES4192)
5'-CTAGGCCACAGAATTGAAAGATCT-3' (ES4193)
5'-GTAGGTGGAAATTCTAGCATCATCC-3' (ES4194)

Step 1
Step 2
Step 3
Step 4
Step 5
Cycles

94°C, 1:50 minute
94°C, 0:30 minute
60°C, 1:00 minute
72°C, 1:00 minute
72°C, 2:00 minute
35

Agarose
Amplification

1.50%
GFP allele- 173bp; Internal control allele- 324bp

Table 2.2 PCR reaction conditions to detect GFP construct.
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AND Construct
Forward Primer
Reverse Primer

5'-GCATTACCGGTCGATGCAACGAGTGATGAG-3' (ES3355)
5'-GAGTGAACGAACCTGGTCGAAATCAGTGCG-3' (ES3356)

Denature 1
Dentaure 2
Anneal
Extension 1
Extension 2
Cycles

94°C, 3:00 minute
94°C, 0:30 minute
65°C, 0:45 minute
72°C, 0:30 minute
72°C, 10:00 minute
35

Agarose
Amplification

2.00%
Wildtype allele-650bp, Mutant allele-340bp

Table 2.3 PCR reaction conditions to detect AND construct.
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RT; TETO Construct
Forward Primer
5’-CTCTGCTGCCTCCTGGCTTCT-3’ (ES3557)
Wildtype Reverse 5’-CGAGGCGGATCACAAGCA ATA-3’ (ES3558)
Mutant Reverse
5’-GATTTTCAGGCATTTGAATGGGTC-3’ (ES3556)
Denature 1
Dentaure 2
Anneal
Extension 1
Extension 2
Cycles

94°C, 3:00 minute
94°C, 0:30 minute
65°C, 0:45 minute
72°C, 0:30 minute
72°C, 10:00 minute
35

Agarose
Amplification

3.00%
Wildtype allele-650bp, Mutant allele-340bp

Table 2.4 PCR reaction conditions to detect RT;TETO constructs.
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Cre Construct
Forward Primer
Reverse Primer

5’-GCGGTCTGGCAGTAAAAACTATC-3’ (ES3253)
5’-GTGAAACAGCATTGCTGTCACTT-3’ (ES3254)

Denature 1
Dentaure 2
Anneal
Extension 1
Extension 2
Cycles

94°C, 5:00 minute
94°C, 0:30 minute
60°C, 0:45 minute
72°C, 0:35 minute
72°C, 10:00 minute
35

Agarose
Amplification

1.00%
843bp

Table 2.5 PCR reaction conditions to detect Cre construct.
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Target

Full Transcript
Name

ACVR1

Activin A receptor type 1

TGTATTGCAGGACGCTGGAAG

CCCCTGAAGTGGAATAACCA

Cebpβ

CCAAT/enhancer binding
protein beta

GCAAGAGCCGCGACAAG

GGCTCGGGCAGCTGTTT

Cyr61

Cysteine-rich angiogenic
inducer 61

CTGCGCTAAACAACTCAACGA

GCAGATCCCTTTCAGAGCGG

Gapdh

Glyceraldehyde 3phosphate
dehydrogenase

CAAGGTCATCCATGACAACTTT

GGCCATCCACAGTCTTCTGG

LP1

Lipoprotein lipase

CCAATGGAGGCACTTTCCAG

CCACGTCTCCGAGTCCTCTC

Osx

Osterix

ATGGCGTCCTCTCTGCTTG

TGAAAGGTCAGCGTATGGCT

PPARγ

Peroxisome proliferatoractivated receptor
gamma

ATCATCTACACGATGCTGGCC

CTCCCTGGTCATGAATCCTTG

Runx2

Runt related transcription
factor 2

GTGCGGTGCAAACTTTCTCC

AATGACTCGGTTGGTCTCGG

Sox9

SRY-box 9

GAAGTCGGTGAAGAACGGAC

CTGAGATTGCCCAGAGTGCT

TAZ

Transcriptional
coactivator with PDZbinding motif

GAAAATCACCACATGGCAAGACCC

TTACAGCCAGGTTAGAAAGGGCTC

YAP1

YES-associated protein 1

ACCCTCGTTTTGCCATGAAC

TGTGCTGGGATTGATATTCCGTA

Forward Primer (3’-5’)

Table 2.6 Quantitative real-time RT-PCR primers.
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Reverse Primer (3’-5’)

Antigen
CD45

Host
Rat

Clone
30-F11

Conjugate
Biotin

CD11b

Rat

M1/70

Biotin

CD31
Sca1/Ly6A/E

Rat
Rat

390
E13-161.7

Biotin
Biotin

Live/Dead

N/A

N/A

7-aminoactinomycin D
(7-AAD)

Streptavidin
Alpha 7integrin
CD34

N/A
Rat

N/A
R2F2

PE-Cy7
AF 647

Rat

Ram34

BV421 AF 647

Table 2.7 Antibodies used in MuSC/FAP FACS.
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Source
BD
Biosciences
BD
Biosciences
e Bioscience
BD
Biosciences
Sigma
Aldrich/Therm
o Fisher
Biolegend
Ablab

Dilution
1/500

BD
Biosciences

1/12.5

1/200
1/200
1/200
1/250

1/25
1/25

Fluor
7-AAD
Alexa Fluor 647
BV421
PE-Cy7
Sca1/Ly6A/E

Laser
Blue
Red
Violet
Green
Violet

Filter
710/50
660/20
450/50
780/60
780/40

Table 2.8 Fluorophores and Aria filter sets.

72

Figure 2.1 Using polyacrylamide to model different substrate stiffness.
Rigidity of native tissues included in this study were mimicked by using an adjustable
hydrogel system. Polyacrylamide (PAA) hydrogel is polymerized onto glass substrate, crosslinked with Sulfo-SANPAH and coated with 20μg/ml fibronectin to facilitate cell attachment.
Stiffness scale adapted from Discher DE, et al. Science. 2009 (1).
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Figure 2.2 Schematic for Isolating MuSCs and FAPs.
After injury, all skeletal muscles are removed from each mouse in the study. Muscles are
digested with collagenase and dispase in DMEM, along with intermittent mechanical
dissociation. Cells are first stained for CD45, CD11b, and CD31. After washing, cells are
then stained for Sca1, PE-Cy7, α7integrin, and CD34. Cells are placed into flow tubes and
are separated into MuSCs, FAPs, and waste based on epitope expression. Sorted cells
are then plated onto collagen-coated slides overnight and stained for BrdU incorporation
the following morning.
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Chapter Three:
Elevated BMP and Mechanical Signaling Through YAP1/RhoA Poises FOP
Mesenchymal Progenitors for Osteogenesis
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3.1 Summary
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease
characterized by the formation of extra-skeletal bone, or heterotopic ossification (HO), in
soft connective tissues such as skeletal muscle. All familial and sporadic cases with a
classic clinical presentation of FOP carry a gain-of-function mutation (R206H; c.617G>A)
in ACVR1, a cell surface receptor that mediates bone morphogenetic protein (BMP)
signaling. The BMP pathway is recognized for its chondro/osteogenic-induction potential,
and HO in FOP patients forms ectopic but qualitatively normal endochondral bone tissue
through misdirected cell fate decisions by tissue-resident mesenchymal stem cells. In
addition to biochemical ligand-receptor signaling, mechanical cues from the physical
environment are transduced to activate intracellular signaling, a process known as
mechanotransduction, and can influence cell fates. I hypothesized that increased BMP
signaling through increased activity of ACVR1 mis-regulates mechanotransduction in
FOP cells, leading to aberrant cell fate decisions. Based on these data, I hypothesized
that Acvr1R206H/+ cells misinterpret their physical environment, leading to increased
activation of mechanotransduction signaling and misdirected mesenchymal progenitor
cell differentiation.
Utilizing an established mesenchymal stem cell model of mouse embryonic
fibroblasts (MEFs) from the Acvr1R206H/+ mouse model that mimics the human disease,
we demonstrated that activation of the mechanotransductive effectors Rho/ROCK and
YAP1 are increased in Acvr1R206H/+ cells. We show that on softer substrates, a condition
associated with low mechanical signaling, the morphology of Acvr1R206H/+ cells is similar
to the morphology of control Acvr1+/+ cells on stiffer substrates, a condition that activates
mechanotransduction. We further determined that Acvr1R206H/+ cells are poised for
osteogenic differentiation, expressing increased levels of chondro/osteogenic markers

76

as compared to Acvr1+/+ cells. We also identified increased YAP1 nuclear localization in
Acvr1R206H/+ cells, which can be rescued by either BMP inhibition or Rho antagonism. Our
results establish RhoA and YAP1 signaling as modulators of mechanotransduction in
FOP and suggest that aberrant mechanical signals, combined with and as a result of the
increased BMP pathway signaling through mutant ACVR1, lead to misinterpretation of
the cellular microenvironment and a lower sensitivity to mechanical stimuli that promotes
commitment of Acvr1R206H/+ progenitor cells to chondro/osteogenic lineages.
3.2 Introduction
Each of the many tissue types within the human body have highly specialized
(119, 351)

functions that are enabled by their specific physical properties

. Bones support the

transfer of large forces to enable human motion, and so are stiff and strong, relative to
adipose tissue which does not play a loadbearing role

(119)

. In order to achieve and

maintain the properties required for their function, cells within these tissues sense and
interpret their physical environment. Cells perceive the context of their surroundings
through environmental cues, such as substrate stiffness and mechanical loading of the
matrix, via mechanoreceptors on the membrane surface. These mechanical inputs can
modulate the morphology and the fate decisions of cells through mechanotransductive
signaling pathways that ultimately result in modification of chromatin organization and
gene expression

(118, 120, 124)

, implicating stiffness in impacting cell fate. Cell fates can be

controlled by substrate stiffness comparably to induction through exogenous ligands or
growth factors: softer substrates support adipogenesis and myogenesis, while stiffer
substrates support chondrogenesis and osteogenesis (111, 119, 120).
Evidence for increased mechanotransduction has been implicated in both nongenetic and genetic diseases

(73, 127, 352)

. The formation of endochondral bone within soft

connective tissues, called heterotopic ossification (HO), could be in part caused by
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increased mechanotransduction, stimulating a cell population to interpret its substrate as
stiffer and modify its genetic profile in response

(52, 73)

. Fibrodysplasia ossificans

progressiva (FOP; MIM #135100) is a rare human genetic disease characterized by the
formation of HO within muscle and other soft connective tissues

(46, 48-50)

. 97% of patients

with a classic clinical presentation of FOP have the same autosomal dominant mutation
(R206H; c.617G>A) in the type l bone morphogenetic protein (BMP) receptor activin A
receptor type 1 (ACVR1) (47, 56). FOP patients present with HO within skeletal muscle and
other soft connective tissues within the first five years of life (50). While this genetic form of
HO is rare, HO arises more commonly from blast-initiated injuries and joint-replacement
surgeries

(353)

, making understanding the mechanism of HO formation highly relevant for

the general population. Developing improved insight into the mechanical signals and
pathways that regulate the functions of cells and bone formation may identify targets for
therapeutic intervention in both genetic and non-genetic causes of HO. We previously
established that HO progression driven by the FOP ACVR1R206H mutation is influenced by
disrupted mechanotransduction (73), but the specific mechanism as to how this contributes
to the disease pathology of FOP is still not well understood.
Here we demonstrate that YAP-associated protein (YAP1) signaling is a main
contributing cellular mechanism in this process. The YAP signaling pathway

(130, 131)

is

regulated by ECM stiffness and cell geometry, and is a key regulator of cell differentiation
(115, 133, 135, 136)

commitment

. YAP, and its paralogue TAZ, are key factors directing MSC lineage

(142, 147)

. Phosphorylation of YAP promotes its cytoplasmic localization,

preventing YAP-mediated transcriptional activation in the nucleus

(133)

. Cytoplasmic YAP

is associated with a soft surrounding ECM, cell cycle arrest, and adipogenic conditions,
while translocation into the nucleus occurs in response to a stiffer ECM, proliferation, and
osteogenic condition (115, 133, 135, 136, 147).
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Another intracellular mechanotransductive pathway, Rho GTPase, regulates
downstream effectors such as Rho kinase (170), necessary for cell migration, adhesion, and
differentiation

(172)

. Rho signaling through ROCK stimulates actin polymerization, a vital

part of cell contractility and cellular mechanotransduction

(173)

. One of the Rho GTPases,

RhoA, regulates ROCK to influence actin filament stability through myosin light chain
(MLC) and cofilin

(176, 192)

. Activation of RhoA in mesenchymal cells largely contributes to

their chondro/osteogenic cellular identity

(172, 179)

. Osteogenic conditions increase cell

spreading, ECM production, BMP signaling, RhoA activation, and nuclear localization of
YAP1(149, 179, 180). This suggests that elevated signaling by both YAP1 and BMP pathways
could coordinately promote the enhanced chondro/osteogenic differentiation that occurs
in FOP. YAP1 responds to cell-cell contact and contractility signals mediated by Rho

(181,

182)

, suggesting an intersection between RhoA, YAP1, and BMP pathway signaling (182, 184,

185)

. Interestingly, basal activation of BMP signaling pathways, even in the absence of

ligand, also regulates cell contractility in mesenchymal stem cells

(345, 354, 355)

, further

supporting that the FOP ACVR1R206H mutation instigates aberrant mechano-signaling in
FOP progenitor cells.
In this study, we utilized mouse embryonic fibroblasts (MEFs) isolated from the
knock-in Acvr1R206H/+ mouse model

(59, 101)

that recapitulates the human disease

progression to examine the effect of the ACVR1R206H mutation on the YAP1 and
Rho/ROCK mechano-signaling molecular pathways and investigate the ability of cells
expressing the FOP mutation to properly sense and respond to the mechanical cues in
their microenvironment.. MEFs are used as an in vitro model system of mesenchymal
stem cells (MSCs), including their ability to differentiate into adipogenic, chondrogenic,
and osteogenic lineages

(60)

. We previously showed increased BMP signaling in FOP

patient-derived stem cells from human exfoliated deciduous teeth (SHED cells)
Acvr1R206H/+ MEFs

(60)

(356)

and

as measured by phosphorylated Smad1/5/8 (pSmad1/5/8) protein
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levels in the presence or absence of BMP ligand. Thus, BMP pathway signaling is
increased downstream due to enhanced activity of ACVR1. Our data support that the
ability of cells to sense their environment and properly signal through mechanical effectors
is altered by the FOP ACVR1R206H mutation, leading to increased chondro/osteogenic cell
fate decisions.
3.3 Results
Acvr1R206H/+ cells misinterpret substrate rigidity through increased BMP pathway
signaling.
To address how the stiffness of the cell microenvironment affects Acvr1R206H/+ cells,
Acvr1+/+ and Acvr1R206H/+ primary MEFs (Fig. 3.1) were cultured on polyacrylamide (PA)
substrates mimicking adipogenic (5kPa), myogenic (10kPa), chondro/osteogenic (55kPa)
stiffness. Thin layers of PA-hydrogels (h=100μm) were polymerized onto glass slides and
then coated with fibronectin to aid cell attachment (Fig. 2.1). Hydrogel stiffness was
controlled by acrylamide content, and the stiffness verified by atomic force microscopy
(AFM)

(339)

. Cell-cell contacts can override cell-ECM-induced mechanosignaling

(105)

, so

MEFs were seeded at a low density. Cellular response to substrate stiffness, or
mechanosensing, was quantified by measuring cell area. Acvr1+/+ cells responded to
increasing levels of stiffness appropriately, with cell spread area increasing with more
apparent stress fibers, as substrate stiffness increased (Fig. 3.2A, upper half of panel).
However, on softer substrates (5 and 10kPa), Acvr1R206H/+ cells showed a similar
morphology to control cells on stiffer substrates (55kPa) (Fig. 3.2A, lower half of panel).
Differences were most pronounced at 10kPa (Fig. 3.2C), a stiffness comparable to normal
skeletal muscle tissue (111, 339), a site where HO commonly forms in FOP patients (50).
To investigate whether BMP pathway signaling through mutant ACVR1 contributes
to the spread morphology of Acvr1R206H/+ cells on soft substrates, we treated Acvr1+/+ and
Acvr1R206H/+ cells with the ACVR1 inhibitor LDN-193189 (LDN) (357) in basal media on 5,10,
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and 55kPa substrates for 2 hours. LDN-treated Acvr1R206H/+ cells were less spread than
without inhibitor, with cell areas more similar to Acvr1+/+, particularly cells on softer
substrates (Fig. 3.2B & C). These data indicate that increased activity of ACVR1 signaling
modulates cell spread area, and that increased BMP signaling through the ACVR1R206H
mutation contributes to the spread morphology of Acvr1R206H/+ cells on softer substrates.
During osteogenic differentiation, cells spread and increase their adhesions to their
substrate

(120)

. This is further increased when BMP is overexpressed

(358)

, indicating that

BMP pathway signaling can modulate cell morphology. Our data support that increased
BMP pathway signaling via ACVR1 influences Acvr1R206H/+ cell interpretation of its
substrate stiffness, with Acvr1R206H/+ cells sensing and interpreting their environment as
stiffer than it actually is, causing them to adopt a more spread cell morphology on softer
substrates.
Acvr1R206H/+ cells are poised for osteogenesis.
Mechanical (physical) cues to cells from their surrounding environments contribute
to cell fates

(1, 111, 119)

. Our findings that elevated BMP pathway signaling through ACVR1

in Acvr1R206H/+ cells causes them to respond to soft substrates as though they were stiffer
(Fig. 3.2) suggested that the FOP mutation leads to promiscuous diversion from normal
cell fate though misregulation of mechanosignaling pathways.
To investigate if altered mechano-sensing is associated with an osteogenic
response in Acvr1R206H/+ cells on softer substrates, we examined a key pro-osteoblast
factor runt related transcription factor 2 (RUNX2; alias: CBFA1) that has been shown to
be essential during early commitment of mesenchymal stem cells to the osteogenic
lineage

(359-362)

. Nuclear localization of RUNX2 is critical for its ability to act as a

transcription factor to induce the expression of genes required for osteogenesis such as
alkaline phosphatase (ALP), osteocalcin (OCN; alias: BGLAP), and osterix (OSX; alias:
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SP7)

(360, 363, 364)

. Previous work has shown that matrix stiffness regulates the nuclear

localization of this factor in stem cells

(104, 365)

, with stiffer substrates promoting more

nuclear localization.
Acvr1+/+ and Acvr1R206H/+ cells were cultured on PA-hydrogels of various stiffnesses
for 16 hours, immunostained for RUNX2 protein localization, and quantified for
nuclear:cytoplasmic localization ratios of RUNX2 (Fig. 3.3). We showed that on all
substrate stiffnesses tested, RUNX2 nuclear localization was higher in Acvr1R206H/+
compared to Acvr1+/+ control cells (Fig. 3.3). Differences were most pronounced on 10kPa,
a stiffness comparable to normal muscle tissue

(111)

. Since heterotopic bone forms within

skeletal muscle tissue in patients with FOP, the difference in RUNX2 protein localization
at 10kPa stiffness may be functionally relevant. Taken together these data strongly
support that Acvr1R206H/+ cells misinterpret their biophysical microenvironment, which leads
to important changes in key factors that direct cellular differentiation and extracellular
matrix production.
We detected the greatest differences between Acvr1+/+ and Acvr1R206H/+ cell
morphology on 10kPa substrates (Fig. 3.2), which represents connective tissues like
skeletal muscle where HO commonly forms in FOP patients (50). We therefore investigated
gene expression of adipogenic and chondro/osteogenic markers by Acvr1+/+ and
Acvr1R206H/+ cells on 10kPa (soft) PA gels. Acvr1+/+ and Acvr1R206H/+ cells on 10kPa
substrates in basal media expressed similar mRNA levels of the adipogenic regulator
PPARγ; however, Acvr1+/+ cells expressed significantly higher levels of the adipogenic
markers CEBPβ and LP1 compared to Acvr1R206H/+ cells (Fig. 3.4A). Lipoprotein lipase 1
(LP1),

peroxisome

proliferator-activated

receptor

gamma

(PPARγ),

and

CCAAT/enhancer-binding protein beta (CEBPβ) are all expressed in early adipogenesis
, with CEBPβ transactivating expression of PPARγ (367). On a stiffer (55kPa) substrate,

(366)

there was a slight increase in adipogenic gene expression in both Acvr1+/+ and Acvr1R206H/+
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cells, but not at significant levels. We also investigated the expression of
chondro/osteogenic genes (Sox9, Runx2, Osx). Sox9 marks the early stages of
chondrogenesis (368), while Runt-related transcription factor 2 (Runx2; alias CBFA1) marks
the initial commitment of mesenchymal cells to the process of osteogenesis

(369, 370)

.

Nuclear localization of Runx2 is essential for its ability to act as a transcription factor to
induce osteogenic gene expression

(370)

, and we previously identified increased nuclear

localization of Runx2 protein in Acvr1R206H/+ cells compared to Acvr1+/+

(73)

. Osterix (Osx;

alias Sp7) is a master-regulator required for formation of bone by osteoblasts

(371)

. We

determined that expression of these chondro/osteogenic genes were significantly
increased in Acvr1R206H/+ cells on soft substrates cultured in basal media as compared to
Acvr1+/+ cells, which further increased on 55kPa (Fig. 3.4A). These data support that
Acvr1R206H/+ cells may be poised towards an osteogenic lineage.
The modulus of substrate can influence stem cell spreading, traction generation,
and fate, including in the absence of soluble differentiation factors (111, 119). We investigated
markers of adipogenic and osteogenic lineage to see if cells were predisposed toward one
lineage or another without the presence of ligand (Fig. 3.4A). To investigate whether there
would be a bias toward one lineage over anther in the presence of ligand, we treated cells
to bipotential adipogenic/osteogenic media

(340, 372)

in equal amounts. We previously

showed that Acvr1+/+ and Acvr1R206H/+ cells differentiated to similar extents under
adipogenic conditions (60). We found that while exposure to adipogenic/osteogenic ligand
increased markers for both lineages in both Acvr1+/+ and Acvr1R206H/+ cells, Acvr1R206H/+
cells expressed chondro/osteogenic markers in higher levels compared to Acvr1+/+ (and
compared to adipogenic markers) (Fig. 3.4B). Acvr1+/+ cells showed significantly
increased expression of the adipogenic genes PPARγ and LP1 compared to Acvr1R206H/+
cells (Fig. 3.4B).
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Together, our data demonstrate that Acvr1R206H/+ cells are poised for
chondro/osteogenic differentiation in the absence of established biochemical or
biomechanical cues, with a preference for osteogenic commitment when differentiation
signals are provided, even on soft substrates that normally directs cells towards an
adipogenic/myogenic lineage.
Acvr1R206H/+ cells show increased nuclear YAP localization on soft substrates.
YAP signaling is influenced by substrate stiffness

(115, 133, 135, 136)

and nuclear

localization of YAP1 and activation of signaling is associated with a stiff extracellular
environment, cell motility, and chondro/osteogenic differentiation
investigate

YAP

signaling,

we

examined

YAP1

protein

(115, 133, 135, 136)

. To

localization

via

immunofluorescence and showed increased nuclear YAP1 in Acvr1R206H/+ cells on softer
substrates compared to Acvr1+/+ cells (Fig. 3.5A & C). In addition to increased cell area
(Fig. 3.5D), two other measurements, circularity and aspect ratio, indicated that
Acvr1R206H/+ cells were more spread and less circular with more protrusions on 10 and
55kPa (Fig. 3.5E & F). Aspect ratio (AR) is the proportion of the width of an object to its
height and circularity represents how close an object is to a perfect circle (AR=1). These
data suggest that YAP1 contributes to the irregular spread cell morphology

(187)

of

Acvr1R206H/+ MEFs on softer substrates as identified in Fig. 3.2.
To demonstrate the influence of YAP1 in cell interpretation of mechanical
environment, we utilized a YAP1 siRNA (siYAP1) to knockdown YAP1 mRNA. After
confirming YAP1 targeting with our siRNA (Fig. 3.11), we examined changes in YAP1
localization and cell morphology. Nuclear YAP1 levels decreased in Acvr1R206H/+ cells in
the presence of siYAP1 (Fig. 3.5B & C), similarly to Acvr1+/+ cells, and cellular morphology
parameters (cell area, aspect ratio, and circularity) of Acvr1R206H/+ cells were rescued and
more similar to Acvr1+/+ cells (Fig. 3.5D, E, & F). Thus, decreasing AR and increasing
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circularity indicate that YAP1 inhibition mitigates increased mechanotransduction in
Acvr1R206H/+ cells.
Interaction between BMP pathway signaling and YAP1 signaling in Acvr1R206H/+
cells.
The BMP signaling pathway has been previously established to communicate with
the YAP signaling pathway

(183, 184)

. Given the increased nuclear localization of YAP1 in

Acvr1R206H/+ cells on soft substrates (Fig. 3.5A), we further investigated the relationship
between BMP and YAP signaling pathways in Acvr1+/+ and Acvr1R206H/+ cells by examining
YAP1 protein expression and localization in response to LDN-193189 (LDN). BMPpSmad1/5/8 signaling inhibition by LDN decreased YAP1 nuclear localization in
Acvr1R206H/+ cells on softer (10 kPa) substrates to levels similar to Acvr1+/+ cells (with or
without LDN treatment) (Fig. 3.6A & B). These data are consistent with the effects on cell
morphology by LDN-treated Acvr1R206H/+ cells, which appear more similar to Acvr1+/+ when
BMP pathway signaling is inhibited (Fig. 3.2C). These data indicate that increased BMP
pathway signaling conferred by enhanced activation of ACVR1 alters cell morphology and
influences the localization of YAP1.
Progressively decreasing cytoplasmic pYAP as substrate stiffness increases is
indicative of increased nuclear YAP1 localization and increased cellular spreading (115, 133,
. To determine the effects of Acvr1R206H/+ on levels of cytoplasmic YAP1 (inactive YAP

181)

that is targeted for degradation), we analyzed phosphorylated-YAP (pYAP) protein levels
in cells on 10 and 55kPa by Western blot. Both Acvr1+/+ and Acvr1R206H/+ cells showed
decreased levels of pYAP on 55kPa as compared to 10kPa substrates (Fig. 3.6C).
Acvr1R206H/+ cells showed slightly more, although not statistically significant, decreased
pYAP protein levels on both 10 and 55kPa compared to Acvr1+/+ (Fig. 3.6C), consistent
with the increased nuclear YAP1 in Acvr1R206H/+ cells (Fig. 3.6C). These data were further
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correlated with increased mRNA expression of YAP1 and its target gene Cysteine-rich
angiogenic inducer 61 (Cyr61)

(142, 145, 146)

(Fig. 3.D), and increased expression of total

YAP1 protein in Acvr1R206H/+ cells (Fig. 3.6E). While total YAP1 was not significantly
different between Acvr1+/+ and Acvr1R206H/+ cells, localization of YAP1 is more indicative of
YAP signaling activity than overall protein abundance

(133, 134)

; nuclear YAP (active YAP)

is increased in Acvr1R206H/+ cells (Fig. 3.5). Taken together, these data suggest that
increased cellular spreading of Acvr1R206H/+ cells on soft substrates is due to increased
nuclear localization of YAP1, causing Acvr1R206H/+ misinterpretation of substrate stiffness.
Cell contractility is increased in in Acvr1R206H/+ cells.
The mechanotransductive effector RhoA, which is associated with cell contractility
and motility through actin cytoskeleton dynamics

(173, 192)

, is more highly expressed in

Acvr1R206H/+ cells (Fig. 3.7 & 3.12), consistent with our previous observations in (73). RhoA
facilitates phosphorylation of Smad1/5/8, connecting RhoA activation and BMP signaling
as two critical pathways that impact cell fate decisions

(16, 26, 179, 373)

. Activation of Rho is

required for the formation of focal adhesions and their associated stress fibers

(173, 192, 372,

374)

. Focal adhesions are located at the edges of the cellular membrane and attach cells

to the ECM

(122, 187, 188)

. Focal adhesions are also regulated downstream from RhoA by

YAP signaling (136, 181, 182, 187, 196). To examine the effect of the increased RhoA expression
by Acvr1R206H/+ cells, we detected paxillin, part of the focal adhesion complex

(189, 190)

by

immunofluorescence, and discovered an increased number of focal adhesions at the
edges of Acvr1R206H/+ cells on softer substrates compared to Acvr1+/+ cells (Fig. 3.8A).
Focal adhesions also appeared more clustered in Acvr1R206H/+ cells compared to the more
sparsely distributed focal adhesions in Acvr1+/+cells (Fig. 3.8A). Elevated paxillin staining
in Acvr1R206H/+ indicates increased cellular adhesion as a consequence of increased RhoA
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signaling activity, implicating RhoA signaling through focal adhesion formation as a key
player in improper mechano-sensation in Acvr1R206H/+ cells.
In order to investigate the impact of Rho signaling on focal adhesion complex
formation and mechanotransduction in Acvr1+/+ and Acvr1R206H/+ cells, we treated cells with
10μM of the ROCK inhibitor Y72362 (Y27)

(104)

. All cells responded by significantly

decreasing paxillin staining and cell area (Fig. 3.8B ii & iii) relative to untreated cells (Fig.
3.8A ii & iii). We also demonstrated that YAP1 protein was more localized to the
cytoplasm on both 10 and 55kPa in Acvr1+/+ and Acvr1R206H/+ cells with Y27 (Fig. 3.8D).
These data support interactions between YAP and RhoA signaling pathways to regulate
cell shape and spreading.
To probe this aspect further, we augmented cell contractility with the RhoA-agonist
CNO3

(375)

and determined that both Acvr1+/+ and Acvr1R206H/+ cells spread more with

increased paxillin staining and more clustered focal adhesions at cell edges on all
stiffnesses (Fig. 3.8C). Relative to control cells, Acvr1R206H/+ cells treated with CNO3 were
more spread, with more paxillin staining, on softer 10kPa substrates (Fig. 3.8C), and were
often detached from the substrate on stiffer 55kPa substrates. On softer substrates, RhoA
and YAP1 signaling pathways are normally less active and cells are smaller and rounder,
however we established that in Acvr1R206H/+ cells on soft substrates, these two pathways
were over-active, suggesting increased cell contractility.
To further directly assess cell contractility in Acvr1+/+ and Acvr1R206H/+ cells, we
used traction force microscopy (TFM)

(376)

and determined that Acvr1R206H/+ cells exert a

higher traction stress on their substrates, and generate a higher total force per cell (Fig.
3.9A). To examine the cellular response and traction force in response to a potent ROCK
inhibitor Fasudil

, we cultured the cells with 10μM of Fasudil, for 30 min. Our TFM

(348)

measurements demonstrated that Fasudil reduced the relative traction stress of
Acvr1R206H/+ cells on 10kPa to levels by Acvr1+/+ cells (Fig. 3.9B). Taken together, these
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data indicate that cellular contractility is increased in Acvr1R206H/+ cells, which can be
rescued with ROCK inhibition via Fasudil, presenting a possible therapeutic target in the
treatment of FOP.
3.4 Discussion
Cellular behavior (proliferation, differentiation, motility, protein production) is
regulated in large part by the surrounding environment (including ECM, exogenous
ligands, and small molecules)

(111, 112, 119, 120)

. Many signals from the cell environment,

including the physical stiffness of tissues, are transduced through mechanical signaling
effectors to influence gene expression and protein secretion

(118, 120)

. The cellular

interpretation of such cues, termed mechanotransduction, is critical for cell response to its
environment (111, 119). The rare genetic disease fibrodysplasia ossificans progressiva (FOP)
is caused by mutations in the BMP receptor ACVR1 that lead to increased BMP pathway
signaling activity and the formation of endochondral bone tissue within soft connective
tissues as a result of misdirection of cell fate decisions within skeletal muscle tissue (46, 48. Utilizing cells from our knock-in Acvr1R206H/+ mouse model

50)

(59, 101)

, we show here that

the ACVR1R206H mutation poises cells for chondro/osteogenic differentiation in the
absence of inductive factors. In this basal, unstimulated state, we additionally found that
mechanotransduction through the YAP1 and RhoA signaling pathways is enhanced,
leading to increased cellular contractility, and indicating that cellular perception of
environment is altered in Acvr1R206H/+ cells. Together, the effects of enhanced
BMP/Rho/YAP1 pathway signaling combine to create a permissive cell state for
chondro/osteogenic differentiation.
Increased cellular spreading is observed in cells under to osteogenic conditions
and/or cells cultured on stiff matrices

. We observed that Acvr1R206H/+ cells have an

(112)

atypical spread morphology on softer, skeletal muscle tissue-like (10kPa), substrates.
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Further, these mutant cells show increased expression of chondro/osteogenic genes
(Sox9, Runx2, Osx) in both basal and mixed adipogenic/osteogenic media, cellular
responses that indicate improper interpretation of mechanical environment. We previously
demonstrated that after injury in the FOP Acvr1R206H/+ mouse model, the skeletal muscle
(73)

tissue environment becomes stiffer than injured control muscle

. Elevated tissue

stiffness leads to increased activation of mechanotransductive signaling pathways, and
promotes chondro/osteogenic differentiation over adipogenic/myogenic cell fates
Formation of HO in FOP patients is not continuous but episodic

(112, 377)

.

(47, 50)

, indicating that

although Acvr1R206H/+ cells are in a state poised for chondro/osteogenic differentiation, a
secondary condition appears necessary to reach a threshold to send them down this
lineage pathway

. Interestingly, when we examined markers of adipogenesis (PPARγ,

(49)

CEBPβ, LP1), we found a significantly decreased expression of CEBPβ in Acvr1R206H/+
cells on soft (10kPa) substrates relative to Acvr1+/+ cells. CCAAT/enhancer-binding protein
beta (CEBPβ) is crucial in macrophage-mediated skeletal muscle repair

(282)

, and we

previously demonstrated that muscle repairs more slowly and less efficiently in FOP
skeletal muscle after injury (79). This provides further support that the ACVR1R206H mutation
poises

cells

toward

a

chondro/osteogenic

lineage,

and

away

from

an

adipogenic/myogenic one.
The YAP/TAZ complex, part of the Hippo signaling pathway (130, 131), is regulated
by ECM elasticity and cell geometry, and is a key intracellular regulator of cell
differentiation (115, 133, 135, 136). YAP/TAZ proteins shuttle between the cytoplasm and
nucleus in response to substrate stiffness and other environmental cues. Cytoplasmic
localization of YAP/TAZ is associated with a soft surrounding ECM and adipogenic
conditions, while YAP translocation to the nucleus occurs with a stiffer ECM,
proliferation, and osteogenic conditions (115, 133, 135, 136). We found that nuclear YAP1, an
indicator of activated pathway signaling, is increased in Acvr1R206H/+ cells on softer
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substrates relative to Acvr1+/+ cells. Interestingly, this activation could be blocked by the
inhibition of BMP pathway signaling with the ACVR1 inhibitor LDN-193189 (LDN),
indicating that BMP signaling through increased activity of ACVR1 and YAP signaling
crosstalk in Acvr1R206H/+ cells. This increased nuclear YAP correlated with less
cytoplasmic (inactive) phosphorylated-YAP (pYAP) in Acvr1R206H/+ cells on all substrates.
Expression of the pro-osteogenic YAP1 target gene Cyr61, an ECM-associated signaling
protein that is a key regulator of cell adhesion, migration, proliferation, and osteogenic
differentiation (142, 145, 146), was also increased, suggesting that Cyr61 may be a
downstream mediator of YAP1 regulation of cell differentiation and stimulation of
chondro/osteogenic gene expression. BMP and YAP1 pathway signaling have both been
shown to promote osteogenesis under normal conditions (17, 147, 179); our data support that
increased signaling in both pathways work together to promote abnormal cell fate
decisions (i.e. bone within skeletal muscle tissue).
The Rho/ROCK pathway provides a link to the extracellular matrix to affect
cellular morphology, migration, contractility, and adhesion to surface substrates (118, 170,
178, 188)

. RhoA is a small GTPase that regulates its kinase effector ROCK to influence

actin filament polymerization through myosin light chain and Rho/ROCK tension-sensing
of the ECM through formation of focal adhesions at the termini of actin filaments (126, 178).
RhoA facilitates phosphorylation of Smad1/5/8, downstream effectors of activated BMP
receptors (179, 180, 378, 379); YAP1 also responds to cell-cell contact and contractility signals
mediated by Rho (181, 182), suggesting an intersection between RhoA, YAP1, and BMP
pathway signaling (185). We previously demonstrated that the Rho/ROCK signaling
pathway was over-activated in Acvr1R206H/+ cells (73), and here we investigated its
interactions with YAP1 and the impact on cell contractility. YAP1 signaling has been
shown to control focal adhesion formation downstream of the RhoA pathway, thereby
impacting cell morphological parameters (133, 187). We quantified focal adhesions to
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assess Rho/ROCK mechanotransduction in Acvr1R206H/+ cells, and identified an increase
in focal adhesion formation and clustering in Acvr1R206H/+ cells on soft substrates. A
larger number of focal adhesions correlates with cellular spreading and increased
adhesion strength (380-382); thus, the increased number and length of focal adhesions in
Acvr1R206H/+ cells supports increased cellular contractility and increased total force
generated by these cells. ROCK inhibition by the ROCK inhibitor Y272362 (Y27) also
decreased nuclear YAP1 localization, confirming that interaction of these pathways
contributes to the improper mechanotransduction by Acvr1R206H/+ cells on soft substrates.
Another contributing factor to osteogenic cell fate decisions is increased cell
contractility (200). Increased substrate stiffness leads to the formation of more focal
adhesions to better anchor the cell to its substrate. Tension in these contractile
actomyosin fibers increases activity of downstream effectors like YAP, resulting in
osteogenic gene expression (147, 201). Traction force microscopy (TFM) evaluates the
extent to which a cell deforms its underlying ECM-coated substrate. From this, one can
calculate the total force generated by a single cell and the average traction stress (force
per unit area) it applies to the substrate (376). A higher average traction stress indicates
that a cell is in a more contractile state (200, 201). TFM showed that Acvr1R206H/+ cells
generated higher contractile forces compared to Acvr1+/+ cells on 10kPa (soft) substrate,
providing further evidence that Acvr1R206H/+ cells interpret their substrate as stiffer than
Acvr1+/+ cells do. This response by Acvr1R206H/+ cells was ameliorated by the ROCK
inhibitor Fasudil. Fasudil has been demonstrated as a potential therapeutic in several
diseases (383-388) and is currently in clinical trials for treatment of cardiac disease (389) and
subarachnoid hemorrhage (390). This raises the potential for repurposing this treatment as
a possible therapeutic for FOP and other forms of HO, in combination with other
treatment approaches. Further studies investigating the impact of small molecule
inhibitors of mechanotransduction, such as Fasudil, on the formation of heterotopic
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ossification in Acvr1R206H/+ mouse models will help determine if this is a plausible new
therapeutic target for future treatment of FOP and other HO patients.
While our studies provide important insight into the molecular pathophysiology of
the mutant ACVR1 receptor on mechanotransductive signaling pathways in FOP,
interpretations of these data are limited to those allowed by the cell type used. We
previously demonstrated that MEFs are able to adopt multiple cell fates, including
osteogenic

(60)

; however, mechanotransduction may be mis-regulated by the FOP

mutation in other progenitor cells within skeletal muscle tissue. Within skeletal muscle
tissue are fibro/adipogenic progenitor cells (FAPs) that have osteogenic potential and
contribute to the formation of HO (93). FAPs are more difficult to isolate than MEFs and are
less amenable to cell culture methods. However, we are beginning to develop protocols
to conduct similar experiments in FAPs. Future studies will investigate mechanical
signaling in Acvr1R206H/+ FAPs, and the impact on chondro/osteogenic potential.
Additionally, there are over twenty BMP ligands (18) and different ligands may have different
downstream effects on mechanotransductive pathways. We previously demonstrated that
the ACVR1R206H mutation acts downstream of BMP ligand and stimulates increased
SMAD1/5/8 phosphorylation independent of BMP ligand

(391)

. Here we demonstrate a

mechanism by which increased BMP pathway signaling through ACVR1 mis-regulates
mechanotransduction to poise cells for chondro/osteogenic differentiation independently
of ligand stimulation. Ongoing studies are working to address ACVR1 responsiveness to
specific ligands.
Taken together, our data elucidate the mechanism by which elevated BMP
pathway and mechanical signaling combine to increase cell contractility and push cells
down a chondro/osteogenic lineage pathway (depicted in the model in Fig. 3.10),
contributing to the progression of disease in FOP. We showed the efficiency of several
inhibitors in mitigating the aberrant mechanotransduction in Acvr1R206H/+ cells (Fig. 3.6),
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and the downstream effect on cell contractility (Fig. 3.8 & 3.9). With this increased
understanding of the mechanism by which cells that are poised for
chondro/osteogenesis are directed to that fate by the secondary cue of improper
mechanotransduction through Rho/ROCK and YAP1 signaling, these data also have
relevance in identifying new potential treatments for FOP. The implications of the
influence of mechanotransduction on FOP pathology reveals several potential
therapeutic targets for combinatorial treatment of not only FOP but also possibly for
other genetic diseases of aberrant cell fate such as progressive osseous heteroplasia (66,
68)

and non-hereditary forms of heterotopic ossification (48, 52, 55). Our data emphasize the

importance of mechanotransduction signaling in cell fate determination, and provide
evidence that increased BMP pathway signaling through ACVR1 predisposes
Acvr1R206H/+ cells towards chondro/osteogenic cell fates and acts synergistically with
increased activity of mechanical-signaling pathways to drive HO formation.
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Figure 3.1 Mouse embryonic fibroblasts (MEFs) as an in vitro model system of MSCs.
A) Harvest of 5 embryos heterozygous for the Acvr1R206H allele and 3 homozygous for Acvr1+/+.
Digestion and separation of the PCR product results in an intact 300bp product for wildtype
(Acvr1+/+) allele and 350bp fragment for the Acvr1R206H allele. Mouse embryos are harvested at
day E12.5 and dissociated to isolate fibroblasts for culture. Mouse embryo image from Arnold et
al. Disease Models & Mechanisms. 2013 (modified) (392). B) Undifferentiated mouse embryonic
fibroblasts in culture. C) MEFs in adipogenic media (14 days) were stained with oil red O to
visualize lipid droplets (i). MEFs in chondrogenic media containing BMP4 (100 ng/ml) (14 days)
were stained with Alcian blue to visualize chondrocyte morphology and matrix (ii). MEFs in
osteogenic media (14 days) were stained with Alizarin Red to visualize calcium deposition (iii).
Panel C adapted from Culbert AL, et al. Stem Cells. 2014 (60).
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Figure 3.2 Acvr1R206H/+ cells misinterpret substrate rigidity through increased BMP pathway
signaling.
A) Response of Acvr1+/+ and Acvr1R206H/+ mouse embryonic fibroblasts (MEFs) to different
substrate stiffness was tested using polyacrylamide (PA) hydrogels at 5, 10, and 55kPa. Cells
were seeded at low density and stained with phalloidin (green) and DAPI (blue). B) Cells were
treated with 50nM of the Acvr1 inhibitor LDN-193189 (LDN) for 2 hours, which decreased the
spread morphology of Acvr1R206H/+ cells on softer substrates. Sale bar= 100µm. C) Cell area,
analyzed as a function of matrix elasticity, clearly scaled with substrate rigidity in Acvr1+/+ cells,
but does not scale in Acvr1R206H/+ cells. This effect is ameliorated with the addition of LDN. Graph
represents mean ± SEM of >350 cells analyzed from 4 independent experiments. Statistical
significance determined by 1-way ANOVA; #p<0.0001. From Stanley AK, et al. J Bone Miner
Res. In Press.
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Figure 3.3 RUNX2 nuclear localization is increased in FOP cells.
A) Acvr1+/+ and Acvr1R206H/+ cells on substrates of various rigidities (5, 10, 15, and 55 kPa) were
detected for RUNX2 (green), phalloidin (red), and DAPI (blue). Nuclear localization of RUNX2
protein indicates activation of osteogenic cell fate programming. Scale bar = 50 μm. B) Relative
nuclear localization of RUNX2 was quantified by the ratio of nuclear/cytoplasmic staining.
Intensity shows that Acvr1R206H/+ cells have more nuclear RUNX2 on softer substrates compared
with Acvr1+/+ cells. Nuclear localization on stiffer substrates does not differ significantly between
the genotypes as is expected. Graph represents mean ± SEM. Assay was repeated in three
independent experiments (n = 50 cells per substrate stiffness per experiment). Statistical
significance relative to Acvr1+/+ controls at a given substrate stiffness (**p < 0.01, ***p < 0.001) or
comparison between genotypes (#p < 0.05, ###p < 0.001) were determined by one-way ANOVA
(Bonferroni’s post hoc). From Haupt J, Stanley A, et al. Mol. Biol Cell. 2019 (73).
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Figure 3.4 Acvr1R206H/+ cells are poised for osteogenesis.
A) Cells were maintained on 10kPa and 55kPa PA gels in basal media for 24 hours (as shown in
the schematic above) and expression of adipogenic and chondro/osteogenic genes of Acvr1+/+
and Acvr1R206H/+ cells was quantified by RT-PCR. Adipogenic genes were expressed similarly, but
there was significant increase in expression of chondro/osteogenic genes in Acvr1R206H/+ cells on
both 10kPa and 55kPa (n=3 independent experiments). B) Cells were cultured on 10kPa and
55kPa PA gels in mixed (1:1) adipogenic/osteogenic media for 72 hours (as shown in the lower
schematic) and expression of adipogenic and chondro/osteogenic genes of Acvr1+/+ and
Acvr1R206H/+ cells was quantified by RT-PCR. While there was a small increase in
chondro/osteogenic gene expression in Acvr1+/+ cells (compared to expression in basal media),
expression levels of chondro/osteogenic genes were significantly higher in Acvr1R206H/+ cells on
both 10kPa and 55kPa (n=3 independent experiments). Data are relative to Acvr1+/+. Graphs
represent mean ± SEM (all samples run in triplicate). Significance determined by two-tailed
Student's t test, *p<0.05, **p<0.01, #p<0.0001. From Stanley AK, et al. J Bone Miner Res. In
Press.
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Figure 3.5 Acvr1R206H/+ cells show increased nuclear YAP localization on soft substrates.
A) Acvr1R206H/+ cells have more nuclear YAP on softer substrates (10kPa) in comparison to Acvr1+/+
cells. Increased nuclear YAP1 is shown alone in monochromatic (cyan) columns, and DAPI (blue),
phallodin (green), and YAP1 (red) are shown together in multicolor columns. B) Cells treated with
siYAP1 have decreased nuclear YAP1 localization. Scale bar= 50µm. C) Quantification of YAP1
nuclear/cytoplasmic ratio with or without siYAP1. Quantification of cell morphology parameters with
or without siYAP1 D) cell area, E) circularity, and F) aspect ratio. Circularity refers to how close an
object is to a perfect circle. Aspect ratio refers to the proportion of the width of an object to its length.
Graphs represent mean from four biologic replicates ± SEM from 4 biologic experiments (>50 cells
per experiment). Statistical significance determined by 1-way ANOVA, *p<0.05, ***p<0.001,
#p<0.0001. From Stanley AK, et al. J Bone Miner Res. In Press.
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Figure 3.6 Interaction between BMP signaling and YAP1 signaling in Acvr1R206H/+ cells.
A) Inhibition of BMP signaling with Acvr1 inhibitor LDN-193189 (LDN) in basal media decreased
nuclear YAP1. Yellow dotted line outlines cell nucleus. Scale bar= 100µm. B) Quantification of
nuclear/cytoplasmic YAP1 localization in the presence of LDN. C) pYAP protein levels in Acvr1+/+
and Acvr1R206H/+ cells on 10 and 55kPa substrates. D) Gene expression of YAP/TAZ and YAP target
Cyr61 in Acvr1+/+ and Acvr1R206H/+ cells on 10 and 55kPa substrates for 24 hours in basal media
quantified by RT-PCR. Data are relative to Acvr1+/+. E) Quantification of YAP1 protein in Acvr1+/+
and Acvr1R206H/+ cells on 10 and 55kPa substrates. Graphs represents mean from three biologic
replicates ± SEM. Statistical significance determined by 1-way ANOVA *p<0.01, **p<0.01,
#p<0.0001. From Stanley AK, et al. J Bone Miner Res. In Press.
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Figure 3.7 Increased Rho signaling pathway in Acvr1R206H/+ cells.
A) Increased activation of mechanotransduction in Acvr1R206H/+ cells was determined by
immunoblot for Rho after pull down of the active form (n = 6). Active Rho protein was normalized
to total Rho. Graphs represent mean ± SEM. Significance was determined by two-tailed Student’s
t test; *p < 0.05). From Haupt, Stanley, et al. Mol Biol of the Cell. 2019 (73). B) G-LISA to confirm
increased Rho activity in Acvr1R206H/+ cells. Percent activated Rho represents the ratio of activated
Rho to total Rho measured (n=1).
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Figure 3.8 Cell contractility increases in Acvr1R206H/+ cells.
A) Acvr1+/+ and Acvr1R206H/+ cells were cultured on 10 and 55kPa substrates and probed for paxillin
(part of the focal adhesion complex). Cells were also treated with the B) ROCK antagonist Y272362
(Y27) or C) ROCK agonist CNO3. Cell area as a function of substrate stiffness is decreased with
Y27 addition (Bi) and increased with CNO3 addition (Ci). Total number of focal adhesions
decreased when Y27 was added (Bii) and increased with CNO3 (Cii). D) Cells treated with Y27
have decreased nuclear YAP1 localization. Scale bar= 100µm. Graphs represent mean from three
biologic replicates ± SEM (SD for focal adhesion number) of >50 cells analyzed from three biologic
replicates. Statistical significance determined by 1-way ANOVA, **p<0.01, ***p<0.001, #p<0.0001.
From Stanley AK, et al. J Bone Miner Res. In Press.
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Figure 3.9 Acvr1R206H/+ cells generate higher levels of contractile forces.
A) Representative traction stress vector maps for Acvr1+/+ and Acvr1R206H/+ cells on 10kPa
substrates. Quantification shows average traction stress and average traction force per cell.
Significance determined by two-tailed Student's t test, *p<0.05,***p<0.001. B) Representativve
traction stress vector maps for Acvr1+/+ and Acvr1R206H/+ cells on 10kPa substrates with the ROCK
inhibitor Fasudil. Quantification shows relative average traction stress and average traction force
per cell as compared to Acvr1+/+. Statistical significance determined by 1-way ANOVA, **p<0.01,
***p<0.001, #p<0.0001 (n>15 cells/group, mean ± SEM). Scale bar = 20µm. From Stanley AK, et
al. J Bone Miner Res. In Press.
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Figure 3.10 Relationship between mechanotransduction and BMP signaling in Acvr1R206H/+
cells.
On soft substrates, mechanotransduction activity in Acvr1+/+ progenitor cells is low, with lower
expression of BMP target genes. On stiffer substrates, mechanotransduction activity is activated,
leading to reinforcement of BMP and osteogenic gene signaling through RhoA and YAP/TAZ
positive feedback. With the ACVR1R206H mutation, cells on soft substrates have
mechanotransduction activated (red arrows), indicating cell mis-interpretation of substrate
stiffness. Increased RhoA, YAP1, and BMP signaling converge to activate cellular contractility
and chondro-/osteogenic gene expression. These data suggest that FOP Acvr1R206H/+ cells are
poised for chondro-/osteogenesis, leading to endochondral ossification within skeletal muscle
following injury. Asterisk indicates location of the FOP ACVR1R206H mutation. From Stanley AK,
et al. J Bone Miner Res. In Press.
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Figure 3.11 Gene and protein expression controls for YAP1 siRNA.
A) YAP1 gene (mRNA) expression in the presence of siRNA against YAP1 (siYAP1) for 24 hours
(cells treated with scrambled siRNA served as controls). B) Protein levels of YAP1 in the presence
of siYAP1 for 24 hours (cells treated with scrambled siRNA served as controls). Graphs represent
mean from three replicates ± SEM. Statistical significance determined by 1-way ANOVA,
***p<0.001. From Stanley AK, et al. J Bone Miner Res. In Press.
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Figure 3.12 RhoA protein level is increased in Acvr1R206H/+ cells.
A) RhoA protein levels are higher in Acvr1R206H/+ cells as compared to Acvr1+/+, suggesting RhoA
may contribute to the changes in YAP1 nuclear localization and cell morphology on softer
substrates. Graphs represent mean from three biologic replicates ± SEM. Statistical significance
determined by 1-way ANOVA, *p=0.0131. From Stanley AK, et al. J Bone Miner Res. In Press.
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Chapter 4:
Aberrant muscle tissue repair by mutant ACVR1 FOP progenitor cells
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4.1 Summary
In the rare genetic disease fibrodysplasia ossificans progressiva (FOP),
progenitor cells are mis-regulated to differentiate to heterotopic extra-skeletal bone in
connective tissues. Mutations in the BMP type I receptor ACVR1/ALK2 cause FOP, with
the R206H mutation as the most prevalent. This increases BMP signaling to promote
increased downstream chondro/osteogenic gene expression and heterotopic ossification
(HO) formation in FOP patients. HO formation is often initiated by injury to skeletal
muscle. In the conditional knock-in mouse model for ACVR1R206H, HO develops within
skeletal muscle cardiotoxin (CTX) injury. Additionally, injured Acvr1R206H/+ muscle tissue
appears more fibrotic and does not repair as efficiently as Acvr1+/+ muscle tissue. Based
on these data, I hypothesized that the ACVR1R206H mutation negatively impacts muscle
progenitor cells to impede skeletal muscle repair.
The regenerative potential of skeletal muscle is dependent on the function of
muscle stem cells (MuSCs). Additionally, non-myogenic mesenchymal progenitor cells
(or fibro/adipogenic progenitors, FAPs) are in close association with regenerating muscle
fibers and support myogenesis; these cells, considered mesenchymal progenitors based
on their ability to differentiate to adipocytes and osteoblasts, are a source of promyogenic signals that support muscle regeneration. We examined the effect of the
ACVR1R206H mutation on MuSCs and FAPs alone by isolating the two populations using
fluorescent activated cell sorting (FACS) and analyzed proliferation based on BrdU
incorporation. Acvr1+/+ and Acvr1R206H/+ MuSCs and FAPs proliferated similarly after CTX
injury. We investigated the ability of Acvr1+/+ and Acvr1R206H/+ MuSCs to differentiate in
vitro. Acvr1+/+ MuSCs cultured in myogenic media differentiate normally and form
branching myofibers by day 7 of culture, but Acvr1R206H/+ MuSCs form underdeveloped
fibers that fail to fuse. Acvr1+/+ FAPs cultured with Acvr1R206H/+ MuSCs leads to proper
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myofibers formation and fusion, while Acvr1R206H/+ FAPs cultured with Acvr1+/+ MuSCs
form undeveloped fibers. This suggests that the FAP population under the influence of
the ACVR1R206H mutation contributes largely to the poor muscle regeneration seen in
FOP lesions. Demonstrating the influence of the mutant ACVR1R206H tissue environment
in vivo, Acvr1+/+ MuSCs transplanted into injured Acvr1R206H/+ skeletal muscle tissue
showed inconsistent engraftment. Taken together, our data support the impact of the
ACVR1R206H FOP mutation on the differentiation capacity of MuSCs to regenerate
skeletal muscle and the impact of FAPs on the function of MuSCs.
4.2 Introduction
Skeletal muscle is a highly regenerative tissue following injury. Muscle stem cells
(MuSCs; also called satellite cells) are required for repair of damaged myofibers

(88, 202)

.

These cells lie quiescent within the basal lamina of the fiber until activation by assault to
the tissue; they then begin the process of proliferation (and self-renewal), increasing
their numbers to efficiently differentiate and fuse to form myofibers (88, 205).
Fibro/adipogenic progenitor cells (FAPs) are an additional skeletal muscle resident
progenitor cell-type that is required to stimulate the activation of MuSCs during skeletal
muscle regeneration (92, 223, 283). FAPs have been implicated in disease settings as the
source for ectopic fibrotic tissue, fat, cartilage, and bone

(93, 313)

.

Heterotopic ossification (HO), or the formation of qualitatively normal ectopic
bone, within skeletal muscle and connective tissue could be due in part to improper
repair of skeletal muscle following an injury. Fibrodysplasia ossificans progressiva (FOP)
is a rare genetic disease in which heterotopic (extra-skeletal) bone forms within skeletal
muscle and other soft connective tissues (49, 56). Our lab previously identified mutations in
the type l bone morphogenetic protein (BMP) receptor activin A receptor type 1 (ACVR1)
as the cause of FOP, with R206H (c.617G>A) bring the most prevalent (47, 56). The
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mutation causes increases both BMP ligand-dependent and ligand-independent
signaling to promote increased downstream chondro/osteogenic gene expression and
HO formation in FOP patients (56). HO formation is frequently induced by injury to skeletal
muscle but can occasionally occur spontaneously (50). HO can also arise in the absence
of a known genetic mutation; in these cases the extra-skeletal bone forms in response to
severe tissue trauma such as from high impact blast injury, spinal cord injury, or jointreplacement surgery (353), making understanding the mechanism of HO formation highly
relevant for the general population.
Muscle regeneration is characterized by a carefully regulated set of events.
Normally quiescent MuSCs are activated within 1-2 days after injury, quickly followed by
proliferation peaking at 3-4 days, and then differentiation and maturation of cells until
muscle architecture is restored (14-21 days after injury) (205, 259, 393). Acvr1R206H/+ knock-in
mice recapitulate human FOP disease progression (59, 101). We have previously
established that the knock-in Acvr1R206H/+ mouse develops HO after cardiotoxin (CTX)
injury to skeletal muscle (61). Our data show that after CTX injury, muscle tissue from
Acvr1R206H/+ mice becomes more fibrotic with an increased inflammatory response
compared to muscle of injured Acvr1+/+ animals that is fully restored at 14 days,
indicating that muscle repair is impeded by the ACVR1R206H mutation (61, 79). Acvr1R206H/+
animals develop a substantial amount of HO within the muscle by 14-21 days after injury
(61, 79)

. Developing improved insight into the mechanism behind the dysregulation of

skeletal muscle repair in FOP may identify targets for therapeutic intervention in both
genetic and non-genetic causes of HO.
In this study, we examined skeletal muscle regeneration in the knock-in
Acvr1R206H/+ mouse model (59, 101) following CTX injury to determine the effect of the
ACVR1R206H mutation on skeletal muscle regeneration. Under the influence of the
mutation, muscle progenitor cell populations MuSCs and FAPs do not function properly,
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failing to form mature myofibers in vitro. The ACVR1R206H mutation also creates a
complex environment for repair, with varying engraftment of transplanted Acvr1+/+
MuSCs. Taken together, our data exhibit the impact of the ACVR1R206H FOP mutation on
the differentiation capacity of myogenic progenitor cells to regenerate skeletal muscle
and the importance of environment during skeletal muscle regeneration.
4.3 Results
FOP skeletal muscle tissue does not repair properly after injury.
Muscle injury frequently triggers heterotopic bone formation in FOP patients,
suggesting an aberrant wound healing response in the presence of the ACVR1R206H
mutation. Expression of Acvr1R206H/+ in a knock-in mouse model of FOP recapitulates all
key clinical features of the disease including HO formation in response to muscle injury
(59, 61, 79)

. We have shown previously that in response to cardiotoxin-induced (CTX)

skeletal muscle injury, mice expressing Acvr1R206H/+ form heterotopic endochondral bone
over a 2-week time course (59). We also demonstrated a fibrotic-like phenotype and
prolonged inflammatory response and muscle damage in injured Acvr1R206H/+ skeletal
muscle tissue that persists throughout regeneration (79). Fibrosis within skeletal muscle
tissue negatively impacts repair (223).
Prior to injury, muscle fiber size between Acvr1+/+ and Acvr1R206H/+ skeletal muscle
tissue was similar with no inherent differences in gross morphology (Fig. 4.1A). To
investigate deficient repair by Acvr1R206H/+ muscle tissue after injury in further detail, we
examined Acvr1R206H/+ skeletal muscle tissue at different time points after CTX injury.
CTX leads to rapid muscle damage and muscle degradation that is accompanied by an
inflammatory response; this catabolic phase is followed by the onset of an anabolic,
reconstruction phase characterized by activation of muscle stem cells that subsequently
form new muscle fibers in Acvr1+/+ tissue (341-344). Compared to Acvr1+/+, there were fewer
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and smaller regenerating myofibers (centri-nucleated fibers) in Acvr1R206H/+ muscle tissue
at day 5 and 10 post-cardiotoxin injury (Fig. 4.1B & C). Lesions also appeared more
fibrotic, which persisted within muscle tissue (as seen in (79)). Twenty-one days after
injury, Acvr1+/+ muscle tissue had properly repaired, while cartilage (as indicated by
Alcian blue hematoxylin/orange G stain staining) and prolonged damage of muscle was
present in Acvr1R206H/+ tissue (Fig. 4.1D, F, & G). These data indicate that along with the
formation of heterotopic endochondral ossification, FOP is classified by delayed and
inefficient repair of skeletal muscle tissue after injury.
Tissue rigidity is increased in fibroproliferative areas following injury of
Acvr1R206H/+ muscle.
To investigate changes in skeletal muscle tissue properties in response to injury,
we injured Acvr1R206H/+ mice with cardiotoxin (Fig. 4.1). To assay lesions in injured
muscle from Acvr1+/+ control littermates and Acvr1R206H/+ mice at the fibroproliferative
stage, tissues were examined at days 4 to 5 post–CTX injury (Fig. 4.2A), before any
heterotopic bone or cartilage forms (61, 79), as verified by H&E staining of the injured
tissues. Phosphate-buffered saline (PBS) injection in Acvr1+/+ and Acvr1R206H/+ mice (Fig.
4.2B) did not induce muscle injury and served as negative controls. Substantial
degeneration of muscle tissue was found after CTX injection in both Acvr1+/+ and
Acvr1R206H/+ mice. Early stages of wound healing were accompanied by robust
fibroproliferation in both Acvr1+/+ and Acvr1R206H/+ littermates (Fig. 4.2B & C).
Tissue stiffness was quantified by measuring Young’s moduli through atomic
force microscopy (AFM) (394) of consecutive nonfixed tissue cryosections (Fig. 4.2, left).
Stiffness of healthy uninjured muscle was ∼20 kPa, with no significant difference
between Acvr1+/+ and Acvr1R206H/+ littermates (Fig. 4.2, right). Fibroproliferative regions
in injured areas of Acvr1+/+ littermates showed a >3.5-fold reduction in rigidity compared
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with healthy muscle (black columns, Fig. 4.2, right), consistent with the ongoing
turnover of damaged muscular tissue and initial stages of wound healing (262). Lesions in
Acvr1+/+ littermates were relatively soft (∼6 kPa), indicating that these tissues are at an
early wound healing (early fibroproliferation) stage, well before the appearance of
repaired muscle fibers (205, 259, 393). However, tissue stiffness in fibroproliferative areas of
injured Acvr1R206H/+ tissue was significantly elevated compared to Acvr1+/+ (≥40 kPa)
(Fig. 4.2, right, red bars); this is similar to the pathological stiffening of tissues that is
observed in fibrosis or scar tissue (∼15–100 kPa) (395) and is consistent with previously
reported AFM measurements of the osteoid microenvironment within bone (111).
These results demonstrate that Acvr1R206H/+ pre-osseous tissues are aberrantly
stiffer and indicate that cells at sites of wound repair are actively constructing and
experiencing a local microenvironment that has greater mechanical signaling properties
compared to Acvr1+/+ tissue. Tissue damage leads to inflammation, a response that is
elevated and prolonged in FOP tissue (79). Inflammation activates FAPs, sometimes
referred to as myofibroblasts, to produce collagens, alpha-smooth muscle actin (αSMA),
and chondroitin sulfate proteoglycan (CSPG4, for stress fiber formation) to prepare the
niche for regeneration (80, 85, 126, 223, 251, 258, 262, 318). Chronic activation of fibroblasts during
repair results in fibrosis (87). This potentially implicates FAPs as the cellular source for
increased tissue stiffness and fibrotic-like appearance of injured Acvr1R206H/+ muscle
tissue.
In vivo proliferation capability is similar between Acvr1+/+ and Acvr1R206H/+ MuSCs
and FAPs.
Both muscle stem cells (MuSCs) and fibro/adipogenic progenitor cells (FAPs), a
muscle tissue-resident population of mesenchymal progenitor cells, are required for
skeletal muscle regeneration (89, 92, 209). FAPs become activated before MuSCs shortly
112

after skeletal muscle injury, with cell numbers peaking at 48-72 hours after injury, then
returning to pre-injury levels 96-120 hours after injury (92). A major role of FAPs is to
promote MuSC activation, which proliferate and then differentiate into mature myofibers
to repair muscle tissue (92, 209). BMP signaling has been shown to promote proliferation of
muscle stem cells and repress their differentiation (15, 296-303), suggesting the possibility
of diminished MuSC ability to repair muscle injury in response to the ACVR1R206H
mutation.
MuSCs are relatively plastic and their ability to proliferate, self-renew, and
differentiate is dependent on the rigidity/stiffness of their niche environment (90).The
efficiency of MuSCs to orchestrate regeneration of damaged muscle tissue is decreased
by a stiffer tissue environment (90). Additionally, insufficient numbers of MuSCs or FAPs
causes insufficient skeletal muscle repair following in vivo injury (265).
To address the presence and proliferative abilities of MuSCs and FAPs in
Acvr1R206H/+ tissue after injury, we injured Acvr1+/+ and Acvr1R206H/+ tibialis anterior (TA)
and gastrocnemius muscles with CTX and then administered BrdU intraperitoneally at 2,
4, and 6 days after injury. We isolated MuSCs and FAPs via fluorescent activated cell
sorting (FACS) 24 hours after BrdU injection (at 3, 5, and 7 days after CTX injury) and
examined them for BrdU incorporation (Fig. 4.3A). We also isolated cells from uninjured
Acvr1+/+ and Acvr1R206H/+ adult animals. As MuSCs and FAPs are typically quiescent
before injury, it was unsurprising that we saw very few proliferating cells from any
uninjured animals (Fig. 4.3B & C). At days 3 and 5 post-CTX injury, there was a large
increase in the percentage of proliferating MuSCs and FAPs from both Acvr1+/+ and
Acvr1R206H/+ skeletal muscle tissue. FAPs were the most proliferative at day 3 post-CTX
injury, while the largest percent of proliferation was seen at day 5 for MuSCs (Fig. 4.3C).
This is consistent with FAPs becoming activated by injury slightly before MuSCs
day 7 post-CTX injury, there were fewer proliferating cells in both Acvr1+/+ and
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(92)

. At

Acvr1R206H/+ skeletal muscle tissue. This finding is in agreement with previous reports,
which demonstrated that FAPs become apoptotic and decrease their numbers at this
time point, while MuSCs begin differentiating to facilitate myogenic regeneration

(92)

. In

our study, at each time point examined, there were no significant differences in
proliferation of MuSCs or FAPs in Acvr1+/+ and Acvr1R206H/+ skeletal muscle tissue (Fig.
4.3C). The ACVR1R206H mutation instigates increased BMP signaling; BMP signaling
stimulates proliferation of progenitor cells in skeletal muscle tissue (15, 300, 302, 311, 396), so
this result was unsurprising. Collectively, these data demonstrate that MuSCs and FAPs
are present in Acvr1R206H/+ skeletal muscle tissue and that their abilities to proliferate are
unaffected by the ACVR1R206H mutation.
FOP MuSCs fail to form mature myofibers.
Since MuSCs and FAPs from Acvr1R206H/+ skeletal muscle tissue are able to
proliferate normally, we next investigated their ability to differentiate utilizing in vitro
assays. We isolated MuSCs from uninjured Acvr1+/+ and Acvr1R206H/+ skeletal muscle
tissue via FACS; 18 hours after isolation, Acvr1+/+ and Acvr1R206H/+ MuSCs appeared
similar in morphology and size (Fig. 4.4A). These cells are very small, with the nucleus
taking up most of the cytoplasmic area. When cultured on collagen-coated chamber
slides in myogenic differentiation media for 7 days, Acvr1+/+ MuSCs fused to form
elongated and branching myofibers (Fig. 4.4Bi), while Acvr1R206H/+ MuSCs did not fuse
as readily and did not form elongated, branching myofibers (Fig. 4.4Bi). After 14 days in
culture, Acvr1+/+ myofibers continued to branch and mature, while Acvr1R206H/+myofibers
remained short and wider, as compared to Acvr1+/+, with no branches forming (Fig.
4.4ii).
To examine maturity of myofibers in vitro, myosin heavy chain (MyHC) (397), was
detected in day 14 cultures, with lower expression levels in Acvr1R206H/+ MuSC cultures
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as compared to Acvr1+/+ (Fig. 4.4Biii). We calculated the fusion index percentage for
Acvr1+/+ and Acvr1R206H/+ MuSCs cultured in myogenic media for 14 days. Fusion
index was calculated as the percentage of total nuclei that resided in cells containing 3
or more nuclei (349). The fusion index percentage for Acvr1R206H/+ MuSCs was significantly
lower as compared to Acvr1+/+ (Fig. 4.4C) This indicates a delay or defect in
differentiation capacity of Acvr1R206H/+ MuSCs to form mature myofibers, leading to poor
muscle repair. These data demonstrate that increased BMP signaling through increased
activity of ACVR1 leads to deficient differentiation capacity of Acvr1R206H/+ MuSCs to form
mature myofibers in vitro.
Myogenesis is rescued in FOP MuSCs cultured with WT FAPs.
FAPs are required for MuSCs to be activated to repair injured skeletal muscle
tissue (92, 209) . FAPs reside in the interstitial space of muscle close to blood vessels and
in regions of damaged and regenerating myofibers, supporting their role in modulating
myogenesis, however FAPs do not fuse with differentiating myofibers (92, 209).
To better assess the relationship between FAPs and MuSCs in FOP, we cultured
FAPs and MuSCs together on collagen-coated slides for 14 days in myogenic
differentiation media (FAPs and MuSCs mixed 1:1). Acvr1+/+ MuSCs co-cultured with
Acvr1+/+ FAPs differentiated normally, forming elongated branching myofibers (Fig.
4.5Ai), while Acvr1R206H/+ MuSCs cultured with Acvr1R206H/+ FAPs showed either little or
no fusion, while the few myofibers observed had no branching myofibers (Fig. 4.5Aii).
Fusion index percentage was quantified as in Fig. 4.4C (Fig. 4.5B).
When we co-cultured Acvr1R206H/+ FAPs with Acvr1+/+ MuSCs, Acvr1+/+ MuSCs did
not fuse efficiently, forming shorter and wider fibers as compared to Acvr1+/+ MuSCs with
Acvr1+/+ FAPs (Fig. 4.5Aiii & B). This indicates that the FOP mutation negatively
influences the function of both MuSCs and FAPs. In contrast, Acvr1+/+ FAPs with
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Acvr1R206H/+ MuSCs rescued the differentiation defect of Acvr1R206H/+ MuSCs, resulting in
fusion of MuSCs and formation of elongated branching fibers (Fig. 4.5Aiv & B). This
result highlights the importance of healthy FAPs in the ability of MuSCs to differentiate
properly during skeletal muscle regeneration.
Both MuSCs and FAPs are impaired by the FOP mutation, compounding the
negative effect on skeletal muscle regeneration. To investigate whether MuSCs and
FAPs require direct contact for proper differentiation or whether FAPs influence MuSCs
through secreted key factors that promote myogenesis, we generated conditioned media
(CM) by culturing FAPs in media independently of MuSCs. After a week, we collected
CM from the FAPs and cultured MuSCs in FAP CM for one week. Acvr1+/+ MuSCs
cultured with Acvr1+/+ FAP CM retained normal differentiation potential (Fig. 4.5Ci & D),
while Acvr1R206H/+ MuSCs cultured with Acvr1R206H/+ FAP CM showed impaired
differentiation (Fig. 4.5Cii & D). Acvr1+/+ MuSCs cultured with Acvr1R206H/+ FAP CM were
unable to fuse and form myofibers as proficiently as Acvr1+/+ MuSCs with Acvr1+/+ FAP
CM (Fig. 4.5Ciii & D). Interestingly, Acvr1R206H/+ MuSCs cultured with Acvr1+/+ FAP CM
responded to Acvr1+/+ FAP factors, showing rescue of the differentiation defect of
Acvr1R206H/+ MuSCs (Fig. 4.5Civ & D). These data indicate that a soluble factor(s)
secreted by Acvr1+/+ FAPs supports myogenesis, and Acvr1R206H/+ FAPs either fail to
secrete this factor(s) at typical levels or secrete an opposing inhibitory factor(s) towards
myogenesis.
Acvr1+/+ and Acvr1R206H/+ FAPs are adipogenic and osteogenic in vitro.
It has previously been demonstrated that FAPs are adipogenic and osteogenic
both in vivo and in vitro

(95, 241, 315, 323)

. To investigate the adipogenic and osteogenic

capacity of Acvr1R206H/+ FAPs, we isolated FAPs from uninjured Acvr1+/+ and Acvr1R206H/+
skeletal muscle tissue and cultured them on collagen-coated chamber slides for 3 days in
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FAP proliferation media. Undifferentiated FAPs appear fibroblastic and Acvr1+/+ and
Acvr1R206H/+ FAPs are similar in appearance (Fig. 4.6A).
We cultured the FAPs in adipogenic differentiation media and stained adipogenic
cultures with Oil Red O after 7 days. There were no significant differences in Oil Red O
staining between Acvr1+/+ and Acvr1R206H/+ FAPs (Fig. 4.6B & C). We also cultured Acvr1+/+
and Acvr1R206H/+ FAPs in and osteogenic differentiation media (with or without BMP4
ligand) and stained osteogenic cultures with Alizarin Red after 14 days. We detected a
slight, but not significant increase in Alizarin Red in Acvr1R206H/+ FAPs with or without the
addition of BMP4 ligand as compared to Acvr1+/+ (Fig. 4.6C & E). These data confirm the
adipogenic and osteogenic capabilities of FAPs in vitro, and suggest that osteogenic
differentiation potential may be slightly elevated in Acvr1R206H/+ FAPs.
These data also indicate an importance of environment on FAP cell function. We
previously demonstrated that Acvr1R206H/+ cells are primed towards chondro/osteogenic
differentiation by increased BMP pathway signaling and mechanotransduction (Chapter
Three). Our data here suggest that Acvr1R206H/+ FAPs may be primed towards osteogenic
differentiation even before injury. In the presence of a stiffer environment and/or chronic
inflammation following injury, Acvr1R206H/+ FAPs may then be stimulated to undergo
osteogenic differentiation. This is supported by the recent publication demonstrating the
contribution of Acvr1R206H/+ FAPs to HO formation in vivo (93).
Acvr1R206H/+ muscle environment has variable impact on muscle tissue repair.
To investigate the effect of Acvr1R206H/+ skeletal muscle tissue environment on the
ability of MuSCs to engraft and repair tissue after injury, we injured and irradiated the
tibialis anterior (TA) muscles of Acvr1+/+ and Acvr1R206H/+ mice. We harvested MuSCs from
wildtype ubiquitous-GFP mice (Jackson Labs) (Fig. 4.8) and transplanted GFP+ MuSCs
into injured/irradiated Acvr1+/+ and Acvr1R206H/+ TAs. Three weeks after transplantation,
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mice were sacrificed and their TAs extracted and analyzed for the formation of HO by
micro computed topography (µCT) (Fig. 4.7A). HO formed in Acvr1R206H/+ mice, as seen
by µCT (Fig. 4.7B & C) and Alcian blue hematoxylin/orange G staining (Fig. 4.7Diii & iv).
GFP+ Acvr1+/+ MuSCs properly engrafted into injured Acvr1+/+ skeletal muscle (Fig. 4.7Ei
& ii). Interestingly, we found that Acvr1+/+ MuSCs either did not engraft in injured
Acvr1R206H/+ muscle tissue or engrafted at the periphery of the HO (as indicated by GFP+
myofibers, Fig. 4.7Eiii & iv). We had expected to see little to no engraftment of MuSCs in
Acvr1R206H/+ muscle tissue, so the presence of GFP+ fibers in Acvr1R206H/+ muscle was a
surprising result. It is possible that because these MuSCs are able to properly engraft and
form fiber because they do not carry the FOP mutation. However, the results were variable
and the experiments need to be repeated to better understand the results. These data
indicate that the Acvr1R206H/+ skeletal muscle environment negatively effects muscle repair
and allows for the formation of ectopic bone formation.

4.4 Discussion
Regeneration of skeletal muscle tissue following injury is orchestrated by several
cell populations within the muscle tissue. Muscle stem cells (MuSCs), located in the
interstitial lamina of myofibers, undergo myogenic differentiation to restore muscle tissue
(88, 203, 204, 206)

. These cells lie quiescent within muscle tissue until activated to begin

proliferating (and self-renewing) to repair damaged muscle

(88, 203-206)

. Fibro/adipogenic

progenitor cells (FAPs) are another progenitor cell population found within skeletal muscle,
and are necessary for proper muscle regeneration. In response to injury, quiescent FAPs
are activated and begin to proliferate, and activated FAPs are necessary to activate MuSC
proliferation and differentiation (92).
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease
characterized by the formation of heterotopic bone (HO) within skeletal muscle tissue and
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soft connective tissues, replacing these tissues and suggesting that the FOP mutation
impairs their maintenance and/or repair. FOP is caused by mutations in the BMP type 1
receptor ACVR1 that leads to increased BMP pathway signaling activity (46, 48-50). Elevated
BMP signaling and increased tissue stiffness are known to antagonize MuSC
differentiation (90, 299, 300, 398). Utilizing a knock-in Acvr1R206H/+ mouse model (59, 101), we show
here that accompanying the development of HO, Acvr1R206H/+ muscle tissue does not repair
as quickly after injury as Acvr1+/+. While the mechanism of HO development has been
widely studied, the questions about impaired muscle tissue repair largely remained
unanswered.
MuSCs are influenced by their substrate stiffness: MuSCs cultured on substrates
mimicking myogenic conditions robustly retain their ability to regenerate (88, 90). However,
after being cultured on a stiffer substrate, MuSCs rapidly lose their engraftment and
regeneration abilities when implanted into the irradiated muscle of a mouse

(90)

. We

previously demonstrated that skeletal muscle tissue is stiffer in Acvr1R206H/+ animals after
injury

(73)

, so it is reasonable to consider that increased tissue stiffness contributes to

impaired regenerative ability of Acvr1R206H/+ MuSCs. MuSC function is also negatively
affected by chronic inflammation, and we previously demonstrated an increased and
prolonged inflammatory response in injured Acvr1R206H/+ skeletal muscle tissue

(79)

.

Together, increased tissue stiffness, chronic inflammation, and increased BMP signaling
activity through the mutant ACVR1 receptor could culminate to create a hostile
environment for MuSC differentiation and FAP function in Acvr1R206H/+ skeletal muscle
tissue.
Prior to injury, Acvr1R206H/+ and Acvr1+/+ skeletal muscle are similar in fiber size,
and the initial response of Acvr1R206H/+ skeletal muscle to injury is qualitatively similar to
Acvr1+/+ control tissue and the usual skeletal muscle repair process

(260, 399)

. Following

injury, we found that regenerating fibers were fewer and smaller compared to Acvr1+/+,
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signifying a deficiency in muscle regeneration. To further investigate this, we examined
the impact of the ACVR1R206H mutation on muscle progenitor cells. Here we demonstrate
that the ACVR1R206H mutation does not significantly impact MuSC or FAP proliferation, but
impairs the ability of MuSCs to differentiate in vitro. This delay in differentiation could
provide an opportunity for cells with osteogenic potential, like FAPs, to undergo osteogenic
differentiation in a stiffer and inflammatory environment, further inhibiting skeletal muscle
regeneration.
FAPs have been heavily implicated as being key players in skeletal muscle
regeneration

. Acvr1R206H/+ MuSCs cultured with Acvr1R206H/+ FAPs resulted in stunted

(92)

differentiation, but Acvr1R206H/+ MuSCs cultured in the presence of Acvr1R206H/+ FAPs
showed improved differentiation. Interestingly, culturing Acvr1+/+ MuSCs with Acvr1R206H/+
FAPs negatively impacted the differentiation ability of Acvr1+/+ MuSCs. These effects were
confirmed in experiments with FAP conditioned media. Our data support that FAPs have
a large effect on skeletal muscle myogenic repair potential. While the concept of the
indispensability of FAPs for proper muscle regeneration is not novel, the interaction
between MuSCs and FAPs in the context of FOP has not been previously described.
Although co-culturing Acvr1R206H/+ MuSCs with Acvr1+/+ FAPs improved the functionality of
Acvr1R206H/+ MuSCs, it is not a full rescue (as indicated by fusion index values). This
indicates that the Acvr1R206H/+ mutation has a negative impact on function of both MuSCs
and FAPs in a cell autonomous manner, concomitantly with influences from the muscle
microenvironment, including inflammation and increased tissue stiffness. This was
compounded by examining the effect of an ACVR1R206H/+ skeletal muscle tissue
environment on the ability of Acvr1+/+ MuSCs to engraft and repair the tissue. Acvr1+/+
MuSCs transplanted into injured Acvr1R206H/+ muscle tissue either did not engraft efficiently
or clustered around the periphery of HO (Fig. 4.7). These data indicate that the
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ACVR1R206H mutation changes both the skeletal muscle environment and influences
specific cell function.
Cells were transplanted two days after injury, and FAPs are mobilized to repair
. Acvr1+/+ and Acvr1R206H/+ skeletal muscle initially

(92)

muscle tissue around the same time
responds similarly to injury

(79)

, making it plausible that FAPs stimulated normally and

begin normal activation of MuSCs. Muscle repair in Acvr1R206H/+ tissue begins to diverge
from Acvr1+/+ day 4-5 after injury

(239)

, the same time point we demonstrated significantly

increased tissue stiffness in Acvr1R206H/+ muscle (73). It Is possible that an increased number
of FAPs at the site of injury early on are still able to recruit transplanted MuSCs to the
injury site prior to the beginnings of HO formation, leading to engraftment of MuSCs
around developed HO. This may indicate a switch from a FAP-secreted pro-myogenic
factor(s) to inhibitory factors around day 4 of injury, reinforced by prolonged inflammation
within the tissue. These data also confirm the strong influence of the Acvr1R206H/+ tissue
environment on skeletal muscle regeneration. Future studies will investigate the impact of
the Acvr1+/+ skeletal muscle environment on the engraftment capabilities of Acvr1R206H/+
MuSCs.
Acvr1R206H/+ MuSCs are not completely unable to fuse (Fig. 4.4B), indicating that
there may not be a defect in the fusion process. Fusion is mediated by the musclespecific plasma membrane protein Myomaker, with its requirement at the step of
membrane fusion of individual myoblasts (279). An additional muscle-specific factor
Myomerger is also required for myoblast fusion, although its mechanism is not fully
understood (280). Adhesion proteins like integrin-α3/β1, ADAM12, M-cadherin, and
VCAM-1are also involved in fusion and are upregulated during the terminal stages of
regeneration (281). Acvr1R206H/+ MuSCs appear to reach a point in vitro where they no
longer fuse and form only short, unbranching fibers. This suggests a defect with the
progression of differentiation that proceeds fusion. Future studies will work to elucidate
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the full mechanism of the delay in Acvr1R206H/+ MuSC differentiation.
Taken together, our data examine the effect of the ACVR1R206H mutation on the
functionality of MuSCs and FAPs following skeletal muscle injury. We showed that
MuSCs are deficient in their ability to undergo myogenic differentiation and that FAPs
are able to either stimulate or antagonize that ability. This was confirmed by the inability
of Acvr1+/+ MuSCs to efficiently engraft into Acvr1R206H/+ muscle following CTX injury.
FAPs have previously been implicated in the formation of HO in FOP (93), but their
interaction with MuSCs in FOP have been unexplored up until now. The observations
made here will inform future work examining the signaling pathways by which MuSCs
and FAPs communicate in vivo, and how those signals go awry in FOP. While little is
concretely known about the pro-myogenic signals that FAPs secrete to facilitate
stimulation of MuSCs during skeletal muscle regeneration (Fig. 1.10), the antiinflammatory myokines IL-6 and IL-10 (through STAT3), TNF-α, and TGFβ have be
submitted as possible candidates (92, 313, 316, 319, 320). Biochemical examination, of
conditioned media from FAP in vitro cultures could lead to identification of one or more
factors regulating myogenesis.
Our data demonstrate that increased BMP pathway signaling through ACVR1
negatively impacts skeletal muscle regeneration and highlights the importance of
environment on the ability of MuSCs to repair muscle tissue. Our data highlight the
detrimental effect of the ACVR1R206H mutation on MuSC and FAP ability to repair muscle
tissue, instead allowing for the formation of HO. We have shown that muscle tissue
damage persists in FOP tissue and this may be due to FOP MuSCs being unable to
form fully mature myofibers in vitro. The reduced efficiency of Acvr1+/+ MuSCs to repair
injured Acvr1R206H/+ muscle tissue in vivo highlights the importance of microenvironment
on cellular fate. We previously demonstrated (Chapter Three) (73) that
mechanotransduction is altered in Acvr1R206H/+ cells, which primes them for
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chondro/osteogenic differentiation. We demonstrated that both Acvr1R206H/+ and Acvr1+/+
FAPs are osteogenic in vitro, so Acvr1R206H/+ FAPs could potentially be influenced by
increased mechanotransduction to undergo osteogenic differentiation within skeletal
muscle tissue. The implications of the negative impact of the ACVR1R206H mutation on
MuSC and FAP function reveals several potential therapeutic targets for combinatorial
treatment for not only FOP but also possibly for other genetic diseases of aberrant cell
fate such as progressive osseous heteroplasia (66, 68) and non-hereditary forms of
heterotopic ossification (48, 52, 55).
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Figure 4.1 FOP skeletal muscle tissue does not repair properly after injury.
A) Uninjured skeletal muscle tissue from Acvr1+/+ and Acvr1R206H/+ displays similar morphology
and fiber size. B) Five days after CTX injury, Acvr1+/+ muscle shows centri-nucleated fibers, a
sign of repairing muscle. Acvr1R206H/+ muscle tissue appears fibrotic with less repairing fibers. C)
At day 10-post injury, Acvr1+/+ muscle tissue has continued to repair, while Acvr1R206H/+ muscle
tissue is more fibrotic and muscle damage persists (stain for A-C is H&E). D-E) At 21 days after
injury, Acvr1+/+ muscle had fully repaired, while ectopic bone with adjacent regions of mature
cartilage and remaining fibroproliferation/damaged muscle was seen in Acvr1R206H/+ muscle (stain
is Alcian blue hematoxylin/orange G stain). Scalebar = 100µm for all images. F) Representative
µCT 3D volume of HO in TA (circled in yellow). Scale bar = 5mm. Dotted lines indicate tissue
area as noted. FP = fibroproliferation; DM = damaged muscle; C = cartilage; B = bone.
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Figure 4.2 Increased fibroproliferative tissue stiffness in response to skeletal muscle
injury in Acvr1R206H/+ mice.
A) Timeline of experimental procedure. The ACVR1R206H mutation was expressed in conditional
Acvr1R206H/+ mice through doxycycline treatment 3 d prior to injection with cardiotoxin or PBS
(uninjured control). Littermate controls were treated equivalently. B) H&E staining of sections
from PBS-injected or CTX-injured quadriceps showing areas of healthy muscle and
fibroproliferation (arrow) 4 d post–injection of FOP mice or littermate controls. Scale bar
represents 100 μm. C) Enlarged images from insets in B. Scale bar: 50 μm. D) Tissue stiffness
was measured via AFM. Consecutive sections demonstrate increased rigidity of fibroproliferative
areas (FP) in FOP lesions compared with healthy muscle (M). Graph represents mean ± SEM for
N = 5–18 (in M: 5 [control] and 6 [FOP]; in FP: 10 [control] and 18 [FOP]) locations measured
across three independently injured limbs. Significance was determined by two-way ANOVA
(Bonferroni posttest); *p < 0.05. Haupt J, Stanley A, et al. Mol. Biol Cell. 2019 (73).
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Figure 4.3 In vivo proliferation capability is similar between Acvr1+/+ and Acvr1R206H/+ MuSCs
and FAPs.
A) Experimental schematic. B) Representative images of BrdU staining in uninjured and injured
settings. Scale bar = 100µm. C) MuSCs and D) FAPs sorted via FACS from injured Acvr1+/+ and
Acvr1R206H/+ muscle similarly proliferate as measured by incorporation of BrdU (n=6-7 2-month old
mice for each group). Tibialis anterior and gastrocnemius were injured and then collected 3, 5, or
7 days after injury for sorting. Error bars represent SEM. Statistical significance as determined by
1-way ANOVA; *p<.05, ***p<.0002, #p<0.0001 (uninjured animals compared to injured).
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Figure 4.4 Acvr1R206H/+ MuSCs fail to form fused myofibers.
A) Freshly isolated (within 18 hours) MuSCs from WT and FOP skeletal muscle are similar in
their morphology and numbers. Image depicts MuSCs on collagen-coated tissue culture plates 18
hours after fluorescent activated cell sorting (FACS); n= 17 for each genotype. B) MuSCs from
Acvr1+/+ skeletal muscle tissue forms normal myofibers that fuse into myotubes after 7 and 14
days in myogenic fusion media (5% HS in DMEM), while MuSCs from Acvr1R206H/+ skeletal
muscle tissue do not differentiate into normal myofibers, nor fuse efficiently in vitro; n= 6 for each
genotype. C) Quantification of fusion index percentage (mean ± SEM). Fusion index was
calculated as the percentage of total nuclei that resided in cells containing 3 or more nuclei. Scale
bars for all images = 100µm. Statistical significance determined by 1-way ANOVA, #p<.0001.
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Figure 4.5 Myogenesis is rescued in Acvr1R206H/+ MuSCs cultured with Acvr1+/+ FAPs.
A) Acvr1+/+ MuSCs cultured with Acvr1R206H/+ FAPs form myofibers do not fuse as efficiently, while
Acvr1+/+ FAPs cultured with Acvr1R206H/+ MuSCs form mature myofibers that fuse in vitro (bottom
right panel). This rescues the myogenic failure of Acvr1R206H/+ MuSCs cultured with Acvr1R206H/+
FAPs. B) Quantification of the fusion index percentage. C) Acvr1R206H/+ MuSCs cultured with
Acvr1+/+ FAP conditioned media for 2 weeks also partially rescues the poor differentiation in FOP
MuSCs, suggesting the FAPs secrete pro-myogenic factor(s). D) Quantification of the fusion
index percentage in all conditions, n= 6 for each genotype (mean ± SEM). Scale bars for all
images = 100µm. Statistical significance determined by 1-way ANOVA, ***p<.0002, #p<.0001.
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Figure 4.6 Acvr1+/+ and Acvr1R206H/+ FAPs are adipogenic and osteogenic in vitro.
A) Acvr1+/+ and Acvr1R206H/+ FAPs have a fibroblastic appearance during proliferation in vitro. B)
Acvr1+/+ and Acvr1R206H/+ FAPs have adipogenic potential (Oil Red O staining). C) Acvr1+/+ and
Acvr1R206H/+ FAPs have osteogenic potential (Alizarin Red staining). There were no significant
differences between adipogenic/osteogenic differentiation of Acvr1+/+ and Acvr1R206H/+ FAPs, but
slight increases in adipogenesis/osteogenesis in Acvr1R206H/+ FAPs suggest that Acvr1R206H/+ FAPs
could be primed toward adipogenesis/osteogenesis (i.e. disease settings). All scale bars = 100µm.
Graphs represent mean of 4 biologic replicates ± SEM. Statistical significance determined by 1way ANOVA; all values were not significant (ns).
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Figure 4.7 The Acvr1R206H/+ muscle environment has variable impact on muscle tissue
repair.
A) Timeline of experimental procedure. B) Representative µCT 3D volume renderings showing
Acvr1+/+ and Acvr1R206H/+ lower hindlimbs (HO developed in Acvr1R206H/+ tibialis anterior muscles).
C) Quantification of HO for each genotype (n = 6 for each genotype). Statistical significance
determined by unpaired student t-test, p<0.001. D) Alcian blue hematoxylin/orange G staining of
Acvr1+/+ (i-ii) and Acvr1R206H/+ (iii-iv) muscle tissue 21 days after transplant. Acvr1R206H/+ muscle
tissue is more fibrotic and muscle damage persists. Scale bar = 100px (i & iii), 100µm (ii & iv).
Dotted lines indicate tissue area as noted. E) Representative images of Acvr1+/+ and Acvr1R206H/+
skeletal muscle tissue transplanted with GFP+ Acvr1+/+ MuSCs. At 21 days after transplant,
Acvr1+/+ muscle had fully repaired, with noticeable engraftment of GFP+ Acvr1+/+ MuSCs (i & ii,
images represent two individual mice). GFP+ Acvr1+/+ MuSCs also engrafted in Acvr1R206H/+
muscle, but either less compared to Acvr1+/+ muscle (iv) or at the periphery of HO formation (iii).
Scale bar = 100µm for all images. Wheat germ agglutin (basal lamina) in red, DAPI (nuclei) in
blue, GFP+ fibers in green. FP = fibroproliferation; DM = damaged muscle; RM = regenerated
muscle; C = cartilage; B = bone.
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Figure 4.8 Gating strategy to identify GFP+ MuSCs.
MuSCs from Ubiquitous-GFP mice were isolated based on expression of several cell surface
markers. Non-GFP mice were used as a control. Image of muscle tissue (tibialis anterior
muscles) depicts control (non-GFP) and GFP+ muscle tissue as color disparity is apparent.
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Chapter Five:
Discussion
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5.1 Summary
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease
characterized by the formation of normal endochondral bone, termed heterotopic
ossification (HO), within skeletal muscle and other connective tissues after injury.
Research has been mainly dedicated to preventing the formation of HO and identifying
the causative cell population(s) (50, 59, 64, 84, 93, 356, 400-403). A previously unexamined
question that is addressed in this thesis is the influence of the mutation on cellular
mechanotransduction. Here we show that FOP cells misinterpret their mechanical
environment as stiffer, thus upregulating mechanical signaling pathways, and ultimately
leading to the promotion of chondro/osteogenic cell fate decisions. Another unaddressed
question is why skeletal muscle tissue in FOP does not repair as quickly or efficiently as
in a non-FOP individual. This thesis examines the effect of the ACVR1R206H mutation on
skeletal muscle, demonstrating that increased BMP signaling conferred by the mutation
hinders the differentiation of muscle stem cells (MuSCs) and alters the function of
fibro/adipogenic progenitor cells (FAPs) during skeletal muscle regeneration. By
investigating these questions, we bring new insights to FOP that suggest potential novel
therapeutic targets.

5.2 Discussion
5.2.1 Elevated BMP and Mechanical Signaling Through YAP1/RhoA Poises FOP
Mesenchymal Progenitors for Osteogenesis
The formation of HO within skeletal muscle tissue suggests that cells within that
tissue are misdirected by surrounding factors to take on alternate cell fates. We have
previously demonstrated that Acvr1R206H/+ progenitor cells are not fully committed toward
chondrogenesis by ligand-independent signaling through ACVR1R206H, but rather show
heighted response and accelerated differentiation in response to BMP-induced
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chondrogenesis (60). However, the mechanisms that interact with the mutation to lead to
heterotopic bone were not well understood. Cell fate is heavily influenced by the
mechanical properties (ECM makeup, exogenous ligands, shear stress, etc.) within their
surrounding environment. Mechanotransduction is the process by which cells sense the
physical state of their surrounding microenvironment and, via intracellular signaling
pathways, respond to these physical signals by subsequently altering gene expression
and protein production (118, 120, 124). Previously, it was thought that cells with inherent
chondro/osteogenic abilities were recruited to an injury site and subsequently formed HO
in FOP patients (404). However, there was little evidence that this was the case (401). That
must mean that resident mesenchymal progenitor cell population(s) within skeletal
muscle tissue are able to assume chondro/osteogenic fates, and also suggested that
resident mesenchymal progenitors would be influenced by their surrounding tissue
environment. Using mouse embryonic fibroblasts (MEFs) as a model for multipotent
progenitor mesenchymal progenitor cells (MSCs) (Fig. 1.2), we investigated the impact
of the ACVR1R206H mutation on mechanotransduction. As discussed in Chapter Three,
FOP cells misinterpret their mechanical environment as stiffer, and subsequently
upregulate mechanical signaling, which poises these cells for chondro/osteogenic
differentiation following skeletal muscle tissue injury.
We examined various signaling pathways related to mechanotransduction,
including YAP/TAZ signaling, Rho/ROCK signaling, and cell contractility. We performed
experiments to demonstrate that elevated BMP signaling through increased ACVR1
activity modulated YAP1 nuclear/cytoplasmic localization (Fig. 3.5). We also
demonstrated increased active YAP in Acvr1R206H/+ cells on soft substrates (Fig. 3.6).
While these experiments did not show whether these pathways directly or indirectly
interacted, YAP/TAZ have been shown to directly interact with the BMP signaling
pathway via binding of phosphorylated (active) Smads (183, 185), so it is possible that the
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increased phosphorylation of Smads seen in FOP cells (60, 391) complexes with YAP to
induce its nuclear localization (Fig. 3.5). Immunoprecipitation experiments could be
performed to confirm a possible interaction. Mutation of the Smad-binding motif WW1 on
YAP (183) could also confirm whether there is increased binding of Smads to induce YAP
activity in FOP.
Our data demonstrate an increase of YAP in the nucleus and an increase of its
target gene Cyr61 (Fig. 3.6). However, YAP could have other possible actions within the
nucleus. ChIP-Seq could be used to investigate whether YAP is directly transcriptionally
regulating the binding of Smads to DNA, or whether they are separately effecting gene
expression independently of one another. It is reasonable to think that FOP cells may
have a more open chromatin structure/chromatin structure and are more responsive
(sensitive) to tissue stiffness. Rabineau et al. demonstrated that decreasing the stiffness
of a substrate shifted cells from a euchromatic state to a heterochromatic state
cells misinterpret their substrate as stiffer

(405)

. FOP

(73)

, and this could be allowing a wider variety

of genetic transcription within a specific tissue type to induce HO formation. One ongoing
experiment is elucidating chromatin organization in FOP cells on different substrates
utilizing Stochastic Optical Reconstruction Microscopy (STORM) Imaging (406) to
visualize the chromatic state of FOP cells on various substrates. This will further
elucidate the relationship between BMP and YAP signaling in FOP, and provide insight
as to whether YAP is a realistic target for FOP therapeutics.
While our studies provide important insight into the molecular pathophysiology of
the mutant ACVR1 receptor on mechanotransductive signaling pathways in FOP,
interpretations of these data are limited to those allowed by the cell type used. We
previously demonstrated that MEFs are able to adopt multiple cell fates, including
osteogenic (60), but these are not skeletal muscle resident cells. Mechanotransduction may
be mis-regulated by the FOP mutation in progenitor cells within skeletal muscle tissue.
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Within skeletal muscle tissue are fibro/adipogenic progenitor cells (FAPs), mesenchymal
progenitor cells that have osteogenic potential (discussed in Chapter Four) and have
been shown to contribute to the formation of HO in FOP mouse models (93). FAPs are more
difficult to isolate than MEFs and are less amenable to cell culture methods (407). However,
we have begun to develop protocols to conduct similar mechanotransduction experiments
in FAPs. Future studies will investigate mechanical signaling in Acvr1R206H/+ FAPs, and the
impact on chondro/osteogenic potential (this will also be further discussed in 5.2.2).
Additionally, there are over twenty BMP ligands (18) and different ligands may have different
downstream effects on mechanotransductive pathways. We previously demonstrated that
the ACVR1R206H mutation can act downstream of BMP ligands but also stimulate increased
Smad1/5/8 phosphorylation independently of ligand

(391)

. This suggests that the

ACVR1R206H mutation is modulating mechanotransduction independent of ligand
stimulation and that the presence of ligand could have a completely different effect on cell
behavior. It is reasonable to consider if specific ligands would alter the performance of
FOP cells on different substrate stiffnesses. In most experiments in the lab, we utilize
BMP2 or 4 to initiate osteogenesis in vitro based on data showing a robust response by
ACVR1R206H/+ cells to these ligands

(60, 400, 402)

, so it would be reasonable to begin with

examining the effects of those ligands in mechanotransductive assays. In Chapter Three,
we demonstrate a general mechanism by which increased BMP pathway signaling
through ACVR1 mis-regulates mechanotransduction to poise cells for chondro/osteogenic
differentiation independent of ligand stimulation. Ongoing studies are working to address
ACVR1 responsiveness to specific ligands.
Taken together, our data reveal for the first time a mechanism by which elevated
BMP pathway signaling and mechanical signaling combine to increase cell contractility
and direct cells to a chondro/osteogenic lineage pathway (Fig. 3.10), culminating in the
formation of HO and progression of disease in FOP.
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5.2.2 Aberrant muscle tissue repair by mutant ACVR1 FOP progenitor cells
Muscle stem cells (MuSCs), located in the interstitial lamina of myofibers, undergo
myogenic differentiation to restore muscle tissue (88, 203, 204, 206). These cells, also known as
satellite cells, remain quiescent within the muscle tissue until activated to begin
proliferating (and self-renewing) to repair damaged muscle

(88, 203-206)

. Elevated BMP

signaling is known to antagonize MuSC differentiation (299, 300, 398). After injury, Acvr1R206H/+
muscle tissue does not repair as quickly as Acvr1+/+, with the development of HO beginning
around 10 days

(79)

. While the mechanism of HO development has been widely studied,

the questions about slow muscle tissue repair largely remained unanswered. As discussed
in Chapter Four, we demonstrated that the ACVR1R206H mutation does not significantly
impact MuSC proliferation, but impairs their ability to differentiate in vitro and in vivo.
Acvr1+/+ MuSCs transplanted into injured Acvr1R206H/+ muscle tissue engrafted into existing
muscle tissue and fused to form myofibers only at the periphery of HO (Fig. 4.7), thus
indicating the influence of the Acvr1R206H/+ muscle environment on skeletal muscle repair
in FOP. While this is an exciting observation, the mechanism behind it is not clear. We
were surprised by this result due to our hypothesis that increased stiffness and
inflammation in AcvrR206H/+ tissue would completely prevent engraftment of transplanted
MuSCs.
There are several possible explanations for our transplant results. Early in muscle
regeneration (day 1-2), FAPs are stimulated by injury to begin the activation of MuSCs (92).
The beginning of muscle regeneration after injury appears similar between Acvr1+/+ and
Acvr1R206H/+ (79). It is plausible that at this stage in FOP, FAPs function properly and begin
activation of MuSCs, as evidenced by similar proliferation of FAPs and MuSCs in Acvr1+/+
and Acvr1R206H/+ mice after injury (Fig. 4.3). Transplanted MuSCs did not carry the FOP
mutation and function normally, so presumably activated FAPs at the site of injury
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recruited these “normal” MuSCs, which then began to engraft. We discovered an increase
in Acvr1R206H/+ tissue stiffness 4 days after CTX injury

(73)

, which could be an indication of

a switch in FAPs from pro-myogenic to inhibitory of myogenesis. It has been demonstrated
that FAPs contribute to tissue stiffness through downregulation of certain ECM proteins
(such as Col IV/V, lamina), and increased expression of genes involved in fibrillar ECM
formation and remodeling

(80, 85, 126, 251, 252)

, so this increase in tissue stiffness day 4 after

injury could be due to FAPs and indicate the beginning of anti-myogenic signaling in FOP
muscle tissue. In order to confirm these results, we plan to transplant Acvr1R206H/+ MuSCs
into injured Acvr1+/+ tissue. We expect that Acvr1R206H/+ MuSCs would engraft normally into
Acvr1+/+ due to the influence of a healthy Acvr1+/+ environment.
Another explanation for our results could be that irradiation did not sufficiently
eradicate the endogenous cell populations before transplantation. While irradiation is a
standard procedure before transplantation, we have data suggesting that irradiation does
not completely eradicate endogenous MuSC or FAP populations, possibly leading to
decreased engraftment of transplanted cells in favor of activity of endogenous cells. This
is supported by the ability of a small number of MuSCs to fully repair injured tissue 3-4
weeks after injury

(265)

; even a single muscle cell is able to repair muscle

(266, 267)

. Genetic

conditional depletion of MuSCs and/or FAPs in Acvr1R206H/+ and Acvr1+/+ mice could
potentially address this issue.
Alternatively, our results could indicate a technical difficulty. Some groups have
reported transplanting <2,000 MuSCs resulting in proper engraftment and repair of muscle
tissue

(90, 245, 266)

. Previous technical difficulties prompted us to transplant 30,000 MuSCs.

This could potentially have led to an artificial overload of the tissue, forcing engraftment in
Acvr1R206H/+ skeletal muscle where it would not have occurred biologically. Future
experiments will transplant fewer than 30,000 cells to validate our results and are in
progress.
138

MuSCs are influenced by their substrate stiffness: MuSCs cultured on substrates
mimicking myogenic conditions potently retain their ability to regenerate (88, 90). Interestingly
however, MuSCs rapidly lose their engraftment and regeneration abilities when implanted
into the irradiated muscle of a mouse after being cultured on a stiffer substrate (90). This
suggests that altered interpretation of tissue environment within Acvr1R206H/+ injured tissue
could lead to impaired regenerative ability of MuSCs. In Chapter Three, we investigated
mechanotransduction in MEF cells. While these cells are a sufficient model for multipotent
MSCs, a next step would be to perform these assays with MuSCs to further examine
mechanotransduction specifically in muscle progenitor cells in the context of FOP. We
demonstrated that muscle tissue is stiffer in Acvr1R206H/+ animals after injury (Fig. 4.2) (73),
so it is reasonable to expect that mechanotransductive signaling pathways are
upregulated in Acvr1R206H/+ MuSCs. However, MuSCs are much more difficult to isolate
and keep viable in culture settings (263), so these experiments would be extremely difficult
technically.
Fibro/adipogenic progenitor cells (FAPs) are another progenitor cell population
found within skeletal muscle, and are necessary for proper muscle regeneration (92). FAPs
begin to proliferate proceeding MuSCs after injury and are stimulatory of MuSC
proliferation and differentiation. Once MuSCs begin to differentiate, FAPs begin to
apoptose (92). In Chapter Four, we demonstrated the ability of Acvr1+/+ FAPs to rescue the
impaired differentiation of MuSCs in vitro, thus implicating them as potential perpetuators
of disease in FOP. Furthermore, we and other groups have demonstrated FAPs have
osteogenic potential in vitro (Fig. 4.6) and in vivo (93). Collectively, these data support FAPs
as a main contributing cell population toward the formation of HO.
Little is known about the characteristics of FAPs; they were described less than a
decade ago and little is known about the mechanisms behind their functions. As discussed
in Chapter One, PDGFRα is the most specific marker currently known for FAPs
139

(92, 209)

,

but is not restricted to FAPs. PDGFRα+ cells are found in most tissue types, in cells with
completely different biological functions (222, 408). A muscle tissue-specific marker Osr-1 has
been shown to be a marker of FAPs during embryonic development and may have
implications for adult muscle regeneration (409), but still little is known about the Osr-1+ cell
population. Until a more specific cell marker is known or Osr-1+ cells are better
characterized, our group will continue to isolate them by established approaches as
discussed in Chapter Two (2.9.3). As discussed in the previous section, since FAPs have
osteogenic potential and contribute to HO, it is plausible that mechanotransductive
signaling is elevated in these cells and stimulates chondro/osteogenic differentiation.
FAPs, like MuSCs, are difficult to isolate and culture in vitro, but they are more fibroblastic
and more adherent than MuSCs. Our group has had moderate success in culture of these
cells and studies to investigate mechanical signaling has been initiated. Contractility
assays such as TFM and paxillin expression analysis are plausible to do in FAPs because
they require fewer cells and less manipulation of the cells. We expect to see similar results
in the FAPs (i.e., increased contractility, more paxillin expression) as a downstream
readout of increased mechanotransduction. The ROCK inhibitor Fasudil was successful
in reducing cell contractility in MEFs, so we would also expect it to decrease FAP
contractility, thus further demonstrating Fasudil as a potential therapeutic to be used
concomitantly with others in the treatment of FOP.
Of note, although HO forms most commonly in most skeletal muscles and other
soft connective tissues, it has not been detected in the tongue or diaphragm muscles (46).
It is reasonable to speculate that this not only implies a requirement for a permissive
environment together with progenitor cells with osteogenic potential for HO formation, but
also that specific types of muscle type (fast vs slow twitch), movement (isometric vs
isotonic) or other environment forces/factors are potentially needed to curate an
environment to induce HO formation. Substrates mimicking average skeletal muscle
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stiffness was examined in our study (Chapter Three) due to the high incidence of HO in
most skeletal muscles

(47)

. There are no reports on a higher occurrence of HO in slow or

fast twitch muscles. The role of mechanical signaling in HO formation has been described
in other soft connective tissues such as tendons and ligaments

(410-412)

; however, these

studies are small and are more phenotypic observations rather than mechanistic
elucidation. Future studies will address the implications of muscle type and function on the
incidence of HO formation in FOP.

5.3 Future Directions
5.3.1 Elevated BMP and Mechanical Signaling Through YAP1/RhoA Poises FOP
Mesenchymal Progenitors for Osteogenesis
We have previously demonstrated that FOP cells do not spontaneously
differentiate in vitro (79), indicating that although they are poised for
chondro/osteogenesis (Chapter Three), there is still either a requirement for some kind
of inciting event (i.e. injury) or that the threshold for activation of chondro/osteogenic
pathways in FOP cells is lower as compared to healthy cells. Our data also
demonstrates that FOP cells are not insensitive to mechanical signaling; the fact that
mutant cells are more sensitive to their environment, for example, with cell areas that do
not appropriately scale with stiffness (Fig. 3.2), suggests that mutant cells have a lower
preset for mechanical sensation and more readily respond to their substrate stiffness.
Our data support that mutant cells are poised for chondro/osteogenesis but require a
secondary input to begin the aberrant bone formation response, similar to Knudsen’s
Two Hit Hypothesis, in that, two events combine to cause a phenotypic change (413). The
presence of the FOP mutation is the first hit and poises FOP cells for
chondro/osteogenic differentiation, but some type of secondary input (i.e. injury) is
required to push the cells down that chondro/osteogenic path. Patients report
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occurrences of “spontaneous HO” in HO, and at this time it is unclear whether these
episodes are attributable to an unperceived (micro) injury (i.e. pulled muscle, small tear
from walking, running, etc.) (49) or the initiation of bone formation based on localized
mutant ACVR1 signaling activity that has accumulated to induce HO.
We have shown that inflammation is a key driver of HO formation (79), and
inflammation arises in response to injury or immune system challenge (414, 415). A second
hit could be partially driven by inflammatory response pathways, which subsequently
interact with FAPs and deter the differentiation of MuSCs. The early activation of FAPs
after injury has been tied to the immune response, with expression of IL-4 required for
proper FAP activation and stimulates FAP clearance of damaged muscle tissue shortly
after injury (Fig. 1.9) (283). IL-4 is a pro-inflammatory cytokine (415), so it’s reasonable to
postulate that the prolonged inflammatory response contributes to the improper function
of FAPs by keeping them activated longer than necessary, leading to poor tissue
regeneration and a fibrotic-like phenotype in FOP (79). Increased inflammation promotes
increased nuclear localization of YAP/TAZ and increased tissue stiffness due to ECM
deposition by myofibroblasts (FAPs) (161). Chronic inflammation stimulates secretion of
pro-fibrotic proteins by FAPs (91). Increased mechanotransduction and prolonged
inflammation could generate positive feedback for cells with chondro/osteogenic
potential (416) that are already primed by the FOP mutation, ultimately pushing them
towards HO development. Examination of adipogenic/osteogenic differentiation potential
in FAPs after challenge with various inflammatory cytokines, as in (417) could also provide
new insight into potential regulators of FAPs.
Here we examined two key mechanical signaling pathways, YAP/TAZ and
Rho/ROCK. These are only two of many mechanical signaling pathways involved in cell
fate determination (123, 418, 419). Another key signaling pathway is the WNT signaling
pathway. As mentioned in Chapter One (1.5.5.3), WNTs are secreted glycoproteins that
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function as ligands critical for important regulator of many adult stem cells (285) with βcatenin as the central mediator of canonical WNT signaling

(285, 287)

. YAP signaling has

been shown to antagonize WNT signaling through direct binding of β-catenin (136, 420).
Our preliminary data demonstrating decreased cytoplasmic localization of β-catenin and
increased β-catenin protein expression in Acvr1R206H/+ cells as compared to Acvr1+/+ (J.
Haupt, unpublished). Less cytoplasmic β-catenin indicates increased nuclear β-catenin
and increased WNT target gene expression (244). Differentiation of mesenchymal stem
cells into cartilage was induced by BMP7 primarily through the WNT/β-catenin pathway
(421)

. These and our data imply that the WNT signaling pathway could contribute to

increased chondro/osteogenic differentiation of Acvr1R206H/+ cells. siRNA experiments
against β-catenin could be used to demonstrate the role for WNTs in
mechanotransduction and chondro/osteogenic gene expression in Acvr1R206H/+ cells.
Another signaling pathway related to BMP and mechanical signaling is TGFβ
pathway activity. TAZ has been implicated in nuclear accumulation and transcriptional
activity of phosphorylated Smad2/3 (422), the canonical signaling mediator of TGFβ, while
Smad1/5 are able to stimulate YAP signaling activity (185). We have preliminary evidence
of increased TGFβ signaling through elevation of pSmad2/3 in FOP cells (A. Culbert,
unpublished), so it is possible that elevated ACVR1 signaling is enhancing both
pSmad1/5 and pSmad2/3, which in turn both elevate YAP signaling and lead to
chondro/osteogenic gene expression. Studies have explored TGFβ signaling in
relationship to FOP (101, 423, 424), but its connection to mechanical signaling has not been
investigated in FOP. Studies similar to those done in Chapter Three could be conducted
in order to elucidate the potential contribution of TGFβ signaling to the mechanical
phenotype observed in FOP cells.
5.3.2 Aberrant muscle tissue repair by mutant ACVR1 FOP progenitor cells
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MuSCs are the potent progenitor cell population required for skeletal muscle
regeneration (89, 204). We have demonstrated that skeletal muscle tissue in Acvr1R206H/+
animals does not repair as efficiently after injury as compared to Acvr1+/+, with fewer and
smaller regenerating fibers in Acvr1R206H/+ muscle tissue (Fig. 4.1). We also
demonstrated that GFP+ Acvr1+/+ MuSCs transplanted into Acvr1R206H/+ muscle tissue did
not engraft as well as in Acvr1+/+ muscle tissue and mainly engrafted at the periphery of
HO. MuSC engraftment is negatively affected by increased tissue stiffness (90), therefore,
it was unsurprising that increased tissue stiffness of FOP tissue after injury (Fig. 4.2) (73)
lead to variable engraftment of transplanted Acvr1+/+ MuSCs. The reciprocal experiment
of transplanting Acvr1R206H/+ MuSCs into Acvr1+/+ animals to examine the effect of a
diseased environment on healthy MuSCs is currently in progress. We hypothesize that a
healthy tissue environment will be able to rescue the deficient differentiation program of
Acvr1R206H/+ MuSCs.
We have demonstrated the ability of Acvr1+/+ FAPs to rescue the poor
differentiation of Acvr1R206H/+ MuSCs in vitro (Fig. 4.5). Due to technical issues, we were
unable to examine the effect of transplantation of FAPs into injured Acvr1+/+ and
Acvr1R206H/+ skeletal muscle tissue. We are now pursuing this area; we postulate that
Acvr1+/+ FAPs will be able to partially rescue poor muscle differentiation in Acvr1R206H/+
tissue after injury, similar to our in vitro results. Muscle regeneration is a concerted
process, with many ligands, growth factors, ECM proteins, and cell types involved (258,
425)

. It is unreasonable to expect that provision of one healthy cell population into a

diseased tissue would be enough to completely rescue a diseased phenotype; however,
FAPs largely influence muscle regeneration (92, 283) and so Acvr1+/+ FAPs could positively
impact FOP muscle regeneration. A large part of the function of FAPs is secretion of promyogenic factor(s) to stimulate skeletal muscle regeneration (Chapter Four), however,
none have been concretely validated as a FAP-secreted factor. This partially relates to
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there being no specific marker to identify FAPs (see section 1.5.1), and also that FAPs
are a recently discovered cell population. Identification of a pro-myogenic secreted factor
or ligand would be a major breakthrough in understanding for the musculoskeletal field.
We demonstrated that Acvr1+/+ FAPs were able to rescue myogenesis of mutant MuSCs
in vitro, and Acvr1R206H/+ FAPs negatively affected differentiation of Acvr1+/+ MuSCs (Fig.
4.5). There are many mechanistic possibilities behind these data; the anti-inflammatory
myokines IL-6 and IL-10 (through STAT3), TNF-α, and TGFβ have be submitted as
possible candidates (92, 313, 316, 319, 320) for pro-myogenic factors secreted by FAPs (Fig.
1.9), so one or more of these could be aberrantly secreted or inhibited in FOP tissue.
BMPs are negative regulators of muscle differentiation, so Acvr1R206H/+ FAPs could be
secreting BMP ligand(s) to deter proper muscle regeneration.
As mentioned previously, FAPs have been identified as a main source of
increased ECM production in disease settings, leading to fibrosis and/or fatty deposits
within skeletal muscle tissue (95, 315). It is possible that increased ACVR1 activity
stimulates secretion of fibrotic factors by FAPs, or inhibits secretion of pro-myogenic
factor(s). Rapamycin decreased fibrosis and improved muscle regeneration in a model
of constitutively active ACVR1 by inhibiting mTOR (426). This suggests that Acvr1R206H/+
FAPs may secrete pro-fibrotic factors in response to injury in FOP tissue, thereby
suppressing muscle regeneration. WNT1-inducible-signaling pathway protein 1 (WISP1)
has been identified as a FAP-derived factor controlling MuSC expansion and
commitment to myogenic differentiation. In aged skeletal muscle, there was a decrease
of FAP-secreted WISP-1, which lead to decreased MuSC proliferation and muscle repair
(427)

. Perhaps through some interaction of WNT signaling and BMP signaling in FOP,

decreased FAP-secreted WISP1 is contributing to poor muscle repair. Biochemical
examination, via ELISA or microarray, of conditioned media from FAP in vitro cultures
could lead to identification of one or more factors regulating myogenesis. Identification of
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a pro-myogenic factor(s) could present as a target for supplemental treatment in FOP
patients, and an anti-fibrotic like Rapamycin could suppress fibrotic activity of FAPs.
Steroids are already given as a therapy to suppress the immune response in FOP
patients (50), and could be working to suppress any pro-inflammatory cytokines secreted
by FAPs in FOP skeletal muscle tissue.
5.4 Concluding Remarks
In this thesis, I have elucidated the role of elevated ACVR1 signaling in
stimulating cellular mechanotransduction and priming cells for chondro/osteogenic
differentiation. Key findings in this work include demonstration of enhanced YAP and
RhoA pathway signaling, resulting in increased cell contractility and expression of
chondro/osteogenic genes in Acvr1R206H/+ on soft substrates. These data support that
FOP misinterpret their mechanical environment as stiffer and respond accordingly. Our
finding that the ROCK inhibitor Fasudil decreases cell contractility in FOP cells is an
important finding, as it suggests that increased mechanotransduction in FOP can be
potentially managed as a contributor to the progression of disease.
Another key finding described in this thesis is the role of the ACVR1R206H mutation
in skeletal muscle regeneration and its impact on muscle progenitor cells MuSCs and
FAPs. Acvr1R206H/+ MuSCs and FAPs proliferate normally, but differentiation of
Acvr1R206H/+ MuSCs in vitro is deficient. Acvr1+/+ FAPs are able to rescue differentiation of
Acvr1R206H/+ MuSCs, while Acvr1R206H/+ FAPs decreases the efficiency of Acvr1+/+ MuSC
differentiation; this demonstrates the effect of the FOP mutation on both the function of
FAPs and MuSCs, and their communication with one another. Transplantation of
Acvr1+/+ MuSCs into injured Acvr1R206H/+ muscle tissue resulted in poor engraftment of
MuSCs or on the periphery of HO.
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Results from both Chapters Three and Four demonstrate the substantial
influence of environment on cell fate decisions and the ability of progenitor cells to
function properly. Increased tissue stiffness, prolonged inflammation, increased
mechanotransduction, and altered interactions of progenitor cell populations all
accumulate to produce the pathology of FOP. Our data demonstrate that HO formation
in FOP is due to multiple effects of the FOP Acvr1R206H mutation that converge and allow
for formation of heterotopic ossification. This highlights the necessity for a multi-pronged
treatment for FOP, and multiple areas of investigation into this complex disease.
While FOP is a rare genetic disease, heterotopic ossification (HO) arises more
commonly from blast-initiated injuries and joint-replacement surgeries, making
understanding the mechanism of HO formation even more important for the general
population. Developing a better comprehension of the mechanical signals and pathways
that regulate the functions of cells and bone formation will provide insight into targets for
therapeutic intervention in both genetic and non-genetic causes of HO. The findings in
this thesis gives us critical insight to the molecular mechanisms governing the
development of HO. While the primary initiating mechanisms involved in formation of
genetic HO and non-genetic HO may not be identical, there is still likely to be enough
overlap so that therapeutic targets identified to treat genetic HO will be relevant for nongenetic HO as well.
The work detailed in this dissertation will contribute to and expand interest in
mechanotransduction and skeletal muscle regeneration outside of the FOP research
community into non-genetic HO. As detailed in the preceding Future Directions section,
there are several stimulating avenues for further research.
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